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Iodine is a micronutrient required for optimal development and growth. Mandatory iodine 
fortification of bread was implemented in Australia in October 2009 following the re-
emergence of iodine deficiency. However, there are limited data on the iodine status of South 
Australians and populations at risk, particularly pregnant women. There is a concern about the 
inconsistent classification of iodine status in the general population and pregnant women by 
different markers. Evidence on the association between iodine nutrition in early life, and 
neurodevelopment and growth in populations with mild iodine deficiency to iodine 
sufficiency, is inconsistent. Newborn thyroid stimulating hormone (TSH) concentration has 
been suggested as a marker of iodine nutrition in early life. 
 
This thesis aims to assess: 1) the agreement between markers of iodine status, 2) iodine status 
(including pregnant women) in South Australia, before and after the mandatory iodine 
fortification using the newborn TSH concentration and urinary iodine concentration (UIC), 
and 3) associations between newborn TSH concentration and childhood neurodevelopment 
and growth. 
 
A systematic review was conducted to assess agreement between markers of population-level 
iodine status (median UIC, newborn TSH concentration and goitre prevalence), while urinary 
iodine data, including an estimated 24-h urinary iodine excretion (UIE), UIC, iodine-to-
creatinine ratio (I/Cr), and UIC-corrected for creatinine, were used to assess agreement 
between markers of individual-level iodine status in pregnant women. The results of the 
systematic review showed that at a population level, newborn TSH concentration >5 mIU/L 
greater than 3% had a better agreement with goitre prevalence than median UIC to define 
iodine deficiency in populations. At an individual level, I/Cr from spot urine samples had a 





Based on the newborn TSH concentration, South Australia was classified as mildly iodine 
deficient in both pre- and post-fortification periods in contrast to iodine sufficiency defined by 
median UIC post-fortification. Iodine status of pregnant women was classified as iodine 
deficiency pre-fortification and iodine sufficiency post-fortification by the UIC marker. 
 
Utilising developmental outcome data from two studies, a null association was observed 
between newborn TSH and childhood neurodevelopment or growth at 18 months. However, 
poorer neurodevelopment or growth in infants with high TSH in a borderline iodine deficient 
setting and better neurodevelopment in infants with high TSH in iodine sufficient setting 
cannot be excluded. 
 
In conclusion, monitoring of iodine status using multiple markers is required to identify 
populations or population groups at increased risk of iodine deficiency disorders. Re-
evaluation of current TSH criteria for classifying iodine status in populations is suggested. As 
neurodevelopmental assessments at 18 months of age may not be stable, data-linkage studies 
that utilise newborn TSH data and examine neurodevelopmental outcomes at later ages are 
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CHAPTER 1: INTRODUCTION  
Iodine is a trace mineral necessary for the synthesis of thyroid hormones which are required 
for optimal growth and development [1, 2]. Insufficient iodine intake may lead to goitre and 
hypothyroidism in all ages, as well as impaired growth, mental retardation and cretinism 
during critical periods of early life [3]. The critical period in child growth and development 
starts from conception and continues to early childhood [4]. A systematic review of studies in 
severe iodine deficient settings in China showed a 12.5 points lower Intelligence Quotient 
(IQ) points in children with severe iodine deficiency compared with children living in an 
iodine sufficient setting [5]. Therefore, it is crucial to ensure iodine sufficiency at all times, 
especially during critical periods of life to prevent the unwanted consequences of iodine 
deficiency.  
 
The goal of eliminating iodine deficiency in the year 2000 was adopted by the world leaders 
who attended the World Summit of Children through the introduction of a universal salt 
iodisation program in their countries [6]. Despite the global initiative to eliminate iodine 
deficiency, and evidence of improvement in iodine status of populations, it remains a public 
health problem in several countries even two decades since it had been assumed to be 
virtually eliminated worldwide. Recently, iodine deficiency has been reported in several 
countries [7, 8] and iodine deficiency remains a public health issue in both the developed and 
developing worlds. A recent Iodine Global Network (IGN) report using a nationally 
representative data until 2018 showed that 105 countries had optimal iodine intake, 14 
countries had insufficient iodine intake, and nine countries had excessive iodine intake [7]. 
The epidemiology of iodine deficiency has shifted from severe forms of iodine deficiency to 
mild and moderate forms of iodine deficiency and excessive iodine intake due to the 
introduction of the iodine fortification programs [9-11]. Although many countries have 
declared iodine sufficiency, pregnant women remained at a higher risk of iodine deficiency in 
some countries, including Australia. This may be due to higher iodine requirements during 
2 
 
pregnancy (250 µg/day) than for non-pregnant women and adults (150 µg/day) [12]. Lack of 
considering the higher iodine demand during pregnancy in the existing fortification programs 
may also contribute for the existence of iodine deficiency in pregnant women.   
 
The damaging effect of severe iodine insufficiency on the brain is recognised, but mild to 
moderate iodine deficiency and iodine excess during pregnancy may also harm the 
neurodevelopmental and growth outcomes in children [2, 13]. These, in turn, may hurt the 
economic performance and productivity of the affected nations as well as their quality of life 
[14]. Therefore, public health efforts towards sustainable elimination of iodine deficiency 
should continue to target at-risk population groups such as infants and pregnant women. As 
confounders of neurodevelopmental and anthropometric outcomes are very complex, a well-
designed follow-up studies that adjust for key confounders are required.  
 
The ability to accurately assess iodine status is crucial in preventing both iodine deficiency 
and excess. The World Health Organization (WHO), United Nations Children’s Fund 
(UNICEF) and International Council for Control of Iodine Deficiency Disorders (ICCIDD) 
recommend the median urinary iodine concentration (UIC), goitre prevalence, and newborn 
thyroid stimulating hormone (TSH) concentration >5 mIU/L as appropriate markers to define 
iodine status in populations [12]. Most countries apply the median UIC to monitor the iodine 
status of populations using a representative sample of School Age Children (SAC). However, 
some evidence showed inconsistent classification of the iodine status of populations between 
these markers of iodine status [15].  
 
In Australia, the mandatory iodine fortification of bread was in place by October 2009 [16] to 
control the re-emergence of iodine deficiency [17]. The intake of an iodine supplement of 150 
μg per day has also been recommended to pregnant and breastfeeding women since January 
2010 [18]. Studies in Australia that used median UIC in SAC showed iodine sufficiency in the 
3 
 
post-fortification periods, but there is little evidence on the iodine status of pregnant women 
using a representative sample. The use of multiple markers of iodine status and linking the 
iodine exposure status with functional outcomes like neurodevelopmental scores will be of 
paramount importance in the prevention and control of iodine deficiency disorders.   
 
The monitoring system that includes iodine nutrition of populations and at-risk population 
groups is essential to make appropriate adjustments on the existing iodine intervention 
programs like the mandatory iodine fortification of bread in Australia. Although different 
markers are recommended to assess iodine status, the agreement between these markers to 
consistently classify iodine status is not known. Sustained adequate iodine intake in all 
population groups will have a vital role in the prevention of neurodevelopmental impairment 
and in boosting economic productivity. However, evidence of the effect of iodine nutrition on 
development and growth of children in populations of mild iodine deficiency or iodine 
sufficiency, is inconclusive. Therefore, the aims of this thesis were:  
1) To evaluate the agreement between different markers of iodine status. 
2) To examine the impact of the iodine fortification program in Australia on the iodine 
status of populations and pregnant women. 
3) To investigate the associations between early life iodine nutrition and 





CHAPTER 2: LITERATURE REVIEW 
The literature review covers the role of iodine nutrition, markers of iodine status, the 
prevalence of iodine deficiency in the general population and pregnant women worldwide and 
in Australia, and the associations between iodine nutrition in early life and neurodevelopment 
and growth of children. A systematic review and meta-analysis was performed to assess the 
relationship between newborn TSH and child neurodevelopment and growth. 
    
2.1 The role of iodine  
Iodine, an essential micronutrient, is needed for the synthesis of thyroid hormones (thyroxine 
(T4) and 3, 5, 3/ tri-iodothyronine (T3)). The thyroid hormones have a significant role in 
many physiological processes in the body [19-21]. One of the key roles of thyroid hormones 
is to maintain a healthy brain development as they are involved in the myelination, 
differentiation, migration, and signalling of the neural cells of the human brain in fetal and 
early postnatal periods [2]. Therefore, optimal iodine nutrition is required during the fetal and 
early critical periods of life [22]. 
  
2.2 Consequences of iodine deficiency or excess 
Both iodine deficiency and excess has adverse effects on human health. Inadequate iodine 
intake impairs thyroid hormone production and leads to adverse health outcomes, which are 
collectively termed ‘Iodine Deficiency Disorders’ (IDD) [3]. IDD include goitre, 
hypothyroidism, impaired growth, mental retardation, cretinism, deaf-mutism, congenital 
anomalies, abortion and stillbirth [3]. IDD affects any stages of the life cycle. For example, 
poor iodine nutrition during pregnancy and early childhood may cause impaired psycho-
neuromotor and intellectual development in children [23, 24]. Iodine deficiency remains a 
cause of preventable neurodevelopmental delay in a growing child [25]. Similarly, excessive 
iodine intake impairs the thyroid system in all stages of life and may cause adverse health 
outcomes like iodine-induced hypothyroidism, iodine-induced hyperthyroidism, goiter, and 
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thyroid autoimmunity [26]. Furthermore, excessive iodine intake during pregnancy may also 
negatively affect the neurodevelopmental outcomes of children [10]. Therefore, adequate 
iodine intake is necessary to improve neurodevelopment and somatic growth of children, and 
reduces the risk of adverse birth outcomes [22].    
2.3 Iodine requirements and food sources  
Iodine needs to be obtained from the diet, and its daily requirements vary according to gender 
and stage of life [1]. Infants and children have high iodine requirements relative to their body 
weight. Furthermore, pregnant women and breastfeeding women have higher iodine 
requirements and are at risk of developing IDD. In Australia, the recommended dietary intake 
(RDI) of iodine for pregnant and breastfeeding women is 220 μg/day and 270 μg/day, 
respectively [27], which is significantly higher than the RDI of 150 μg/day for adults 
including non-pregnant women (Table 2.1).  
Table 2. 1 Reference iodine intake by life stage in Australia [27]. 
Life stage  RDI (μg/day) EAR (μg/day) UL (μg/day) 
Infants     
0-6 month  90 (AI)   
7-12 month 110 (AI)   
Children     
1-3 years  90  65  200 
4-8 years  90  65  300 
Adolescents    
Boys     
9-13 years  120  75  600 
14-18 years  150  95  900 
Girls     
9-13 years  120  75  600 
14-18 years  150  95  900 
Adults  150  100  1100 
Pregnant women 220  160  11001 
Lactating women 270  190  11001 
AI, adequate intake; EAR, estimated average requirement; RDI, recommended dietary intake 
and UL, upper level of intake.  




Iodine is a trace element mainly found in the shallow layers of soil and prone to washout from 
the soil [1]. The natural iodine content of food is influenced by the iodine content of the 
environment where the food is grown. Most foods are naturally low in iodine content; only a 
few foods are good sources of iodine such as fish and seafood, eggs and milk products [28, 
29]. Therefore, the iodine requirements may be challenging to achieve in people who 
consume few or none of the iodine-rich food. 
 
Iodine can be obtained from food fortified with iodine to fulfil the daily iodine requirements. 
Universal salt iodisation (USI) and mandatory iodine fortification of bread or other 
condiments are strategies recommended by the World Health Organization (WHO) to 
improve the iodine status of the general population. In countries that practise the USI 
program, all salt available on the market for human consumption, as well as feed stock for 
animals, need to be iodised, at a level recommended by the WHO and ICCIDD [12]. 
Similarly, in the mandatory iodine fortification of bread, all bread makers are mandated to use 
iodised salt with a few exceptions [30]. Besides salt, iodine can also be fortified with other 
food, beverages and condiments [31]. Iodine supplementation is also a valuable source of 
iodine in vulnerable groups, which include infants, pregnant women, and breastfeeding 
women.  
 
As the iodine requirement is higher in pregnant women than the general population, they will 
significantly benefit from the USI designed for the general population or the targeted iodine 
supplementations during pregnancy. If population-wide iodine deficiency persists (median 
UIC <50 μg/L in SAC or goitre prevalence >20% in SAC) following the introduction of the 
USI, the WHO and UNICEF jointly recommend intake of iodine-containing supplements for 
all pregnant and breastfeeding women, as well as children 7-24 months of age [32]. For 
example, with the absence of a USI program and the decreased iodine intake in pregnant 
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women, the American Thyroid Association recommended intake of iodine-containing 
supplements for pregnant and breastfeeding women in the US and Canada [33]. 
 
2.4 Assessment of iodine status 
2.4.1 Assessment of population-level iodine status  
 
Iodine status of populations can be assessed using a physical examination of the thyroid gland 
and biochemical markers including UIC, as well as TSH concentration [12]. 
  
Goitre or thyroid volume by ultrasound 
Enlargement of the thyroid gland reflects longer-term exposure to low iodine intake [12]. 
Even though palpation of the thyroid gland is a commonly used technique, the WHO also 
recommend ultrasonography to measure the thyroid size. Therefore, goitre or thyroid volume 
by ultrasound can be used as epidemiological markers to assess or monitor population iodine 
status. 
  
As shown in Table 2.2, iodine deficiency is classified by the WHO as a mild, moderate and 
severe public health problem when the prevalence of goitre is 5-19%, 20-29% and ≥30% in 
SAC, respectively. Goitre is also defined as thyroid volume >97th percentile in SAC [34]. The 
percentiles of thyroid size by ultrasound were obtained from iodine sufficient SAC 
worldwide. 
  
Prevalence of goitre by palpation or ultrasound is recommended to be used for assessing 
baseline levels of IDD and the long-term impact of iodine intervention programs [12, 35]. 
Assessment of goitre by palpation or ultrasound is non-invasive, simple and quick [36]. 
However, goitre is not the appropriate marker for monitoring iodine status shortly after iodine 
interventions, since it takes longer for changes in the prevalence of goitre to occur [35]. 
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Goitre is not a good marker in neonates and young children since the gland is too small to be 
detected by inspection and palpation in these groups of the population. SAC are important 
target groups for assessment of goitre prevalence because of their vulnerability, ease of access 
and representativeness of the population [37]. Measuring thyroid size by ultrasound is a more 
precise method, but it needs an experienced assessor [38]. Therefore, unlike goitre prevalence 
by palpation, measuring thyroid size by ultrasound may not be feasible to assess IDD in field 
surveys of low-income countries. 
  
Urinary iodine concentration  
UIC reflects recent iodine intake in populations over a short period of time. UIC is not 
normally distributed in the population and the median value of UIC is used to classify 
population iodine status [12, 37]. Median UIC has been recommended by the WHO, UNICEF 
and ICCIDD to be used as a first choice to assess population-level iodine status [12] and 
becomes the most widely used marker to assess iodine status of populations [17, 29, 39, 40]. 
UIC is convenient and cheap marker, since only a small amount of urine (0.5-1.0 ml) is 
needed, and the assessment can be done with simple methods using the Sandell-Kolthoff 
reaction.  
 
As depicted in Table 2.2, populations are classified as iodine sufficient if the median UIC is 
≥100 μg/L in SAC [12]. This criterion was established in 1994 from the lowest level of 24 
hours (24-h) urinary iodine excretion (UIE) associated with the absence of goitre, a functional 
outcome of iodine deficiency, from a study conducted in Central America [37]. The study 
showed that areas with 24-h UIE >100 µg/day had no goitre in adults and SAC [41]. As the 
average 24-h urine volume in SAC is 1 L, the UIC in SAC would be comparable with 24-h 
UIE in SAC. Hence, the WHO recommends using UIC instead of 24-h UIE in population 
surveys [37]. To obtain a representative national sample of SAC, the WHO recommends 
selecting at least 1200 SAC from 30 clusters and at least 40 SAC per cluster to classify 
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population iodine status using the median UIC. However, cluster sampling technique may not 
be feasible when including populations of pregnant women in household-based surveys as the 
number of pregnant women may be small in the clusters [12].  
Table 2. 2 Criteria for assessing iodine status in populations1  
  
Iodine sufficient  
Iodine deficiency  
Mild Moderate Severe 
Proportion of neonatal TSH >5 mIU/l (%) <3 3-19 20-39 ≥40 
Median UIC in SAC (µg/L) ≥100 50-99 20-49 <20 
Goitre prevalence in SAC (%)2   <5 5-19 20-29 ≥30 
1SAC, school age children; TSH, thyroid stimulating hormone; UIC, urinary iodine 
concentration.  
2Goitre prevalence assessed by either palpation or ultrasound [12].  
 
Thyroid stimulating hormone concentration  
The TSH concentration of newborns can be affected by maternal iodine intake during 
pregnancy and is used to monitor the iodine status of populations [12, 37, 42]. Newborns have 
higher iodine turnover than adults due to lower iodine stores in their thyroid gland [25]. 
Hence, newborns are highly sensitive to even mild iodine deficiency, and newborn TSH 
concentration can indicate the iodine status of populations [37]. According to WHO, UNICEF 
and ICCIDD joint criteria, populations are classified as iodine deficient if more than 3% of 
newborns have TSH concentration >5 mIU/L in whole blood samples collected at 3-4 days 
after birth (Table 2.2) [37].  
 
The TSH marker is practical for monitoring iodine status of countries which have a neonatal 
screening program to screen newborns for congenital hypothyroidism (CH) [25]. Neonatal 
TSH concentration may be affected by several factors including the timing of neonatal blood 
sample collection (early vs late) [43, 44], the type of blood sample (cord vs heel) [45], mode 
of delivery (vaginal vs caesarean section) [45, 46], gestational age (term vs preterm) [47], 
birthweight (normal vs low birthweight) [43, 47, 48], sex [48], season of birth [43, 49], use of 
iodine-containing antiseptics [45], organochlorine pesticides exposure in the perinatal period 
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[50], and the TSH assay used [44, 51]. Thus, appropriate caution is needed to interpret the 
findings of TSH as a marker of iodine status in populations. Due to the cost associated with 
screening all children for TSH levels, this marker is not widely used to report the iodine status 
of populations in developing countries.  
 
Questions have been raised on whether the current criterion based on the proportion of 
newborns with TSH concentration >5 mIU/L is appropriate in mildly iodine deficient or 
iodine sufficient settings [45, 51-54]. Burns et al. [54] and Vandevijvere et al. [51] suggested 
using the trend over time, rather than a numerical cut-off, to see changes in the iodine status 
of populations. Evans et al. [53] also suggested the WHO modify the criterion, and 
recommended using a lower than 5 mIU/L cut-off to identify mild iodine deficiency in 
populations. The time of blood sample collection and other determinants of newborn TSH 
concentration needs to be considered in the interpretation of newborn TSH results. Despite the 
criticism, the proportion of the population with newborn TSH concentration >5 mIU/L has 
been used as an effective measure of monitoring population iodine status in a number of 
countries [44, 55-60]. 
 
2.4.2 Assessment of individual-level iodine status 
Currently there is lack of recommended markers to classify iodine status in individuals; UIC 
and newborn TSH has been widely used to define individual-level iodine status in populations 
and at-risk population groups including pregnant women. 
 
Urinary iodine concentration  
Although UIC is not a suitable marker to determine the iodine status of individuals due to 
large day-to-day and within-day variations in urinary iodine excretion [12], the within-day 
variation in the iodine excretion minimises when assessed as 24-h UIE or as iodine to 
creatinine ratio (I/Cr) [12, 61]. To overcome the drawbacks of spot UIC, measuring UIC from 
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repeated urine samples over the 24-h period [62, 63] or adjusting for urinary creatinine 
concentration [64-66] has been recommended. Creatinine adjusted urinary iodine biomarkers 
are considered as alternatives to the actual 24-h UIE, since creatinine excretion is constant 
throughout the day [67]. However, urinary creatinine may vary depending on the age, sex, 
ethnicity and anthropometric status of individuals, and the different methods that have been 
used to estimate 24-h urinary creatinine [68, 69]. Although I/Cr and 24-h UIE minimise the 
within-day variation, these markers do not address the day-to-day variation in iodine 
excretion.  
Despite the fact that spot UIC is not an appropriate marker of individual iodine status [12], 
several studies applied the WHO cut-off of median UIC <150 µg/L to divide pregnant women 
into groups of iodine deficiency (UIC <150 μg/L) and iodine sufficiency (UIC ≥150 μg/L) 
(Table 2.3) [37]. This classification has been used frequently to assess maternal exposure to 
iodine nutrition during pregnancy, and its association with child development [70] and health 
outcomes [71].  
 
Table 2. 3 Criteria for assessing iodine status in pregnant women1  
Median UIC in μg/L Iodine status2   
>500 Iodine excess  
250-499 Above requirement  
150-249 Adequate iodine nutrition  
<150 Iodine deficiency 
1UIC, urinary iodine concentration. 
2The classification of iodine status is based on the WHO criteria [12]. 
 
Agreements between the urinary iodine markers in assessing iodine status of individuals  
Only a few of the previous studies assessed agreement between spot urinary iodine markers 
and actual 24-h UIE in populations [66, 72-74], infants and adolescents [75] and lactating 
women [76]. A comparative study of population iodine status from 400 volunteers aged 18-39 
years showed a better agreement between actual 24-h UIE and estimated 24-h UIE than actual 
24-h UIE and I/Cr or actual 24-h UIE and UIC [72]. The estimated 24-h UIE was based on 
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24-h creatinine estimations using published equations by Mage et al. that consider the age, 
sex, ethnicity and anthropometric status from healthy adult populations [69]. A study on 123 
urine samples from 31 hospital staff aged 27-71 years also showed the estimated 24-h UIE 
had a better agreement with actual 24-h UIE than the agreement between actual 24-h UIE and 
spot UIC or actual 24-h UIE and I/Cr [66]. In that study, the estimated 24-h UIE was obtained 
by adjusting the I/Cr by age and sex using Kesteloot and Jansson’s [68] published values. The 
study concluded that both UIC and I/Cr underestimated the iodine values compared with the 
24-h UIE.  
 
In populations with different socio-economic status (SES) and anthropometry, I/Cr poorly 
predicts 24-h UIE unless the necessary adjustments have been made for confounders [73, 76]. 
A study of 22 healthy adults with 95 24-h urine samples found a higher correlation coefficient 
for UIC (r = 0.83) than crude I/Cr (r = 0.69) when both markers were compared with actual 
24-h UIE [73]. The significant difference in creatinine excretion in the study population may 
have contributed to the decreased correlation between I/Cr and 24-h UIE. The crude I/Cr also 
showed poor agreement with actual 24-h UIE in a study from 16 breastfeeding women with 
52 24-h urine samples [76].  
 
There are no published studies examining the agreement between spot urinary iodine 
biomarkers like I/Cr and estimated 24-h UIE and 24-h UIE during pregnancy. Several studies 
have assessed iodine status at the first trimester of pregnancy using both the UIC and I/Cr 
markers [67, 71, 77-81] but none of them reported the agreement between these markers. 
Determining UIE from 24-h urine collection is labour intensive and needs several assessments 
to check the completeness of 24-h urine samples [74]. Thus, further study assessing the 
agreement between urinary iodine markers including UIC, I/Cr and actual or estimated 24-h 
UIE in pregnant women is required. If spot urine markers have a better agreement with UIE, 




Thyroid stimulating hormone concentration  
As the newborn TSH concentration reflects the levels of thyroid hormones synthesised by the 
thyroid gland during pregnancy [20], and it can be used as a marker of iodine nutrition in 
early life [48]. The TSH concentration of newborns will be high in early neonatal life when 
there is insufficient iodine intake during the late pregnancy period [42, 48]. Moreover, 
excessive iodine intake during pregnancy may also increase the newborn TSH concentration, 
as infants are sensitive to inhibitory effects of excess iodine intake during pregnancy [82]. 
The classifications of iodine status were the same based on newborn TSH and UIC in 
pregnancy in few previous studies that measured both newborn TSH and median UIC in 
pregnant women from the same area and at the same time period [83-85]. Therefore, newborn 
TSH could be used as a marker of iodine nutrition during pregnancy [36]. In addition to 
newborn TSH’s role in screening children with CH, it may also help to identify children at 
risk of impaired growth and neurodevelopment as there is existing evidence showing 
associations between borderline newborn TSH concentration below the newborn screening 
cut-off, and developmental delay and poor school achievement [86]. 
 
2.4.3 Other markers of iodine status 
Thyroid hormones, T3 and T4 are more expensive and less sensitive methods of measuring 
iodine concentration and are not recommended by the WHO to assess the iodine status of 
populations [12, 87]. Serum thyroglobulin (Tg) is also considered to be a good indicator of 
iodine nutrition in children [12, 88] and adults [89]. Based on a study by Zimmerman et al. 
[88], populations are classified as iodine sufficient if the median Tg is <13 µg/L in SAC. 
Unlike the thyroid hormones that are suggested as markers of iodine status in individuals, 
thyroglobulin can be used as a functional marker of long-term exposure to low or excessive 




In summary, multiple markers including median UIC in SAC, prevalence of goitre in SAC, 
and the percentage of newborns with TSH concentration >5% have been recommended to 
assess iodine status in populations. However, these markers have different applications and 
target groups. Whilst each marker has its own strength, there are situations where the markers 
may not be applicable, such as the assessment of recent iodine intake by goitre prevalence. 
Hence, it is important to apply the most suitable marker of population iodine status, when 
appropriate. These biomarkers are also helpful in assessing exposure to low or excessive 
iodine intake at individual-level, especially in vulnerable groups including pregnant women 
and infants.  
 
2.5 Iodine nutrition status worldwide   
Globally, IDD was a public health problem in 118 countries and approximately 1.6 billion 
people were living in an iodine deficient environment at the beginning of 1990s [90]. By 
2004, due to the widespread implementation of the USI, the number of countries with IDD 
had reduced to 54 countries [91]. The role of USI to improve iodine status and prevent mental 
retardation in children is one of the great public health triumphs of the 21st century.  
 
Multiple studies have demonstrated that the USI was effective in preventing and controlling 
IDD in general populations. A systematic review of Randomised Controlled Trials (RCTs) 
and observational studies showed that salt iodisation increased UIC, increased I/Cr and 
decreased goitre prevalence in adults and SAC [92]. Studies published after that systematic 
review also showed that iodine intervention programs were successful in improving the iodine 
status of the general population in a number of countries [93, 94]. A multicentre cross-
sectional study on SAC in three countries (China, Philippines and Croatia) that implemented 
USI reported adequate iodine intake in China and Croatia but excessive iodine intake in the 
Philippines [93]. This multicentre study found a sufficient iodine status in women of 
reproductive age in all three countries. Doggui et al. [94] also reported iodine sufficiency 
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(median UIC of 220 μg/L) in SAC after two decades of USI in Tunisia. Zimmerman et al. 
[55] reported that the USI program in Switzerland in 1999 decreased the proportion of 
newborns with a TSH concentration >5 mIU/L from 2.9% to 1.7%.  
 
The USI is designed for general populations and may not be enough for pregnant women. If 
the iodine level in the USI is high enough to fulfil the high requirement of pregnant women, 
there will be a high risk of excessive iodine intake when using for young children. Using 
surveys of iodine nutritional status in pregnant women, several countries documented 
improved iodine status in pregnant women following the introduction of the USI for the 
general population [29, 84, 93, 95]. For instance, the salt iodisation program in India [95] and 
Switzerland [55] prevented iodine deficiency in pregnant women. A cross-sectional study in 
India revealed adequate iodine status (median UIC of 172 μg/L) of pregnant women after the 
salt iodisation program [95]. Likewise, the salt iodisation program of Switzerland in 1999 also 
improved the iodine status of pregnant women from 115 μg/L in the pre-fortification period to 
249 μg/L in the post-fortification period [55]. Also, iodine supplementation during pregnancy 
has improved the iodine status of pregnant women in countries with mild to moderate iodine 
deficiency [96, 97]. 
 
In contrast, maternal iodine deficiency during pregnancy remains a public health problem in 
many countries, including Denmark [98], Croatia [93], Turkey [99], Madagascar [100] and 
the United States [101, 102], even with USI or iodine fortification programs. This may be 
partly due to inadequate monitoring of iodine status in pregnant women in many countries, 
although even mild-to-moderate iodine deficiency during pregnancy is linked to poor 
developmental outcomes later in life. 
 
Despite global initiatives to eliminate IDD and evidence of improvement in iodine status of 
populations, it remains a public health problem worldwide. Recently, iodine deficiency has 
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been reported in a number of industrialised countries [7, 8] and iodine deficiency remains a 
significant public health issue in both the developed and developing worlds. A recent IGN 
report using nationally representative data up until 2018 documented either iodine deficiency 
or excess in several countries [7]. Several factors may contribute to the delay in global 
progress towards eliminating all forms of IDD. These include a low coverage and access of 
iodised salt or iodine fortified food, lack of commitment from the government to take legal 
action against manufacturers who are not compliant, lack of integration of iodine 
interventions with other public health programs like salt reduction, low awareness about 
iodine nutrition and its consequences, lack of surveillance systems, and resistance of 
governments to introduce iodine intervention programs [103, 104]. Discrepancies in the 
iodine status of populations according to different markers is also a challenge to properly 
monitor and take appropriate public health measures [105]. In recent years, the epidemiology 
of iodine deficiency has shifted from severe forms of iodine deficiency to mild-to-moderate 
forms of iodine deficiency and excessive iodine intake [9-11].  
 
Though the public health importance of the USI outweighs its adverse effects at a population 
level, there are few countries that has been classified with excessive iodine intake following 
the implementation of the USI [7]. The USI program may also contribute to the rise in 
cardiovascular mortality associated with increased salt intake unless the USI program is 
integrated with the public health measures to reduce salt intake [106]. Therefore, a strong 
monitoring and evaluation system should be in placed to monitor the iodine as well as the salt 
intake of individuals from the iodised salt.  
 
2.6 Iodine nutrition status in Australia  
Mandatory iodine fortification of bread was introduced in Australia in October 2009 [16]. The 
program was in place after the results of the national survey that revealed the re-emergence of 
iodine deficiency [17]. The fortification program aimed to prevent iodine deficiency in the 
17 
 
general population and mandated the use of an iodised salt instead of non-iodised salt in 
bread-making, with a few exception such as organic bread. Whilst the type of iodine could be 
potassium/sodium iodide/iodate, the recommended level of iodine is 25-65 mg of iodine per 
kg of salt [30]. In January 2010 the fortification program was followed by the National Health 
and Medical Research Council recommendation that pregnant and breastfeeding women take 
an iodine supplement of 150 µg/day [107]. This recommendation was partly due to concerns 
about mandatory fortification not being enough to satisfy the iodine requirements of pregnant 
women, and fear that even mild iodine deficiency during pregnancy may have adverse health 
outcomes [108]. Despite the fact that there is the lack of consideration and data on food 
patterns of pregnant women or women of child bearing age, encouraging the intake of iodine 
rich food may be a sustainable approach to prevent iodine deficiency in all population groups.   
 
2.6.1 Iodine status pre-fortification in the general population 
Studies that used UIC marker  
The national iodine nutrition survey conducted in 2003-2004 showed that the population 
weighted median UIC of SAC in mainland Australia was 98 μg/L with significant 
geographical variation in major states [17, 109]. The change in sanitary practices in the dairy 
industry, from iodophors to other chemicals, and the use of non-iodised salt instead of iodised 
salt were suggested as causes for insufficient iodine intake in Australians [81]. Other studies 
in pre-fortification periods that used median UIC in SAC and adults also reported mild iodine 
deficiency in several states in Australia, including Victoria [110], New South Wales [81, 111-
113] and Tasmania [114]. All of these studies were conducted in different states of Australia 







Studies that used newborn TSH marker 
Population studies using newborn TSH concentration in Victoria [115], Western Australia 
[52] and New South Wales [116] showed mild iodine deficiency consistent with results from 
median UIC in SAC and adults. Moreover, a cross-sectional study in northern Sydney  
(n = 84) in pre-fortification periods, showed mild iodine deficiency using the proportion of 
the population having newborn TSH concentration >5 mIU/L [117].  
 
Overall, studies using either median UIC or newborn TSH showed iodine deficiency in 
Australians in the pre-fortification periods. 
 
2.6.2 Iodine status post-fortification in the general population  
Iodine status by UIC marker 
Although Australia was classified as borderline iodine deficient in 2003-2004 [17], the iodine 
status of Australian children and non-pregnant women has changed to sufficient since the 
mandatory iodine fortification of bread in October 2009 [118]. Difference in iodine status of 
the population across all states and between major cities and inner regional areas has been 
observed in the Australian Health Survey in 2011-2012 [118]. This is the only national survey 
of iodine status of Australians since the fortification program took place. The samples were 
nationally representative and were collected using a multistage area sample design. Adult 
populations of Western Australia recorded the highest median UIC in the national survey 
post-fortification, followed by the Northern Territory and South Australia, respectively; while 
adults in Tasmania had the lowest median UIC [119]. However, UIC data were not collected 
in a representative sample of highly vulnerable population groups including infants, pregnant 






Iodine status by newborn TSH marker 
A study in Western Australia showed mild iodine deficiency after two years of the 
fortification program using TSH as a marker [52]. In the Western Australia study, newborns 
conceived after fortification were grouped with those born after fortification (they used June 
2010 as a cut-off). This may be the reason why the post-fortification group was classified as 
iodine deficient. The authors also reported a difference in the proportion of the population 
having TSH concentration >5 mIU/L while using blood samples collected at 3 and 4 days 
after birth, such that the proportion was higher in day 3 samples. These studies are reported by 
researchers and there has been no nationally representative survey in Australia before and 
after the implementation of the fortification program using newborn TSH as a marker.  
 
Monitoring of the iodine status of the population using multiple markers will contribute to 
early detection of IDD and enable appropriate public health measures to be put in place. 
However, little evidence is available as to whether overall Australia and South Australia, in 
particular, are iodine sufficient post-fortification by multiple markers. 
  
2.6.3 Iodine status in pregnant women in Australia: pre- and post-fortification  
As shown in Table 2.4, studies before the introduction of mandatory iodine fortification of 
bread, and the routine recommendation of taking iodine supplements, showed iodine 
deficiency in pregnant women in New South Wales [40, 81, 117, 119-121] and other states 
[122-124]. All of these studies showed mild to moderate iodine deficiency, in which the 
median UIC ranged from 24 μg/L to 109 μg/L. All studies were conducted using small sample 
sizes of less than 300 participants, except for a study in New South Wales by Travers et al. 
[40] using 796 participants. There had been no nationally representative studies of iodine 
status in pregnant women before mandatory iodine fortification of bread, and the extent of 




Following the introduction of the two strategies between 2009 and 2010 to improve iodine 
status, there was widespread renewed interest in the iodine status of pregnant women in 
Australia. Discrepant results were reported with iodine sufficiency reported in studies from 
South Australia [29] and New South Wales [119], but a deficiency in four studies [39, 125-
127], including a small study (n = 196) by Clifton et al. [39] in northern Adelaide among 
women of low SES, and a small number of pregnant women (n = 53) who participated in the 
Australian Health Survey in 2011-2012 [125]. The reason for the different levels of iodine 
status in pregnant women across states in Australia remains unclear. Disparities in dietary 
pattern and in the number of pregnant women taking iodine-containing supplements may 
contribute to variations in the median UIC across different regions. Pregnant women who did 
not take iodine-containing supplements were classified as iodine deficient with median UIC 
<150 μg/L post-fortification [39, 119]. The cost of iodine-containing supplements may 
constrain pregnant women from taking these supplements. However, women with the lowest 
SES had higher median UIC compared with women from the highest SES in the Australian 
Health Survey [125]. The success of both strategies to improve the iodine status of pregnant 
women remains uncertain in Australia.  
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Table 2. 4 Studies on iodine status of pregnant women in Australia in the pre- and post-fortification periods1  
 Author, year   Study design  Setting, year and GA of urine 
sample collection, sample size 
UIC Assessment 
methods  




study/comment   





March 2014 to November 2015  
All GA eligible 
n = 255 
Trimester 1 (0-13 weeks) n = 
42 
Trimester 2 (14-26 weeks) n = 
144 




All GA: 133 (82, 233) 
Trimester 1: 161 (92, 
233) 
Trimester 2: 137.5 
(81.5, 243) 
Trimester 3: 119 (78, 
185) 
Small sample size 
at each trimester   













93 (62, 171) Small sample size  




data from a 
prospective 
cohort  
South Australia  
August 2011 to December 
2012 
Assessments at study entry 
(<20 weeks) and 28 weeks of 
gestation 
n = 783 
Spectrophotometric 
method for UIC  
 
Median UIC 
20 weeks GA: 189  








health survey  
All states of Australia  
2011-2012 
Small number of pregnant 
women from the Australian 
health survey  
All GA aged 16-44 years  
n = 53  
Not reported  116  
 
Small sample size  
GA not reported  
Specific states 
not reported  
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5 Clifton, 2013 
[39] 
Multiple cross-
sectional survey  
Northern Adelaide, South 
Australia   
January 2009 to July 
2010  
GA at urine sample collection: 
12, 18, 30, 36 weeks  
n = 196 
Spectrophotometric 
method 
12 weeks: 73  
18 weeks: 68  
30 weeks: 84  
36 weeks: 118  
In women of low 
socio-economic 
status 





Regional area of NSW 
2008 (n = 110)  
2011 (n = 106) 
2012 (n = 95) 
All GA 
Spectrophotometric 
method for  
 
2008: 87.5 (62, 123.5) 
2011: 145.5 (91, 252)  




cross-sectional  North Western Sydney, NSW  
November 2007 to March 2009 
GA: 7-11 weeks  
n = 367  
ICPMS  81 (41, 169)  
8 Rahman, 2011 
[130] 
Cross-sectional 
analysis of a 
cohort study 
Gippsland, Victoria  January 
2009 to February 2010 
GA ≥28 weeks  
n = 86 (pre-fortification n = 24, 
post-fortification n= 62) 
Spectrophotometric 
method   
Pre-fortification: 96 
(45, 153)  
Post-fortification 95.5 
(60, 156 ) 








Darwin region, Northern 
Territory 
1987-1990 
 n = 24 
Spectrophotometric 
method   
49 (40, 72) Small sample size  
GA not reported 
 
10 Charlton, 2010 
[121]  




n = 110 
Spectrophotometric 
method   
 
 






11 Burgess, 2007 
[122] 
Cross-sectional  Tasmania  
Royal Hobart Hospital 
Pre-voluntary fortification 
October 2000 to September 
2001 
n = 285  
Post-voluntary fortification  
2006 n = 229 
Spectrophotometric 







2006: 86 (57, 160) 
Voluntary iodine 
fortification of 
bread was in 
place in October 
2001.  




Central Coast area, NSW 
March to June 2004 
GA ≥28 weeks 
n = 796 
Spectrophotometric 
method   
 
85 (range 19-1510 
μg/L) 
 
13 Hamrosi, 2005 
[123] 
Cross-sectional 
analysis of a 
prospective 
cohort study  
Melbourne, Victoria 
1998 - 2002 
Caucasian n = 277 
Indian/Sri Lankan n = 262  
Vietnamese n = 263 
In-house semi-
automated  
Caucasian: 52 (28, 80) 
Vietnamese: 58 (35, 
91)  
Indian/Sri Lankan: 61 
(30, 95) 
Participants were 
from a Down 
Syndrome 
screening study  
 
14 McElduff, 2002 
[117] 
Cross-sectional  Northern Sydney, NSW 
n = 84  
ICPMS 109 (65, 168)  
 
Small sample size  
GA not reported 
15 Li, 2001 [120] Cross-sectional  Sydney, NSW  
1998-1999 
Term pregnant women  
n = 101 
In-house semi-
automated 
88 (range 20-448 μg/L)  
16 Gunton, 1999 
[81] 
Cross-sectional  Sydney, NSW 
1998-1999 
n = 81  
ICPMS 104 (89, 129) Participants were 
from high-risk 
pregnancy clinic  
1Values are median (IQR) if not specified. GA, gestational age; ICPMS, Inductively Coupled Plasma Mass Spectrometry; IDD, iodine deficiency 
disorders; IQR, interquartile range; n, sample size; NA, not reported; NSW, New South Wales; UIC, urinary iodine concentration.  
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In summary, even though iodine intervention programs have been successful in improving the 
iodine status of the population in general [131], the effect of both interventions to improve the 
iodine status of pregnant women in Australia is inconclusive. Frequent monitoring of iodine 
status in pregnant women is important to prevent adverse effects of both inadequate and 
excessive iodine intake [132]. There is no nationally representative data on the iodine status 
of pregnant women in Australia, either overall or from low SES areas, using a representative 
sample. 
  
2.7. Association of iodine nutrition in pregnancy (as indicated by newborn TSH) with 
child neurodevelopment and growth 
This part of the literature review is presented in a systematic review form according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Checklist 




Iodine nutrition during pregnancy can affect newborn TSH concentration (TSH). Studies that 
assessed associations of newborn TSH with the neurodevelopment and growth of children are 
inconsistent. The literature on associations between newborn TSH and neurodevelopment and 
growth was systematically reviewed. Databases including PubMed, Scopus, CINAHL, 
Embase, PsycINFO, WHO and Iodine Global Network were searched for eligible studies. 
Seventeen studies were included. The studies applied different ways of newborn TSH 
classification to indicate iodine deficiency during pregnancy. Neurodevelopment was assessed 
using different tools in children aged 1-12 years of old. Most of the included studies had an 
inadequate adjustment for confounding or not adjusted for confounding. The associations 
between newborn TSH and cognitive development were negative in studies from iodine 
deficient populations, while null or negative associations were found in studies from iodine 
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sufficient populations. A null association was reported between TSH and psychomotor 
development regardless of iodine status. There was no evidence of an association between 
newborn TSH and child anthropometry, but evidence of negative association was found 
between newborn TSH and birthweight. The associations between newborn TSH and 
neurodevelopment may differ based on the iodine status of populations. Long-term follow-up 
studies that utilise newborn TSH data from newborn screening and adjust for potential 
confounding variables are required to identify the association between newborn TSH and 
neurodevelopment and growth in all settings.   
Key words: TSH, iodine, growth, development, child
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2.7.1 Introduction  
Thyroid Stimulating Hormone (TSH) is regulated by the hypothalamic-pituitary axis and 
modulates the synthesis of thyroid hormones thyroxine and 3, 5, 3/ tri-iodothyronine through a 
negative feedback mechanism [135]. Low thyroid hormone production increases TSH to 
stimulate the synthesis of thyroid hormones and vice versa. Thyroid dysfunction can affect 
thyroid hormone level, but both iodine deficiency and excess can also affect thyroid hormone 
synthesis [20]. Therefore, both thyroid dysfunction [136] and poor iodine nutrition during 
pregnancy [137] may lead to elevated TSH in pregnant women as well as their newborns.  
 
Newborn TSH concentration is used to screen children with congenital hypothyroidism (CH), 
mainly caused by inadequate thyroid hormone secretion in infants due to structural 
abnormality in their thyroid gland [138]. It is well known that children with untreated CH are 
at higher risk of impaired neurodevelopment and growth as thyroid hormones are required for 
optimal growth and neurodevelopment in early life [139]. 
 
Evidence showed elevated TSH even below the CH cut-off, which is TSH below <15 mIU/L 
from whole blood [140], associated with poor child neurodevelopment [86] and 
anthropometry [141]. Transient increase in newborn TSH concentration may also affect 
neurodevelopmental outcomes [142]. Identification of children at risk of impaired 
neurodevelopment may help for subsequent developmental screening and treatment [143]. 
Hence, newborn TSH concentration may be used as a potential screening tool for identifying 
children at risk of impaired neurodevelopment and growth [144]. Newborn TSH data can be 
obtained from routine newborn screening databases in countries where newborn screening 
programs are practised. 
 
To the best of our knowledge, a review by Bougma et al. [145] was the only published review 
that assessed associations between newborn TSH and neurodevelopment of children under 
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five years of age, but this review did not include the associations of newborn TSH with child 
growth. The review showed that children with elevated TSH or with CH had poorer mental 
development compared with children with normal TSH or without CH. While the review 
included a meta-analysis, half of the studies (4/8 included studies) were on children born with 
CH. Hence, the relationship between newborn TSH and neurodevelopment in children 
without CH is uncertain as there may be different causes for elevated TSH. That review 
combined studies that used infant blood TSH and cord blood TSH as well as newborn TSH 
and infant thyroxine in the meta-analysis. A subgroup analysis including by the degree of 
iodine status (iodine deficiency, sufficiency and excess) was also not performed [145].  
 
Whether the association between newborn TSH and child development differ by iodine status 
of populations remain unclear [143]. Furthermore, the newborn TSH cut-off associated with 
poor developmental or anthropometric scores is unclear. Hence, this systematic review 
examined the association between newborn TSH concentration and child neurodevelopment 
and growth in different settings. 
  
2.7.2 Methods  
Study Selection  
Studies that reported the relationship between newborn TSH concentration (from either infant 
or cord blood) and the development or education performance or growth of children, were 
included. Participants were children up to 18 years of age. Studies assessing the association 
between TSH concentration and development and growth in children with newborn errors of 
metabolism including CH were excluded. Studies with newborn TSH data obtained from 
either the newborn screening database or measured as part of the studies were eligible. 
Neurodevelopmental outcomes included cognitive, motor and behavioural outcomes. Studies 
were included in anthropometry outcomes if they reported any measures of weight, length, 
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head circumference, waist circumference and skinfolds, or converted such measures into  
z-scores. 
 
Data sources and Search strategy 
A systematic literature search was conducted in June 2018, then last updated in August 2019. 
Databases including PubMed, Embase, PsycINFO, Scopus, Cumulative Index to Nursing and 
Allied Health Literature (CINAHL) and WEB OF SCIENCE were searched and the search 
was limited to the English language. The World Health Organization (WHO) and Iodine 
Global Network databases were also reviewed. The key terms applied in database search 
included: TSH, thyrotropin, thyroid stimulating hormone, iodine, iodides, iodate, iodine 
deficiency, iodine status, transient neonatal hyperthyrotropinemia and hypothyroxinaemia, 
child development, Bayley outcomes, cognition, intelligence, motor skills, psychomotor 
performance, IQ, neurological development, cognition disorders, cognitive function, neural 
development, intellectual disability, post-natal/postnatal development, memory, executive 
function, mental process, learning, child behaviour, developmental delay, brain, language, 
growth, child anthropometry, weight, height and head circumference. The search was 
conducted using the predefined search strategy in all selected databases. Details of the search 
strategies for each database are depicted in Supplemental Table 2.1. 
 
Data extraction 
All retrieved articles were exported to an Endnote Library. After removing duplicate records, 
eligibility of articles was screened by title and abstract (by MMW). A further review of full-
text articles was performed to determine eligibility in studies with insufficient information in 
the abstract to judge for eligibility. Uncertainties in eligibility were resolved by discussion 
with a co-author (SJZ). MMW extracted the data using a data extraction form. Data on the 
first author, year of publication, the country where the study was conducted, study design, 
iodine status of the study population, sample size, exposure assessment (the type of blood for 
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newborn TSH assessment and age at blood sampling), outcome assessment (type, 
measurement or scale and age at assessment), measures of association and effect size (small 
and adequate), and information on adjustment of confounders were extracted. The key 
confounders of neurodevelopment and growth identified from the literature include maternal 
socio-economic status, maternal smoking, home environment, maternal IQ, maternal body 
mass index and dietary intake, gestational age, birthweight and infant’s age at TSH 
assessment. 
   
Quality of evidence  
We used the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) 
assessment tool [146] to assess the quality of evidence. The ROBINS-I tool has seven 
domains to assess the risk of bias in included studies. The domains include confounding, 
selection bias, bias in classification of interventions, bias due to deviations from intended 
interventions, missing data, bias in the measurement of outcomes and in the selection of the 
reported result (Supplemental Table 2.2). 
  
Data analysis  
The analysis was performed according to the analysis plan [134]. A narrative synthesis was 
performed when data were not suitable for meta-analysis. Studies were classified based on 
newborn TSH concentration and neurodevelopmental domains. Meta-analysis was performed 
to assess associations between TSH and outcomes when TSH was treated as a continuous 
variable or classified based on different categories (dichotomised to <5 vs ≥5 mIU/L or in 
quartiles. Meta-analysis was performed separately for different neurodevelopmental domains. 
  
Meta-analysis was performed using STATA. Random effects models were used to synthesise 
results in a meta-analysis as the included studies were heterogeneous. Heterogeneity between 
the studies was assessed by I2 and classified as low (I2 : <25%), moderate (I2: 25-75%) and 
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high (I2: >75%) [147, 148]. If the included studies reported effect measures, we used them in 
the meta-analysis as reported by the original studies (odds ratio (OR) or Coefficient). When 
effect measures were not reported, effect size as Hedges’ g (g) with 95% CIs was calculated 
to include the studies in the meta-analysis [149, 150]. The 95% CI of effect size were 
calculated from p values when any measures of variance were not reported [151]. 
Classification of effect sizes was based on literature rather than using the small (~0.2 standard 
deviation (SD)), medium (~0.5 SD), and large (~0.8 SD) classification suggested by Cohen 
[152]. In nutrition literature, a five-point difference on average in the neurodevelopmental 
score between children with adequate vs deficient iodine or iron intake was considered as 
clinically significant [70, 153, 154]. The effect size (g) reported can be converted into points 
on a standardised neurodevelopmental scale by multiplying with a SD of 15 as a standardiser. 
The minimum sample size required to detect a five-point (or standardised neurodevelopment 
points = 0.33) difference (SD = 15 points, two-tailed α = 0.05 and Power = 90%) in a 
standardised neurodevelopmental scale between children with normal TSH or adequate 
maternal iodine intake during pregnancy vs elevated TSH or deficient/excess maternal iodine 
intake during pregnancy was 388 participants. Therefore, studies that had a sample size of less 
than 388 participants were considered as small. 
 
The risk of bias was reported as low, moderate, serious and critical at domain and study level. 
Studies were classified as low risk of bias if all domains had a low risk of bias and are 
considered as comparable to well-performed RCT; moderate risk of bias if all domains had a 
mixed of low or moderate risk of bias and studies cannot be considered as comparable to a 
RCT; serious risk of bias if at least one domain had a serious risk of bias; and critical if at 
least one domain had a critical risk of bias [146].  
 
Narrative synthesis, as well as meta-analyses, were performed according to 1) the types of 
blood for TSH assessment (infant’s blood or cord blood). 2) Level of TSH elevation 
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(Dichotomised to TSH <5 vs ≥5 mIU/L or normal TSH vs transient neonatal 
hyperthyrotropinemia (TNH)). TNH was defined as a transient elevation of TSH 
concentration, even a TSH value higher than the CH cut-off, after 2 days of life but returns to 
the normal range at re-examination without treatment [155]. Classification of newborns for 
TNH was based on authors’ reports, and the TSH cut-off to classify newborns with TNH may 
differ across studies. 3) Types of neurodevelopmental scale (cognitive, psychomotor, 
language or behaviour). If two or more items were reported for each domain of 
neurodevelopmental assessment, the combined score was used for the meta-analysis. 4) 
Iodine status of the study population (iodine deficient vs sufficient). We used the country-
level iodine status data from the WHO database [156, 157] if available, if not, we used the 
Iodine Global Network data [158, 159] to classify iodine status of the study populations. If 
country-level data were not reported in either of the two databases, we used the authors’ 
reports. 
 
2.7.3 Results  
2.7.3.1 Characteristics of the included studies  
As shown in Figure 2.1, a total of 3,984 records were identified in database searching and 17 
were eligible for inclusion. As depicted in Table 2.5, a majority of the studies reported TSH 
from the infant’s blood and used standard scales to assess neurodevelopment. The age range 
for the neurodevelopmental assessment was between 1 and 12 years of age, and birth to 6 



















































Figure 2. 1 PRISMA Flow Diagram for selection of studies.  
Records identified through database searching  
(total n = 3984) 
PubMed (n = 2444) 
CINAHL (n = 293) 
Scopus (n = 199) 
PsycINFO (n = 282) 
Web of science (n = 416) 
Additional records identified 
through other sources  
(n = 6) 
Records after duplicates removed  
(n = 3571) 
Records screened by abstract  
(n = 244) 
Records excluded, with 
reasons (n = 200) 
- Studies during pregnancy 
that assessed iodine status 
by other markers (n=72) 
- Studies during childhood 
that assessed iodine status 
by other markers (n=120) 
Full-text articles assessed for eligibility  
(n = 44) 
Full text articles excluded, with 
reasons (n = 27) 
- Late (after one month) 
exposure assessment (n = 4) 
- Incorrect participants (n = 2)  
- Incorrect exposure (n = 21) Studies included in qualitative synthesis  
(n = 17) 
Studies included in quantitative synthesis 
(meta-analysis)  
(n = 3) 
Records excluded (n = 3327) 
Not relevant by screening of 
title or further duplicates.   
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2.7.3.2 Risk of bias assessment  
Using the ROBINS-I tool, eight studies [86, 160-166] had a moderate risk of bias and nine 
[141, 142, 167-173] had a serious risk of bias. The main reasons for bias were: 1) did not 
control confounding or had an inadequate adjustment for confounding 2) used an arbitrary 
classification of exposure or did not describe the actual TSH cut-off points to define TNH, 
and 3) did not account for missing data. Full details of the risk of bias assessments are shown 
in Supplemental Table 2.3. 
  
 2.7.3.3 Associations between TSH concentration and neurodevelopment  
Studies using TSH concentration from newborns blood  
Cognitive outcome  
As shown in Table 2.5, ten studies [86, 141, 142, 160, 161, 167, 169-172] reported 
associations between newborn TSH concentration and cognitive development. Of studies 
conducted in iodine deficient populations (5/10), the associations were negative in 4/5 studies 
[86, 167, 169, 170] and null in one study [160]. Of the studies in iodine sufficient populations 
(5/10), the associations were null in 3/5 studies [141, 171, 172], negative in one study [142] 
and both low (<5 mIU/L) and high (>10 mIU/L) TSH was associated with poorer outcome in 
one study [161].  
 
Only three studies (n ranged from 61 to 691) compared with the mean cognitive scores 
between two TSH categories: ≥5 mIU/L vs <5 mIU/L. Figure 2.2 displays a meta-analysis on 
three studies. In two studies from iodine deficient populations, children with newborn TSH 
concentration ≥5 mIU/L had 0.41 SD (equivalent to 6 cognitive points) lower cognitive score 
on average compared with children whose newborn TSH concentration was <5 mIU/L (g: -
0.41; 95% CI: -0.74, -0.09; I2 = 56.0%). However, a null association was found between the 
two TSH categories (g: 0.22; 95% CI: -0.02, 0.46) in a study from an iodine sufficient 
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population. In the pooled result across all three studies, there were no difference in mean 
cognitive scores between the two categories. 
 
 
Figure 2. 2 Associations between dichotomised TSH from infant blood (≥5 mIU/L vs <5 
mIU/L) and cognitive scores.  






Table 2. 5 Summary of key literatures for associations between newborn TSH and neurodevelopment  
 Author, year, 
Country   
Design and setting TSH assessment  Neurodevelop
ment 
assessment  
Key Finding Limitations/gap of 
the study/comment   
 Studies on Infant 
blood  
     
1 Riano Galan, 2005 
[167], Northern 
Spain  
Prospective cohort  
N = 61  






3 days of age   
 
G1: >5 mIU/L (n 
= 12) 











memory and  
motor  
MSCA scores:  
Verbal (± SD): 53.8 ± 7.4 
G1 = 49.2 (n = 12), G2 = 
56.9 (n = 49); P >0.05 
Perceptual (± SD): 52.9 ± 
8.7 
G1 = 48.6 (n = 12), G2 = 
54.2 (n = 49); P <0.05 
Quantitative: 46.9 ± 7.2 
G1 = 43.7 (n = 12), G2 = 
47.3 (n = 49); P >0.05 
Cognitive general index (± 
SD): 103.1 ± 11.6 
G1 = 95.1 (n = 12), G2 = 
104.9 (n = 49); P <0.05 
Memory (± SD): 48.7 ± 8.1  
G1 = 43.1 (n = 12), G2 = 
50.1 (n = 49); P <0.05 
Motor (± SD): 54.6 ± 9.9   
G1 = 50.9 (n = 12), G2 = 
55.1 (n = 49); P >0.05 
Small sample size.  
Did not adjust for 




2 Murcia, 2011 [160], 
Spain  
Cohort  
N = 691 
Children from the 
INMA population 
based cohort in 
Valencia  
Healthy infants  
1-7 days  
 
G1: TSH >4 
mIU/L (n = 28) 
G2: TSH ≤4 
mIU/L (n = 652) 
Bayley-I 
 




MDI (n = 669):  
G1: 96.2 ± 17.0  
G2: 100.2 ± 14.9 
 
PDI (n = 669):  
G1: 95.8 ± 15.4 
G2: 100.3 ± 15.0 
Did not adjust for 
maternal IQ and 
home-environment. 
N for Bayley-I 
assessment was not 




 Author, year, 
Country   
Design and setting TSH assessment  Neurodevelop
ment 
assessment  
Key Finding Limitations/gap of 




Delay (<85) vs 




G1: β = -3.2 (-8.9, 2.6) 
G1: OR = 1.4 (0.5, 3.7)  
3 Belcari, 2011 [169], 
Italy  
Cohort  
N = 55 
Preterm infants 
admitted to the 
neonatal intensive 





3-4 days of life 
 
G1: TSH >4.3 
mIU/L (n = 10) 
G2: TSH <4.3 









OR (95% CI)  
G1 (n = 10): 14.6 (2.49, 
86.02) 
 
Ref: G2 (n = 45) 
 
Small sample size. 
Confounders like 
maternal IQ were 
not controlled.  
 
4 Costeira, 2011 
[170], Portugal 
Cohort  
N = 86 
Healthy term infants  
Hospital setting 









3 days of age  
 







r = -0.27 (n = 86) 
d= -0.56082901 
 
Small sample size 
Only correlation test 
was conducted.  
Mean TSH and MDI 
were not reported.  
Outcome assessment 
were not blinded. 
 
 
5 Korzeniewski, 2014 
[141],  
ELGAN Multicentre 
study, US  
Cohort  
N = 120 
Hospital setting 
14 days of age  
 
G1: newborns 
with TNH   
BSID-II  
2 years  
 
OR, 95% CI (n = 120) 
Mental delay 
 G1: 1.2 (0.8, 1.9) 
Motor delay 
Preterm infants. 
Late TSH sampling 




 Author, year, 
Country   
Design and setting TSH assessment  Neurodevelop
ment 
assessment  
Key Finding Limitations/gap of 
the study/comment   
Preterm infants (GA 











G1: 1.3 (0.9, 2.0) and age at sampling 
was not considered 
in the analysis. 
Did not adjust for 
SES, maternal IQ 
and home 
environment. 
The TSH value for 
each quartile cut-
points was not 
reported.  
6 Cuestas, 2015 [142], 
Argentina 
Prospective cohort  
N = 250 
Healthy infants  
Excluded: preterm 
birth, birthweight 
<2500 g, Down’s 
syndrome, 
descendants of 


























N, % for developmental 
delay (95% CI) 
G1: 15/65 (23%, 95% CI 12, 
34.1)  
G2: 21/185 (11.3%, 95% CI 
6.5, 16.2)  
P = 0.03 
 
G1: Crude OR 95% CI 
2.0 (1.0, 4.2) P = 0.05 (n = 
65) 
 
NB: OR was not reported 
(crude OR calculated 
manually by the reviewers).  
Outcome from 
parents report.  
Did not adjust for 




7 Trumpff, 2015 
[161], Belgium 
Retrospective cohort  
N = 315  
Healthy infants from 
the PsychoTSH study 
Exclusion criteria: 
LBW, preterm, CH or 
3-5 days of age 
 
G1: <5 mIU/L (n 
= 198) 








Mean ± SD  
Full Scale IQ: 
G1: 95.9 ± 16.9 (n = 198) 
G2: 99.4 ± 14.2 (n = 102) 
G3: 88.9 ± 26.1 (n = 11) 
P = 0.06 
On highly educated 






 Author, year, 
Country   
Design and setting TSH assessment  Neurodevelop
ment 
assessment  
Key Finding Limitations/gap of 





population   
G3: ≥10 mIU/L (n 
= 11) 
 Performance IQ:  
G1: 98.0 ± 16.3 (n = 198) 
G2: 99.4 ± 13.1 (n = 102) 
G3: 94.5 ± 21.6 (n = 11) 
P = 0.53 
Verbal IQ:  
G1: 94 ± 19.8 (n = 198) 
G2: 100.8 ± 14.2 (n = 102) 
G3: 86.7 ± 22.8 (n = 11) 
P = 0.006 
The effect measures 
from the regression 
models were not 
reported. 
N for G3 was very 
small   
8 Trumpff, 2016 
[168], Belgium 
Retrospective Cohort  
N = 310 
Healthy infants from 
the PsychoTSH study 
Exclusion criteria: 






3-5 days  
 
G1: ≥5 mIU/L (n 
= 113) 









Mean (SD) score  
G2 = 48.6 (10.3) (n = 197) 
G1 = 46.9 (9.7) (n = 113) 
P = 0.15 
CBCL, β (SE) 




Did not adjust for 
home environment 
and maternal IQ. 
9 Trumpff, 2016 
[162], Belgium 
Retrospective cohort  
N = 284 
Healthy infants from 
the PsychoTSH study 
Exclusion criteria: 






3-5 days  
 















β (95% CI) 
- Total motor score :  
0.04 (-0.01 to 0.09) 
P = 0.10 
- Objective motor score:  
 0.02 (-0.02 to 0.07)  
P = 0.26 
- Subjective motor score:  
0.03 (-0.01 to 0.08)  
P = 0.11 
Multiple imputation 
was performed.  
Did not adjust for 
home environment 
and maternal IQ. 
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 Author, year, 
Country   
Design and setting TSH assessment  Neurodevelop
ment 
assessment  
Key Finding Limitations/gap of 
the study/comment   
1
0 
Lain, 2016 [86], 




newborn TSH data 
(1994-2008) 
 
N of infants linked 
with AEDC = 149 
569 
 
N of infants linked 







deficient population  
 
Cut-off for CH 
was 20 mIU/L 
 







(<~4 mIU/L)  




























below 10% in 







Numeracy performance [OR 
95% CI]  
G2: 1.57 (1.29, 1.90) (n = 
1378) 
Reading [OR 95% CI]   











Developmentally high risk 
[OR 95% CI]   
G2: 1.52 (1.20, 1.93) (n = 
510)  
 
Special needs [OR 95% CI] 




score for educational 
outcomes was not 
described.  
National minimum 
value was not 
reported. 
Infants lost to follow 
up for outcome 
assessment but 




by teachers.  
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 Author, year, 
Country   
Design and setting TSH assessment  Neurodevelop
ment 
assessment  
Key Finding Limitations/gap of 
the study/comment   
1
1 




day 21 (N = 749) and 
day 28 (N = 697) 
Hospital setting  






21 days  
28 days  
 
G1: Newborns 
with TNH   














OR, 95% CI 
 
MDI (scores <55) 
G1 (Day 21): 1.1 (0.7, 1.7) 
G1 (Day 28): 1.2 (0.8, 1.9) 
 
MDI (scores 55-69) 
G1 (Day 21): 1.1 (0.6, 1.8) 
G1 (Day 28): 1.0 (0.6, 1.7) 
 
PDI (scores <55) 
G1 (Day 21): 1.1 (0.7, 1.8) 
G1 (Day 28): 1.3 (0.8, 2.1) 
 
PDI (scores 55-69) 
G1 (Day 21): 1.0 (0.6, 1.5) 
G1 (Day 28): 1.0 (0.6, 1.6) 
 
Preterm infants. 
Late TSH sampling 
outside the WHO 
recommended range 
and the late 
sampling was not 
considered in the 
analysis.    
Did not adjust for 
SES, maternal IQ 
and home 
environment. 
The TSH value for 
each quartile cut-
points was not 
reported.  
N for G1 and G2 




Kuban, 2017 [172], 
ELGAN Multicentre 
study, US  
Prospective cohort 
N = 873  
Hospital setting  
Preterm infants  
 
Iodine sufficient 
population   
 
First 1 month  
 
G1: elevated TSH 
(n = 164) 
G2: normal TSH 









DASS IQ z 
score  
-2 to ≤-1 SD 
≤-2 SD  
OR (95% CI) 
DASS IQ -2 to ≤-1 
z score 
G1: 1.0 (0.6, 1.5) (n = 164) 
DASS IQ ≤-2 z score  
G1: 1.2 (0.7, 1.9) (n = 645) 
 
On extremely 
preterm infants.  
Late TSH sampling 
outside the WHO 
recommended age 
range.  
Did not adjust for 
home environment, 
SES, and Maternal 
IQ.   
The TSH value for 




 Author, year, 
Country   
Design and setting TSH assessment  Neurodevelop
ment 
assessment  
Key Finding Limitations/gap of 
the study/comment   
 Studies on Cord 
blood TSH  
     
1 Calaciura,1995 
[163] Sicily, Italy 
Retrospective cohort  
N = 18  
Healthy infants  
Participants were 
from  




G1: elevated TSH 
due to TNH (TSH 
>50 mIU/L), (n = 
9) 
G2: normal TSH 
(TSH <10 
mIU/L), (n = 9) 
WISC-revised 
  
8.5 y  
 
IQ (GIQ, VIQ, 
PIQ) 
GIQ 
G1: 78.3 ± 11.1 (n = 9)  
G2: 90.9 ± 14.2 (n = 9) 
P <0.05 
VIQ 
G1: 84.4 ± 15.4 (n = 9) 
G2: 96.2 ± 14.8 (n = 9) 
P >0.05 
PIQ  
G1: 75.0 ± 8.5 (n = 9) 
G2: 89.2 ± 12.5 (n = 9) 
P <0.01 
Small sample size  
Did not adjust for 




2 Azizi, 2001 [164], 
Iran  
Historic cohort 
N = 37  
Healthy infants  





with TNH (TSH 




(TSH <5 mIU/L), 
(n = 19) 
Raven 
 











G1: 98 ± 11 (n = 18) 





Psychomotor performance  
No correlation between 
serum TSH and 
psychomotor performance  
 
Non-representative 
sample (no sample 
size calculation). 
Did not adjust for 
SES, maternal IQ 
and home-
environment.    









N = 284 
Full-term and normal 
birthweight infants  
Community setting  
 
Continuous (all 
newborns, n = 
275) 
 G1 (TSH <5 
mIU/L) (n = 58) 
FTI-I  
 
7 months  
 
Information 
processing task  
Continuous exposure  
Information processing 
skills: β = -0.14, P <0.05) 
95% CI (-0.21, -0.08) 
MDI: β = -0.34, P <0.05) 
95% CI(-0.50, -0.18) 
Follow-up not long 
enough for outcome 




 Author, year, 
Country   
Design and setting TSH assessment  Neurodevelop
ment 
assessment  
Key Finding Limitations/gap of 
the study/comment   
Mild Iodine deficient 
population   
G2 (TSH 10.0-
19.9 mIU/L) (n = 
94) 
G3 (TSH 20.0-
29.9) (n = 82) 
G4 (TSH ≥30 








PDI: β = not reported, P = 
0.56 
 
Categorical exposure  
Information processing 
skills: 
G1 (n = 58) = 59.6 ± 3.0 
G2 (n = 94) = 58.9 ± 4.3 
G3 (n = 82) = 57.7 ± 5.6 
G4 (n = 41) = 57.5 ± 3.1 
MDI 
G1 (n = 58) = 102.5 ± 8.2 
G2 (n = 94) = 98.2 ± 8.3 
G3 (n = 82) = 98.7 ± 9.3 
G4 (n = 41) = 93.5 ± 11.1 
PDI 
G1 (n = 58) = 102.7 ± 11.3 
G2 (n = 94) = 105.1 ± 12.2 
G3 (n = 82) = 107.8 ± 13.9 
G4 (n = 41) = 104.8 ± 12.1 
4 Freire, 2010 [166], 
Spain  
Prospective cohort  




Healthy infants  
Excluded: mothers 









Per unit increase 
in TSH  
 
Categories 















Continuous exposure  
General cognitive (β)  
-3.52 (-6.81, -0.23) 
Memory (OR)  
1.61 (0.60, 3.80) 
Motor skills (OR)  
0.65 (0.32, 1.47) 
Fine motor 
1.48 (0.63, 3.66) 
Gross motor 
0.69 (0.26, 1.99)  
Executive function (β)  
None representative 
sample (only boys). 
Did not control 
maternal IQ. 
N was not reported 
for each TSH 
category.  
More than one effect 
measure used to 
report results.   
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 Author, year, 
Country   
Design and setting TSH assessment  Neurodevelop
ment 
assessment  
Key Finding Limitations/gap of 










function)    
Developmental 
delay vs 
normal   
Continuous 
scores   
-3.15 (-6.66, -0.19) 
Categorical exposure  
General cognitive (B) 
G2: -0.36 (-6.29, 5.67) 
G3: -3.03 (-8.78, 2.74) 
G4: -5.42 (-11.30, -0.61) 
Memory (OR) 
G2: 0.83 (0.13, 3.60) 
G3: 0.92 (0.18, 3.74) 
G4: 3.51 (0.65, 15.26) 
Motor skills (OR) 
G2: 0.39 (0.11, 1.87  
G3: 0.42 (0.13, 1.73) 
G4: 0.80 (0.24, 3.10)  
Executive function  
G2: -0.30 (-6.51, 5.96) 
G3: -3.37 (-9.46, 2.56) 
G4: -4.29 (-10.56, 1.86) 
Abbreviations: AEDC, Australian Early Development Census; BSID, Bayley Scales of Infant Development; CBCL, Child Behaviours Check 
List; CI, confidence internal; CH, congenital hypothyroidism; DAS, Differential Ability Scale; ELGAN, extremely low gestational age 
newborns; FIQ, full intelligence quotient; G, group; GA, gestational age; ID, intellectual disability; IQ, intelligence quotient; MDI, mental 
development index; MSCA scores, McCarthy scales of children’s abilities, N, sample size; NAPLAN, National Assessment Program Literacy 
and Numeracy; OR, odds ratio; P, p value; PARCA, Parent Report of Children’s Abilities; PDI, Psychomotor developmental index; PIQ, 
performance IQ; RR, risk ratio; SBIS, Stanford–Binet Intelligence Scale; TNH, transient neonatal hyperthyrotropinemia; VIQ, verbal IQ; WISC, 
Wechsler Intelligence Scale for children; WPPSI, Wechsler Preschool and Primary Scale of Intelligence 
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Five studies compared the odds of cognitive delay between newborns who had TNH and 
newborns without TNH at birth were pooled in a meta-analysis (Figure 2.3). Children with 
TNH had 33% higher odds of developmental delay (OR: 1.33; 95% CI: 1.10, 1.63; I2 = 
12.6%) compared with children without TNH in a pooled analysis of studies from both iodine 
deficient and sufficient populations. However, 3/5 studies [141, 171, 172] in the pooled meta-
analysis were in preterm newborns. Besides the results of developmental delay included in the 
pooled meta-analysis, the population-based study in Australia [86] showed that infants in the 
highest percentile of TSH approaching the CH screening cut-off had higher odds of poor 
educational performance. The study reported that infants whose TSH concentration was 
between the 99.5th and 99.9th percentile (~7-12.4 mIU/L) had a 1.6 higher odds of poor 
numeric performance (OR: 1.57; 95% CI: 1.29, 1.90) and a 1.4 higher odds of poor reading 
score (OR: 1.42; 95% CI: 1.18, 1.69) than infants with <75th TSH percentile (equates TSH 
concentration <~4 mIU/L).  
 
Two small studies were not suitable for meta-analysis. The first study [169] (n = 55) showed 
higher odds of composite mental development delay (OR: 14.6; 95% CI: 2.5, 86.0) at 18 
months corrected age in children with TSH >4.3 mIU/L compared with TSH <4.3 mIU/L and 
the other study [170] (n = 86) showed a negative correlation between newborn TSH and 





Figure 2. 3 Associations between TNH defined by elevated TSH from infant blood and 
cognitive delay.  
CI, confidence interval; OR, odds ratio; TNH, transient neonatal hyperthyrotropinemia; TSH, 
thyroid-stimulating hormone.  
 
Psychomotor outcome  
All included studies that reported psychomotor outcomes (5/5) showed a null association 
between newborn TSH concentration and psychomotor development and 3/5 [160, 162, 167] 
were in full-term infants while 2/5 [141, 171] were in preterm infants. Data were not suitable 
for one pooled meta-analysis as the included studies assessed newborn TSH in different ways 
which include <5 mIU/L vs ≥5 mIU/L categories (Riano Galan et al., 2005, Murcia et al., 







Adaptive behaviour and social emotional outcomes  
The only study [168] (n = 310) that assessed psychosocial development at 4-5 years of age 
reported a null association between newborn TSH concentration and psychosocial 
development.  
 
Studies using TSH concentration from cord blood  
Cognitive outcome  
All of the studies (4/4) [163-166] reported a negative association between cord blood TSH 
and cognitive development. Meta-analysis was performed on two studies that compared 
infants with TNH and without TNH and Figure 2.4 reports children with TNH had 0.88 SD 
(equivalent to 13.2 cognitive points) lower cognitive score on average compared with children 
without TNH (g: -0.88; 95% CI: -1.44, -0.33; I2 = 0%) irrespective of iodine status in the 
study populations. Based on the pooled analysis from two studies [165, 166] that analysed 
TSH as a continuous exposure, a 1 mIU/L increase in cord blood TSH was associated with a 







Figure 2. 4 Associations between TNH defined by elevated TSH from cord blood and 
cognitive scores.  
CI, confidence interval; SMD, standardise mean difference; TNH, transient neonatal 
hyperthyrotropinemia; TSH, thyroid-stimulating hormone.   
 
 
Figure 2. 5 Associations between cord blood TSH as continuous exposure and cognitive 
scores.  





The studies in iodine deficient populations showed negative [166] or null [165] association 
while the study from the iodine sufficient population reported a null association [164]. 
 
2.7.3.4 Associations between newborn TSH and child anthropometry   
As depicted in Table 2.6, 4 studies reported anthropometric outcomes. Two studies reported 
associations between newborn TSH and head circumference at birth [141] and 2 years of age 
[171] and showed a null association, one study (n = 250) [142] assessed associations between 
newborn TSH and child anthropometry at 6 years of age and showed no associations, and one 
study (n = 616) [173] assessed the correlation between cord blood TSH and anthropometric 
outcomes at birth and showed no correlation. One of the studies [141] showed newborns at 
the highest TSH quartile had a 2.2 higher odds of a birthweight z score <-2 SD (OR: 2.2; 95% 
CI: 1.2, 4.1) compared with infants in the lower three TSH quartiles.  
49 
 
Table 2. 6 Summary of key literature for assessment of associations between TSH and growth1  
 Author, year, 
Country   
Design, sample size, 
setting, iodine status 
of country/region  
TSH 
assessment(type 
of blood, age at 
assessment, 




tool, age in 
years at 
assessment 
Outcome type   
Key Finding Limitations/gap of 
the 
study/comment   
1 Shields, 2011 
[173], UK 
Cohort  
N = 616 
Healthy infants 
participated in the 
Exeter Family Study 






Mild iodine deficient 
population   




Birthweight   







At birth  
Fetal growth  
Birthweight (r = 0.04; P 
>0.05),  
Birth length (r = -0.02; P 
>0.05),  
Birth head circumference (r = 
0.05, P >0.05) 
Sum of skinfolds (r = -0.02; P 
>0.05).  




long enough for 









N = 120 
Hospital setting  
Preterm infants  





Newborn TSH  
14 days of age  
 
G1: newborns at 
4th TSH quartile   
G2: newborns at 









e z score <-2 
SD 
OR (95% CI)  
Low birthweight  
G1:2.0 (1.3, 2.9) 
Birthweight z score <-2 SD  
G1:2.2 (1.2, 4.1) 
Head circumference z score 
<-2 SD  




sampling and did 
not considered in 
the analysis.  
Did not adjust for 
SES. 
The TSH value for 
each quartile cut-





3 Cuestas, et al 
2015 [142] 
Argentina  
Prospective cohort  
N = 250 
Healthy infants  
 
Iodine sufficient 
population   
 
Newborn TSH  








<10 mIU/L) (n = 
185) 
Weight  
Height   
 
6 years  
Height 
G1: 110.3 ± 16.8  
G2: 109.5 ± 17.1  
P = 0.74 
Weight G1:19.6 ± 1.7  
G2:19.3 ± 1.5  
P = 0.21 








day 21 (N = 749) 
and day 28 (N = 
697) 
Hospital setting  
Preterm infants  





Newborn TSH  
21 days  
28 days  
 
G1: newborns at 
4th TSH quartile   
G2: newborns at 




score <-2 SD 
 
2 years  
 OR, 95% CI 
Day 21 
G1: 1.1 (0.7, 1.8) 
Day 28) 
G1: 1.6 (0.9, 2.6) 
Preterm infants. 
Measurement bias 
due late TSH 
sampling and 
confounding due 
to not considering 
late sampling in 
the analysis.    
Did not adjust for 
SES, maternal IQ, 
and home 
environment. 
The TSH value for 
each quartile cut-
points was not 
reported. 
1CI, confidence internal; ELGAN, extremely low gestational age newborns; GA, gestational age; N, sample size; OR, odds ratio; RR, risk ratio; 





2.7.4 Discussion  
Overall, the association between newborn TSH and neurodevelopmental outcomes was 
inconclusive. Higher newborn TSH was associated with lower cognitive developmental 
scores in studies from mild-to-moderate iodine deficient populations, while a null association 
was observed in studies from iodine sufficient populations, however, this results should be 
interpreted with caution as all the studies were assessed as having a moderate or serious risk 
of bias. Studies using the cord blood TSH as the exposure measure showed a negative 
association between TSH and cognitive development regardless of the population iodine 
status. We found a null association between TSH and psychomotor development. Although 
few studies assessed associations between TSH and anthropometry, there was evidence of 
lower anthropometric outcomes at birth in children with elevated TSH at birth, but this may 
not affect long-term growth.  
 
Among iodine deficient populations, the finding of the negative association between newborn 
TSH and neurodevelopment may be attributable to poor maternal iodine intake in pregnancy. 
There is evidence of negative consequences of severe [145, 174] and mild-to-moderate iodine 
deficiency [96] in pregnancy on child development. While meta-analysis was planned, only 
two studies [160, 167] (n = 752) with moderate and serious risk of bias in iodine deficient 
populations that dichotomised TSH to ≥5 mIU/L vs 5 mIU/L were suitable for the meta-
analysis. The result showed that children with TSH ≥5 mIU/L had six cognitive points lower 
than infants with TSH <5 mIU/L. Even though there was no established TSH cut-off to 
classify iodine status at individual-level, children with mildly elevated newborn TSH 
concentration above 5 mIU/L or increased TSH concentration due to TNH showed lower 
cognitive performance in most studies included in the review. A new newborn screening cut-
off, which considers the risk of impaired neurodevelopment due to mildly elevated newborn 





needs to be established [143]. Therefore, until the new newborn screening cut-off is 
established, infants with mildly elevated newborn TSH concentration ≥5 mIU/L in iodine 
deficient populations could benefit from continuous monitoring and early intervention, as 
needed, to prevent cognitive impairments in childhood. 
 
The null findings in the iodine sufficient populations could be due to change in the 
distribution of TSH concentration as there is a transient increase in newborn TSH following 
the change in iodine status of populations from deficiency to sufficiency [82]. However, 
identifying the TSH threshold where the association between TSH and neurodevelopmental 
scores was lost is beyond the scope of the review. In iodine sufficient populations, maternal 
iodine status during pregnancy, defined as iodine-to-creatinine ratio <150 µg/g or UIC <150 
µg/L, were not associated with non-verbal IQ and language development [175, 176]. An 
infant’s thyroid gland is sensitive to both deficient and excess levels of iodine intake during 
pregnancy [177]. Therefore, in iodine sufficient populations, the mild TSH elevation or TNH 
may not be due to iodine deficiency and may be associated with higher iodine intake from 
iodine-containing supplements during pregnancy and may not affect childhood 
neurodevelopmental outcomes. Most of the included studies in the iodine sufficient 
populations were on preterm infants, small sample size, assessed neurodevelopmental 
outcomes at early ages and did not adjust for key confounding variables. Adequately powered 
studies and controlled for key confounders are required to identify a TSH threshold, in 
children without CH, associated with neurodevelopmental deficits in iodine sufficient 
populations. 
 
While the level of TSH is different in cord and newborn blood [137], the relationship between 
TSH and neurodevelopment was consistent regardless of the type of blood. Based on the 





points (n = 55) lower than children without TNH. Moreover, a 1 mIU/L increase in cord blood 
TSH was also associated with a 0.3 point lower cognitive score in studies from iodine 
deficient populations. However, the evidence was from low-quality studies with a small 
sample size ranging from 18 to 275 participants, and did not adjust for key confounding 
variables.  
  
Most of the included studies used standard scales to assess neurodevelopment. More data on 
the association between newborn TSH and other developmental outcomes like psychosocial 
and adaptive behaviour scales are needed. A null association was found between newborn 
TSH and psychosocial development but only one study [168] was included in the review. 
However, a parent-reported scale was used to assess the outcome and may introduce bias in 
the measurement of the outcome variable. Further study using standard psychosocial and 
adaptive behaviour assessment tools is warranted to confirm this finding in all settings. 
  
Of the studies that assessed the association between newborn TSH and child anthropometry, 
only one study [141] showed a negative association and the other two [142, 171] showed a 
null association. The study [141] from an iodine sufficient population showed that infants in 
the fourth TSH quartile had higher odds of low birthweight and birthweight z score < -2 SD 
compared with the other quartiles, but participants were preterm infants with late TSH 
sampling outside of the WHO’s recommended age range. Moreover, the study did not adjust 
for key confounders of child growth including maternal socio-economic status. Key 
confounders of child growth were not also controlled in the two studies [142, 171] that 
reported a null association. The only study that used cord blood TSH reported no correlation 
between cord blood TSH and birth anthropometry [173]. Evidence from large studies that 





anthropometry are required to examine the association of newborn TSH concentration and 
child growth. 
 
There is no established newborn TSH cut-off to screen children at risk of impaired 
neurodevelopment and growth other than to screen children with CH [140] and to define 
iodine status in populations [12]. There are a paucity of studies that use newborn TSH from 
newborn screening and link to neurodevelopmental or growth outcomes. More quality 
population-based studies on the associations between newborn TSH and neurodevelopment 
and growth that adequately adjust for key confounders in populations with different iodine 
status are needed to define a newborn TSH cut-off associated with poor outcomes in different 
settings. 
  
2.7.5 Conclusion  
There is evidence of a negative association between newborn TSH and cognitive development 
in iodine deficient populations. However, newborn TSH shows a null association with 
cognitive and psychomotor development in iodine sufficient populations. There is little 
evidence that newborn TSH concentration is associated with birth anthropometry, but there is 
limited evidence on associations between TSH and child anthropometry at later ages.  
More quality follow-up studies that assess associations between newborn TSH and 
neurodevelopmental and anthropometric outcomes by adjusting all potential confounding 





2.8 Summary of literature review and the rationale for the study presented in this thesis 
IDD remains a public health problem worldwide, and iodine deficiency in pregnancy remains 
a concern in several countries, including Australia. In Australia, this is partly because the 
fortification is aimed at the general population, acknowledging that it might not be enough for 
pregnant women. Therefore, it may be difficult to meet the RDI of iodine in pregnant women 
and breastfeeding women in Australia from the fortification program alone. 
 
UIC, I/Cr and UIC-corrected for creatinine and predicted 24-h UIE markers have been widely 
used in the literature despite their specific use and applications. No study has assessed 
agreement between urinary iodine measurements from spot urine samples in pregnant women, 
including discrepancies in iodine status of populations as measured by different markers. To 
date, there has been no systematic examination of agreement between different markers of 
population iodine status. Comparison of markers to classify iodine status will help to investigate 
whether these markers consistently classify iodine status in populations or pregnant women and 
to identify appropriate markers in different settings. 
 
In Australia, although the recent National Health Survey conducted in Australia between 2011 
and 2012 showed improvement in the iodine status of the population based on UIC in SAC, 
assessing iodine status using multiple markers of population iodine status including newborn 
TSH and goitre prevalence is limited. There is only one study [52] in Western Australia that 
evaluated the effect of the mandatory iodine fortification on the iodine status of the population 
using the newborn TSH concentration as a marker, but the study was conducted in the 
transitional period; and there is also a geographical variation in iodine status in Australia. 
Assessing iodine status in SAC and at-risk populations, including pregnant women, 
breastfeeding women and infants, gives a better picture of population-level iodine nutrition. 





reported in a small study in northern Adelaide in the transitional period. Therefore, evaluating 
the iodine status of pregnant women of low socio-economic position in pre- and post-iodine 
fortification periods with adequate sample size is needed to evaluate the impact of fortification 
on the iodine status of this at-risk population. 
  
Newborn TSH concentration could be a useful marker to identify children at risk of suboptimal 
neurodevelopmental or growth outcomes in countries where newborn screening is routinely 
practised. There is evidence of a negative association between newborn TSH concentration and 
the cognitive development of children in iodine deficient populations, and no associations in 
iodine sufficient populations though the evidence was inconclusive for other developmental 
scales and child growth. However, the quality of the studies that assessed the associations 
between newborn TSH and child development and growth is limited, mainly due to inadequate 
adjustment of confounding variables and small sample size. Hence, prospective follow-up 
studies with an adequate sample size investigating the association between newborn TSH 
concentration and the neurodevelopmental and growth outcomes with adequate adjustment of 
confounding variables in both iodine deficient and sufficient settings are required.  
 
2.9 Research questions and objectives of the thesis  
The thesis addressed the following questions:  
1. What is the agreement between the different markers used to assess the iodine status 
of general populations, populations of pregnant women and individual pregnant 
women?   
2. What is the impact of the mandatory iodine fortification program in Australia on the 
iodine status of the general population and pregnant women from a low socio-





3. What is the relationship between newborn TSH concentration and childhood growth 
and development?  
Objectives of the thesis are:  
1. To evaluate the agreement between different markers used to define iodine status:  
a) in the populations (Chapter 3) 
b) in pregnant women (Chapter 4) 
2. To examine the impact of the iodine fortification program in Australia by comparing 
the iodine status before and after the mandatory iodine fortification of bread:  
a) in the general South Australian population using newborn TSH concentration 
as a marker (Chapter 5) 
b) in pregnant women from a low SES region in South Australia using UIC as a 
marker (Chapter 6)  
3. To investigate the associations between newborn TSH concentration and development 






CHAPTER 3 AGREEMENT BETWEEN MARKERS OF POPULATION IODINE 
STATUS: A SYSTEMATIC REVIEW 
 
This chapter has been published in the American Journal of Clinical Nutrition [15]. 
 
3.1 Publication  
Wassie MM, Middleton, P., & Zhou, S. (2019). Agreement between markers of 
population iodine status in classifying iodine status of populations: a systematic review. 
The American Journal of Clinical Nutrition, 110(4), 949-958. DOI: 
https://doi.org/10.1093/ajcn/nqz118 
To adapt to the format of the thesis, the form of the published version of the paper has been 
slightly modified in the following ways without any changes to the text content; 
1. Re-numbered the consecutive page numbering. 
2. Used Australian English instead of American English. 
3. Re-numbered the consecutive reference numbering and used the numbered format of 
the references to be consistent with the rest of the chapters. 
4. Re-numbered the tables, figures and supplemental tables.  
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Background: Population iodine deficiency is indicated by > 3% of the population with 
newborn thyroid stimulating hormone (TSH) concentration >5 mIU/L, median urinary iodine 
concentration (MUIC) <100 µg/L or prevalence of goitre > 5% in school age children. 
However, the agreement between these population markers has not been systematically 
investigated.  
Objective: To assess the agreement between TSH, MUIC and goitre as markers of population 
iodine status.   
Design: We performed a systematic search for studies published on PubMed, Scopus, 
CINAHL, Embase, and PsycINFO to 29 October 2018. Studies assessing iodine status in the 
population using the TSH marker and either MUIC or goitre prevalence in school age children 
were included. The agreement between markers in classifying iodine status of the population 
was assessed. The sensitivity and specificity of the TSH marker was determined against the 
MUIC and goitre prevalence as the reference markers.  
Results: Of 17,435 records identified by the search strategy, 57 eligible studies were included 
in the review. The agreement between markers in classifying the iodine status of populations 
into the same category was 65% for TSH and MUIC, and 83% for TSH and goitre prevalence. 
The TSH marker had a sensitivity of 0.75 and specificity of 0.53 when compared with MUIC, 
and 0.86 and 0.50 when compared with goitre prevalence.  
Conclusion: The TSH marker has a better agreement with goitre prevalence than MUIC 
when classifying the iodine status of populations. Re-evaluation of the current criteria for 
classifying iodine status of populations using the TSH marker is warranted.   
Key words: iodine deficiency, thyroid stimulating hormone concentration, urinary iodine 








Iodine is an essential micronutrient which is important for growth and development. Iodine 
deficiency can lead to goitre, hypothyroidism and hyperthyroidism; miscarriage, congenital 
anomalies, cretinism and deaf mutism in newborns and impaired physical growth and mental 
function in children which are collectively termed as iodine deficiency disorders [3]. Iodine 
fortification of staple foods and iodine supplementation of at risk population groups are the 
common strategies to prevent iodine deficiency [1]. The World Health Organization (WHO) 
recommends the use of the median urinary iodine concentration (MUIC) and prevalence of 
goitre in school age children as the principal markers of population iodine status [1, 12, 178]. 
It also recommends the use of thyroid stimulating hormone (TSH) concentration in newborns 
to classify iodine status of populations [12, 178].  
 
Populations are classified as iodine sufficient if the proportion of the newborn TSH >5 mIU/L 
in the population is < 3%, or the MUIC of school age children is 100 - 299 μg/L, or goitre 
prevalence < 5% (by palpation or ultrasound examination) in school age children aged 6-12 
years [1, 12, 34]. Ideally classification of iodine status of populations at the same time point 
should be consistent regardless of which of the markers is used. However, inconsistent 
classification of population iodine status has been reported when using the TSH marker 
versus MUIC [45, 52, 54, 179, 180] or goitre [181-184].  
 
There is no single gold standard marker for population iodine status. The MUIC reflects 
recent iodine intake in populations while the percentage of newborn TSH >5 mIU/L and 
goitre prevalence reflect longer-term exposure (months to years) to iodine intake [12]. The 
MUIC requires a large representative sample from school age children to account for the 
diurnal variation in urinary iodine excretion [87]. Goitre prevalence is a less sensitive marker 





recent iodine interventions [185]. The newborn TSH concentration can be affected by factors 
such as exposure to iodine-containing antiseptics during delivery [183, 186] and timing of 
newborn’s blood sampling [52]. The current TSH cut-off has been criticized for its inability to 
correctly classify iodine status in populations [45]. The WHO recommends the use of 
newborn’s blood collected between three and four days after birth for newborn TSH 
determination [12] but this recommendation is not always followed. Some studies used 
newborn blood samples collected before day three [183, 187, 188] or after day four [54, 60, 
179, 181] to assess iodine status of populations using TSH as a marker.  
 
To the best of our knowledge there has been no systematic evaluation of the consistency 
between the markers of population iodine status, TSH, MUIC and goitre prevalence, in 
classifying the iodine status of populations. The aims of this systematic review were to 
investigate the agreement between markers of population iodine status, and the sensitivity and 
specificity of the TSH compared with MUIC and goitre prevalence.   
 
Methods  
Study selection  
Studies which assessed the iodine status of populations using the proportion of neonatal (or 
cord blood) TSH concentration >5 mIU/L and at least one of the other recommended markers 
of population iodine status, including MUIC or prevalence of goitre in school age children 
(aged 6-12 years) were included. Goitre was defined according to the WHO criteria as school 
age children having either grade 1 or grade 2 goitre by palpation or thyroid volume > 97th 
percentile by ultrasound. Studies in which MUIC or goitre was assessed in school aged 
children outside of the recommended 6-12 years were also be eligible for inclusion if the 
school children were below 18 years of age. Studies where data on the iodine status of a 





reported in separate publications, were also eligible to be included in the review. Results from 
multiple surveys in different regions of a country, or different time points, or different 
neonatal age at sampling reported in a same publication were counted as separate studies to 
assess the agreement between markers.   
 
Search strategy  
A systematic literature search was conducted on August 1, 2017, then last updated on October 
29, 2018. Databases included PubMed, Scopus, Cumulative Index to Nursing and Allied 
Health Literature (CINAHL), Embase, and PsycINFO were searched. Reference lists of 
included studies and other databases including WHO and Iodine Global Network were also 
reviewed. The key terms used in literature search included: Thyroid stimulating hormone, 
TSH, thyrotropin, thyrotrophin, thyreotropin, hypothyroidism, hypothyroxine, iodine 
deficiency, goitre, thyroid volume, urinary iodine concentration, iodine nutritional status, 
iodide status, infant, newborn, neonate, child, children and school aged children. The search 
was limited to human studies, but no other restrictions were applied. See Supplemental 
Table 3.1 for more details of the search strategies for each database. 
 
Data collection 
All retrieved articles from the search strategy were exported to endnote X7 library and 
duplicates were removed. Articles were then screened by title and abstract for eligibility (by 
MMW), if not enough information in the abstract to determine eligibility, then review of full 
text was performed. Uncertainty in eligibility was resolved by discussion with a co-author 
(SJZ). Data were extracted (by MMW) using a data extraction form and was double-checked 







Quality assessment  
We used the American Dietetic Association’s “Evidence Analysis Library” manual [189] to 
evaluate the quality of the included studies. Quality of the studies was assessed using the 10 
item questions (Supplemental Table 3.2). Four of the 10 items were defined as important 
items for assessing the quality of studies, which included item 2 (study subjects), item 3 
(comparability of study groups), item 6 (description of exposure) and item 7 (validity of 
measurements). Studies were classified as low quality (high risk of bias) and denoted with a 
negative (-) sign if the answer to the quality assessment questions was “yes” for three or less 
of the ten items. Conversely, studies were classified as high quality (low risk of bias) and 
denoted with a positive (+) sign if the answer was “yes” for a total of five or more items 
including all four important items. Studies were denoted with a neutral (Ø) sign if the answer 
was “yes” for a total of four or more items including three or less of the important items 
(Supplemental Table 3.3). Quality was assessed and scored at a study level as follow: 1) for 
studies that involved two publications: the quality of each publication was rated separately. If 
the quality of the publications differed, the lowest quality among the publications was 
assigned to the study; 2) for publications that reported multiple studies, the quality assessment 
was done for each study separately. The overall grade for the strength of the evidence 
supporting the conclusion of the review was based on the grading definition of the American 
Dietetic Association’s Evidence Analysis Manual as: 1) Good: evidence consists of results 
from studies of strong design for answering the question addressed, results with no serious 
concern about the generalizability, bias, and flaws in study design and consistent results at 
most; 2) Fair: evidence from studies of strong designs for answering the question addressed 
but inconsistencies among the results from different studies, or with consistent results from 
weaker designs for the question addressed only, or with minor concerns about the 
generalizability, bias, study design flaws, or adequacy of sample size; 3) Limited: evidence 





inconclusive results due to lack of generalizability, bias, study design flaws, or inadequacy of 
sample size or unexplained inconsistency among results from different studies [189].  
 
Statistical analysis  
The data were analysed using SPSS Statistics 25 (IBM Corp, Armonk, NY). We assessed the 
agreement between the TSH marker and MUIC or goitre in school age children to classify 
iodine status in the populations as a primary outcome. An agreement is defined as having the 
same classification of iodine status of the populations while using TSH vs MUIC and/or TSH 
vs goitre. The agreement between these markers was assessed in two stages: firstly, the 
agreement between the markers in defining iodine sufficient and deficient; secondly, the 
agreement between the markers in defining the degree of iodine deficiency as mild, moderate 
or severe deficiency. The degree of iodine deficiency in the included studies is classified 
according to the WHO criteria to classify iodine status in populations [1, 12] (Supplemental 
Table 3.4). The overall agreement was assessed separately for studies that used neonatal TSH 
and those used cord blood TSH as the marker. In addition, subgroup analysis by age of 
neonatal blood sampling (before day 3, at 3-4 days, 3-5 days and those after 5 days of age), 
publication type (the markers were reported in the same publication vs. different publications) 
and country level iodine status (iodine deficiency vs. sufficiency countries) was also 
conducted to assess the agreement between markers. For the purpose of the subgroup analysis 
by the country level iodine status (deficient vs. sufficient), population iodine status was 
defined as follow: 1) based on the country level iodine status data from the WHO database if 
the data were available [156, 157]; 2) based on the Iodine Global Network if the data were not 
available in the WHO database [158, 159]; or 3) based on the authors’ report when country 
level data were not reported in either the WHO or Iodine Global Network databases. We used 
MUIC as the primary marker to classify country level iodine status and used goitre as the 





prevalence by both palpation and ultrasound examination, results from the ultrasound 
examination were used as it is generally considered more accurate in the assessment of goitre 
in school age children [12, 34]. We also performed an exploratory analysis to assess the 
agreement between newborn TSH and MUIC of pregnant women in studies where the MUIC 
data for pregnant women were reported.  
 
The secondary outcome was to assess the sensitivity and specificity of the TSH compared 
with MUIC and goitre prevalence. To calculate the sensitivity and specificity of the TSH 
marker in classifying the iodine status of populations compared with the MUIC or goitre 
prevalence, studies which consistently classified iodine deficiency using both the TSH and 
MUIC/goitre were categorised as true positives while those consistently diagnosing iodine 
sufficiency were considered as true negatives. Sensitivity indicates the ability of the TSH 
marker to correctly classify iodine deficient populations while specificity refers to the ability 
of the TSH marker to correctly classify iodine sufficient populations [190]. Youden’s index 
[191] was also calculated ((Specificity + Sensitivity) - 1) to compare the performance of the 
markers [191]. The index has a value between zero (poor accuracy) and one (excellent 
accuracy). If the classification of population iodine status was the same using TSH and 
MUIC, or TSH and goitre, the index has a value of one. The receiver operating curve (ROC) 
analysis was performed and used in two ways: 1) to assess the predictive ability of newborn 
TSH to classify population iodine status based on MUIC and goitre prevalence; 2) to 
determine the optimal cut-off point for the proportion of TSH >5 mIU/L that gave the highest 
specificity and sensitivity when compared with MUIC and goitre prevalence [192]. Mann-
Whitney statistics was used to determine the area under the ROC (AUC) [192, 193]. The 
AUC was used to compare the accuracy (both sensitivity and specificity) of the TSH to 





accurate the marker is. The accuracy of the TSH was categorised as excellent (AUC : 0.9-1.0), 




The search strategy identified 17,435 records and 30 eligible publications [17, 52, 54, 57, 60, 
83-85, 116, 131, 179-184, 186-188, 195-205] were included in this systematic review (Figure 
3.1). TSH and UIC or goitre were reported in a same publication for 17/30 publications [60, 
83-85, 181-184, 188, 195-199, 201, 203, 205]. For the remaining 13 publications, TSH and 
UIC or goitre were reported separately in eight (TSH only) [52, 54, 57, 116, 179, 186, 187, 












































Figure 3. 1 Flowchart of publications for inclusion in the systematic review.  





17,428 records identified through data base 
searching 
         PubMed:  2,542     Scopus: 7,187 
         EMBASE: 5,976    CINHAL: 1,683 
         PsycINFO: 40 
 
15,752 records screened by title   




39 full-text articles assessed for eligibility   
 
30 publications (57 studies) included in the 
review: 
44 studies assessed heel prick blood  
13 studies assessed cord blood  
 
293 records screened by abstract 
 
15,439 records excluded  
 
7 records identified through 
other sources 
Cross reference: 6 
IGN database:1 
 
1,683 duplicated studies 
excluded   
9 excluded  
2 only TSH   
2 only UIC/goitre  








Supplemental Table 3.5 summarizes the characteristics of the studies and Supplemental 
Table 3.6 reports the iodine status of studies by different markers. Overall, a total of 57 
studies from 30 publications were included in the analysis (Supplemental Table 3.7). Of the 
57 studies, 56 studies reported TSH and MUIC of school age children (43 studies assessed 
TSH from infant blood samples and 13 studies assessed TSH from cord blood samples), and 
36/57 studies reported TSH and goitre of school age children (23 studies assessed TSH from 
infant blood samples and 13 studies assessed TSH from cord blood samples) (Tables 3.1 and 
2). Of the 36 studies that assessed goitre prevalence, 35 of them assessed goitre by palpation 
[17, 60, 83, 85, 181-184, 186, 188, 195, 196, 198, 201-203], one study assessed goitre by 
ultrasound examination [198] and nine studies assessed goitre by both palpation and 
ultrasound examination [60, 182, 184, 198, 201] (Supplemental Table 3.5). Both methods 
consistently classified iodine status of the populations in all nine studies used both methods 
[60, 182, 184, 198, 201]. The included studies were conducted in 29 countries representing all 
WHO regions of the world. Fifty seven percent (32/56) of the studies were in countries 





Table 3. 1 The agreement between newborn TSH and other markers to classify population iodine status1  










AGE AT TSH ASSESSMENT: 3-4 DAYS3 
Yamada, 2000, Mongolia [203] Deficiency4 Study (Ulaanbaatar)  No Yes 
Study (Uvurkhangai)  Yes Yes 
Study (Huvsgol) No Yes 
Study (Dornod) Yes Yes 
Study (Hovd) Yes Yes 






Clapin, 2014 [52]; ABS report, 2013, 
Western Australia [131]  
Sufficiency5  Single study No NA 
 
Evans 2014[179]; Vanderpump, 
2011,Wales UK [180]  
Deficiency5 Single study  No NA 
 
Rahman 2010 [200]; Li 2005, Victoria, 
Australia [17]  
Deficiency4 Single study  Yes NA 
 
Fuse, 2003, Ulaan Baatar, Mongolia 
[198]  
 
Deficiency4 Study (1996) No Yes 
Study (1996-1999) No Yes 
Wilcken , 2011 [116]; Li, 2005, NSW, 
Australia [17]  




AGE AT TSH ASSESSMENT: < 3 DAYS OR > 4 DAYS6 
Gruneiro- Papendieck, 2004, Argentina 
[183]  
Sufficiency7 Single study No No 
Al-Hosani, 2003, United Arab Emirates 
[181] 
















Wachter,1985, Tanzania [188]  
 
Deficiency7 Study (Pre-intervention 
population) 
No No 
Study (Post intervention 
population) 
No NA 
Evans, 2014, UK [179]; Vanderpump et 
al., 2011, UK[180]  
Deficiency4 Single study  
 
No NA 
AGE AT TSH ASSESSMENT: 3-4 DAYS AND < 3 DAYS OR > 4 DAYS8 
Mehran, 2016, Iran [205]  Sufficiency5 Single study  Yes NA 
Dalili, 2012, Iran [197]  
 
Sufficiency5  Study (2006) Yes NA 
Study (2007) Yes  
Study (2008) Yes  
Study (2009)  Yes  
Study (2010)  Yes  
Costan, 2002, Italy [196] 
 
Deficiency4 Study (Inland territory) Yes Yes 
Study (Sea level territory) Yes Yes 
Costan,1997, Italy [195]  Deficiency4 Single study  Yes Yes 
Burns, 2008 [54]; Vanderpump, 2011, 
Ireland [180]  
Sufficiency4 Single study  No NA 
 
Mikelsaar, 1999, Estonia [57] 
 
Deficiency4 Study (North):  Yes NA 
Study (Central) Yes NA 
Study (South) Yes NA 
Vandevijvere, 2012 [186] Vandevijvere, 
2012, Belgium [202]   
Sufficiency4 Study (2009-2011) Yes No 
Study (2010-2011) No Yes 
Study (2011-2011) No Yes 
Simsek, 2003, Turkey[60]  Deficiency4 Study (Turkey) NA Yes 
Study (Bolu) Yes Yes 















Study (Zongulda) Yes Yes 
Konrade, 2014, Latvia [199]  Sufficiency5 Single study  No NA 
Svinaryov, 2003, Russia[201]  Deficiency4 Single study  Yes Yes 
Wachter,1985, Tanzania [188]  
 
Deficiency7 Study (Pre-intervention 
population) 
Yes Yes 
Study (Post intervention 
population) 
Yes NA 
Gruneiro- Papendieck, 2004, Argentina 
[183]  
Sufficiency7 Single study  Yes Yes 
Gyurjyan, 2006, Latvia [187];  
Selga, 2000, Latvia [204] 





1NA, not applicable; TSH, thyroid stimulating hormone; MUIC, median urinary iodine concentration.  
2Study conducted at different regions or different time periods within the same publication were classified as separate studies, with the region 
/time period in the brackets. The term ‘Single study’ denotes if the study was conducted in only one region or one time point within 
publication(s). 
3 Studies where the newborns’ heel prick samples were collected within the World Health Organization’s recommended age (at 3-4 days of 
infant’s age). 
4Data were obtained from the World Health Organization database to indicate iodine status of the countries where the studies were conducted.  
5Data were obtained from the Iodine Global Network database to indicate iodine status of the countries where the studies were conducted.  
6 Studies where the newborns’ heel prick samples were collected outside the World Health Organization’s recommended age (at < 3 or > 4 days 
of infant’s age). 
7The iodine status of the population were classified based the authors’ report when the population-level data are not reported in the World Health 
Organization or the Iodine Global Network databases.  
8Studies where the newborns’ heel prick samples were collected within (3-4 days of infant age) and outside (< 3 and > 4 days of infants age) the 





Quality of included studies 
The quality of the included studies is reported in the Supplemental Table 3.3. Twenty-two 
studies had low risk of bias and the remaining studies were classified as neutral in quality. 
Overall, the strength of evidence was graded as “Limited” mainly due to lack of 
generalizability [52, 54, 57, 83, 116, 181, 184, 187, 200] or inadequate sample size [183, 188, 
196] or bias in participant selections [57, 116, 183, 187, 188, 198], and inconsistent results 
from different studies [179, 180, 186, 202].  
 
Agreement between newborn TSH and MUIC in defining iodine status of populations  
Forty-three studies reported data on iodine status based on TSH and MUIC, data on iodine 
status from the two markers being compared were extracted from the same publication in 33 
studies and from different publications in 10 studies. The agreement between the markers 
were 73% in the studies where the data were from the same publication and 40% in the 
studies from different publications (Supplemental Table 3.8). Overall, 65% (28/43) of the 
studies showed an agreement between MUIC and newborn TSH in classifying iodine status 
[57, 60, 84, 116, 183, 186-188, 195-197, 200, 201, 205] (Supplemental Table 3.9). The 
agreement in classifying iodine status of populations was observed in 69% (22/32) of the 
studies from iodine deficient populations and 56% (6/11) of the studies from iodine sufficient 
populations. Seventy eight percent (14/18) of the studies showed an agreement in classifying 
the severity of iodine deficiency. The agreement was 50% (7/14) in classifying mild iodine 
deficiency, 43% (6/14) in moderate iodine deficiency and 7% (1/14) in severe iodine 
deficiency (Table 3.1, Supplemental Tables 3.5 and 3.6). In the exploratory analysis, the 
agreement between newborn TSH and the MUIC of pregnant women in classifying iodine 






Agreement between newborn TSH and goitre prevalence in defining iodine status of the 
population  
Twenty-three studies reported data on iodine status based on TSH and goitre, data on iodine 
status from the two markers being compared were extracted from the same publication in 20 
of the studies and from different publications in three of the studies. The agreement in 
classifying iodine status of populations was 85% in the studies where the data were from the 
same publication and 67% (only three studies) in the studies from different publications 
(Supplemental Table 3.8). Overall, 83% (19/23) of the studies showed an agreement 
between goitre and newborn TSH in classifying iodine status (Supplemental Table 3.9). 
Agreement in classifying iodine status of populations was observed in 89% (16/18) of the 
studies from iodine deficient populations and 80% (4/5) of the studies from iodine sufficient 
populations. Thirty-nine percent (7/18) [183, 186, 188, 195, 201-203] of the studies showed 
an agreement in classifying the degree of iodine deficiency (mild versus moderate versus 
severe) between the two markers (Table 3.1, Supplemental Tables 3.5 and 3.6).   
 
Newborn’s age at heel prick blood sampling and the agreement between markers  
Of the 13 studies assessing TSH concentration from samples collected at 3 to 4 days after 
birth according to the WHO recommendation, agreement in classifying iodine status of the 
populations was reported in 54% (7/13) [84, 116, 200, 203] of the studies that assessed iodine 
status by TSH and MUIC and 100% (7/7) [198, 203] of the studies that assessed iodine status 
by TSH and goitre. There was no agreement with MUIC or goitre for the studies that assessed 








Agreement between cord blood TSH, MUIC and goitre prevalence in defining iodine 
status of populations  
Iodine status of the populations was classified as iodine deficient in all 13 studies that used 
cord blood TSH as a marker. All 13 studies reported data on TSH, MUIC and goitre 
prevalence, 38% (5/13) [85, 182, 184] showed an agreement between TSH and MUIC and 
77% (10/13) [83, 85, 182, 184] showed an agreement between TSH and goitre prevalence. No 
agreement was observed between the cord blood TSH and MUIC or goitre in classifying the 
degree of iodine deficiency (mild vs. moderate vs. severe) (Table 3.2, Supplemental Tables 





Table 3. 2 The agreement between cord blood TSH and other markers to classify population iodine status1 
Publication, country   Country-level iodine 
status 
Study2 Agreement between TSH 
& MUIC 
Agreement between TSH 
& goitre 
Kapil, 2015, India [85]  
 
Sufficiency3 Study (Kangra) No Yes 
Study (Kullu) No Yes 
Study (Solan) Yes Yes 








Copeland, 2002, USA [182]  Sufficiency4 Single Study No No 




Sufficiency3 Study (Udham Singh 
Nagar) 
No Yes 
Study (Nainital) No Yes 
 
Study (Pauri Garhwal) No Yes 
 
Sullivan, 1997, Kyrgyzstan [184]   
 
Deficiency4 Study (Bishkek) Yes Yes 
Study (OSH) Yes Yes 
Sullivan,1997, Philippines [184]  Deficiency4 Single study Yes No 
 
Gruneiro-Papendieck, 2004, 
Argentina [183]  
Sufficiency5 Single study No No 
 
 
1NA, not applicable; TSH, thyroid stimulating hormone; MUIC, median urinary iodine concentration.  
2Study conducted at different regions within the same publication were classified as separate studies, with the region in the brackets. ‘Single 
study’ denotes if the study was conducted in only one region or one time point only within one publication or between two publications. 
3Data were obtained from the Iodine Global Network database to indicate iodine status of the countries where the studies were conducted.  
4Data were obtained from the World Health Organization database to indicate iodine status of the countries where the studies were conducted.  
5The iodine status of the population were classified based the authors’ report when the population-level data are not reported in the World Health 





Sensitivity and specificity of newborn TSH  
Figures 3.2 and 3.3 show the ROC curves for the ability of newborn TSH in predicting iodine 
status compared with MUIC and goitre prevalence, respectively. The sensitivity, specificity 
and Youden’s index was 0.75, 0.53 and 0.28, respectively for TSH compared to MUIC in 
classifying iodine status and 0.86, 0.50 and 0.36, respectively for TSH compared with goitre.  
 
Figure 3. 2 The receiver operating curve (ROC) of the TSH marker to predict iodine status 
using the MUIC as a reference marker (Forty-three studies included in the analysis).  
The area under the curve (AUC) was 0.71 (95% CI: 0.56, 0.87). TSH, thyroid stimulating 









Figure 3. 3 The receiver operating curve (ROC) of the TSH marker to predict iodine status of 
populations using goitre prevalence as a reference marker (Twenty-three studies included in 
the analysis).  
The area under curve (AUC) was 0.82 (95% CI: 0.65, 0.99). TSH, thyroid stimulating 
hormone.  
 
Cut-off for the percentage of TSH >5 mIU/L from heel prick samples to define iodine 
sufficiency 
The AUC was 0.71 (95% CI: 0.56, 0.87) for TSH vs MUIC and 0.82 (95% CI: 0.65, 0.99) for 
TSH vs goitre. Based on the coordinates of the ROC, the cut-off to define iodine sufficiency 
in populations using the percentage of newborn TSH >5 mIU/L was between 4.31% and 
5.36% when using MUIC as a reference marker (Supplemental Table 3.11) and between 









To the best of our knowledge, this is the first systematic review which compares the 
agreement between newborn TSH concentration and MUIC or goitre prevalence to classify 
iodine status in populations. We showed that based on the current criteria, TSH has a better 
agreement with goitre prevalence than MUIC in school age children. We also found that the 
current newborn TSH criteria (newborn TSH >5 mIU/L greater than 3%) in classifying iodine 
deficiency is supported when using goitre prevalence as a reference marker, but a higher cut-
off of approximately 5% was indicated using MUIC in school age children as the reference 
marker.  
 
MUIC of school age children from spot urine samples is recommended by the WHO as the 
first choice to assess iodine status in populations [12, 178]. It is a simple, convenient, 
inexpensive and widely used marker to classify iodine status of populations [178]. Revision of 
the TSH cut-off has been suggested by previous research [45, 52, 54, 179]. Based on the ROC 
analysis, we showed that a cut-off between 4.3% and 5.4% of newborn with TSH >5 mIU/L 
resulted in the highest specificity and sensitivity to define iodine status when the MUIC of 
school age children was used as a reference marker. MUIC, TSH, and goitre prevalence 
reflect iodine status over different periods. MUIC is a sensitive marker to identify short term 
changes in iodine intake of the populations unlike goitre prevalence which mainly reflects 
longer term low iodine intake [12]. Elevated neonatal TSH is an indicator of exposure to 
iodine deficiency during the fetal life while goitre indicates chronic iodine deficiency in 
school age children [12, 206]. Enlargement of the thyroid gland and elevation of newborn 
TSH concentration have also been linked to excessive iodine intake, they also have common 
causes other than chronic iodine deficiency including hypothalamic dysfunction and exposure 





that newborn TSH had a better agreement with goitre prevalence than MUIC, TSH or goitre 
prevalence may not be the appropriate markers to monitor short term effects of iodine 
interventions [1, 87]. Inter-observer variations in the classification of goitre by palpation or 
ultrasound examination, even among experienced examiners, make goitre prevalence a less-
preferred marker for population iodine status [12].Nevertheless, both palpation and ultrasound 
examination methods consistently classified the iodine status of populations in the limited 
number of studies that used both methods to detect the presence of goitre.  
 
A number of studies classified populations as iodine sufficient by MUIC but mildly iodine 
deficient by TSH concentration [47, 52, 183, 186, 198, 199, 202, 203]. However, many 
studies used newborn heel prick blood samples outside of the WHO’s recommended time 
frame of 3-4 days after birth [54, 60, 181, 183, 187, 188]. The lack of an agreement between 
markers when newborn blood samples were collected outside of the WHO’s recommendation 
suggests that TSH from newborn blood samples collected outside of 3-4 days is not suitable 
for classifying the iodine status of populations based on the current criteria. The current 
criteria may not be appropriate in countries where the newborn screening is performed before 
day 3 of birth due to early discharge from hospitals. Differences in the type of urine sample 
(spot urine or 24-hour urine) and the timing of urine sample collection may contribute to the 
low agreement between the MUIC and TSH [72, 210]. We are unable to conduct a sensitivity 
analysis based on different urine collection methods as approximately half of the included 
studies reported using spot urine samples while the remaining did not report what type of 
urine samples were collected for the UIC analysis. 
 
In studies which assessed iodine status after one year of the introduction of an iodine 
intervention program, both TSH and MUIC showed an improvement in iodine status of 





MUIC [54, 84, 179, 180, 188, 197]. Currently there are no specific guidelines regarding 
which of the population markers would be the most appropriate for use following iodine 
intervention programs. A re-evaluation of the TSH criteria with clear guidelines may improve 
the sensitivity and specificity of the TSH to classify iodine status of populations. Application 
of the same TSH cut-off across all ethnic groups may also be a potential factor contributing to 
the disagreement among markers of population iodine status as it has been showed that 
differences in the newborn TSH concentration across different ethnic groups existed [211].  
 
Our finding of a higher agreement between TSH and MUIC or goitre in iodine deficient than 
iodine sufficient populations also highlights the need for further research to formulate 
population specific guidelines in terms of which marker is the most appropriate to use in 
different settings. When disagreement occurs between markers of population iodine status, 
using MUIC in school age children as the first choice would facilitate the decision making 
process in determining appropriate population strategies to prevent iodine deficiency or 
monitor the efficacy and safety of any intervention programs [45]. In addition, iodine intake 
data from population surveys and from the vulnerable groups like pregnant women should 
also be considered in the decision-making process. The higher agreement between the 
newborn TSH and MUIC of the pregnant reflects the strong correlation between newborn 
TSH and maternal iodine status during pregnancy [57, 116, 198], suggesting that the newborn 
TSH marker may be a good indicator of the iodine status of pregnant women.  
 
Our results indicate that the cord blood TSH is not a good marker based on the current cut-off. 
Of studies analysing cord blood TSH, there was no agreement between TSH and MUIC or 
goitre in classifying the degree of iodine deficiency [83, 85, 182, 183]. The discrepancy may 
be due to the use of the same cut-off in both heel prick and cord blood samples to classify 





newborn heel prick samples [178, 183]. The methods used to analyse newborn vs. cord blood 
TSH were also different. All studies analysed cord blood TSH using Enzyme Linked Immune 
Sorbent Assay (ELISA) while Dissociation Enhanced Fluroimmunoassay (DELFIA) was used 
for most of heel prick samples. Hence, the TSH assay methods used to measure the TSH 
concentration need to be considered in the interpretation of the results. A different TSH cut-
off (cord blood vs. infant blood samples) may improve the agreement between TSH and 
MUIC or goitre in classifying iodine status in populations.    
 
Our review has some limitations. Firstly, we retrieved some data on iodine status from 
different publications for the same country or region at the same time to assess the agreement 
between markers. Whether the study populations in the different publications matched was 
difficult to ascertain. Secondly, some studies assessed MUIC and/or goitre prevalence in 
school age children outside of the recommended age range of 6 - 12 years. Lastly, neonatal 
TSH is used as an indicator of population iodine status mainly in countries which have 
congenital hypothyroidism screening programs. Hence, our findings may not be applicable to 
those countries which do not have TSH screening programs currently.   
 
In conclusion, this systematic review shows that neonatal TSH concentration >5 mIU/L 
greater than 3% as a population iodine status marker has a better agreement with goitre 
prevalence than MUIC in school age children. TSH concentration from heel prick samples 
outside of the WHO’s recommendation of 3-4 days after birth or from cord blood samples is 
not suitable to classify iodine status of populations. Further research to determine the 
appropriate TSH cut-off as well as clear guidelines on which population markers is the most 
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Background: Multiple markers of iodine excretion from urine, including the 24-hours urinary 
iodine excretion (24-h UIE), urinary iodine concentration (UIC), iodine-to-creatinine ratio 
(I/Cr) and UIC-corrected for creatinine (UIC~Cr) have been used to assess iodine status of 
populations. There is limited evidence on the agreement between these markers in pregnant 
women.  
Objectives: To assess the agreement between urinary iodine excretion measurements in 
pregnant women.  
Methods: Spot UIC and urinary creatinine were measured in 534 pregnant women at 12 
weeks of gestation. Iodine deficiency was defined based on the World Health Organization 
criteria of median UIC <150 µg/L. 24-h creatinine was estimated by using published 
equations by Mage et al., which was then used to calculate 24-h UIE. UIC~Cr was calculated 
from a regression of UIC over urine creatinine. Agreements between markers (estimated 24-h 
UIE, UIC, I/Cr and UIC~Cr) were assessed using the Bland-Altman plot and kappa 
coefficient (K). 
Results: The median [Inter Quartile Range (IQR)] UIC was lower than estimated 24-h UIE 
[207.7 (121.7, 335.5) µg/L vs 261.0 (154.9, 466.3) µg/day, P <0.001], but did not differ from 
I/Cr or UIC~Cr. Based on the Bland-Altman plot, estimated 24-h UIE was 71.8, 76.8 and 86.0 
units higher than I/Cr, UIC and UIC~Cr, respectively. I/Cr was 5.0 and 14.2 units higher than 
UIC and UIC~Cr, respectively. The agreement between the markers to classify iodine status 
in pregnant women was substantial between estimated 24-h UIE and I/Cr (k = 0.7) or UIC~Cr 
(K = 0.6), but fair (k = 0.3) between UIC and estimated 24-h UIE or between UIC and I/Cr.  
Conclusions: All markers classified the study population as iodine sufficient. I/Cr has a better 
agreement with estimated 24-h UIE than UIC or UIC~Cr. Further study assessing which of 












Iodine deficiency or excess during pregnancy has been linked to impaired neurodevelopment 
and poor child growth [65, 212]. Hence, assessing iodine status in pregnant women using 
appropriate markers is an important public health measure [213]. There are several markers of 
iodine excretion from urine that have been used to assess iodine status of populations as 
approximately 90% of dietary iodine is excreted in the urine [214]. The 24-h urinary iodine 
excretion (UIE) in µg/day is viewed as the gold standard for assessing iodine status [12] 
because the original World Health Organization’s (WHO) criteria established in 1994 to 
define iodine sufficiency were based on the lowest level of 24-h UIE associated with the 
absence of goitre, a functional outcome of iodine deficiency [37]. The study conducted in 
Central America, where the WHO’s criteria were derived, showed that areas with 24-h UIE 
>100 µg/day had no goitre in adults and school age children (SAC) [41].  
  
As collecting 24-h urine is a significant burden on participants and is not feasible in 
fieldwork, WHO subsequently recommended the use of spot urinary iodine concentration 
(UIC) expressed in µg/L [12] over 24-h UIE to assess iodine status of populations. This was 
based on the assumption that the average volume of 24-h urine is 1 L in SAC. The 24-h UIE 
and UIC would be comparable in SAC as their average 24-h urine volume is close to 1 L 
[215], but they may not be compatible in adults as their 24-h urine volume is approximately 
1.5 L [216]. Hence, spot UIC is 60-65% lower than the 24-h UIE in adults [217]. Iodine-to-
creatinine ratio (I/Cr) has been shown to be comparable with 24-h UIE when the 24-h urine 
creatinine excretion was 1 g and the 24-h urine volume was 1 L [214, 218]. However, the 
creatinine excretion level and 24-h urine volume vary across different age, sex, ethnicity and 
nutritional status, and these factors affect the compatibility of the 24-h UIE and I/Cr [68, 73, 
219]. A recent systematic review showed that neither UIC nor I/Cr were good predictors of 





sample sizes (ranged from 29 to 188 participants) [220]. It has been shown that 24-h UIE 
calculated from spot UIC and 24-h creatinine excretion estimated using published equations 
had a better agreement with 24-h UIE in healthy adults [66, 69]. 
 
Recently, UIC corrected for creatinine by a regression method (UIC~Cr) was also used as a 
marker of iodine status [64]. In this method, UIC was regressed over the urinary creatinine 
excretion to compute residuals of the model, which represent the difference between the 
actual UIC and UIC predicted by urinary creatinine concentration, were added to the UIC [64, 
221] and expressed as µg/L. Unlike I/Cr, the UIC~Cr value is uncorrelated with factors 
affecting urinary creatinine concentration. Due to this, UIC~Cr may be a better marker than 
I/Cr to define iodine status at an individual level. 
 
Several studies have applied the WHO criteria to define iodine deficiency based on UIC  
(< 150 µg/L) to the 24-h UIE, UIC and I/Cr to define iodine status in pregnant women [65, 
67, 71], but little is known about the agreement between these markers in pregnancy except in 
a small study (n = 143) by Li et al. [67] which showed a better agreement between I/Cr and 
24-h UIE than UIC and 24-h UIE. While spot UIC is recommended by WHO as a marker of 
population iodine status, there is a scarcity of evidence to guide the choice of a suitable 
marker to assess individual iodine status in pregnancy. This study assessed the agreement 
between UIC, estimated 24-h UIE, I/Cr and UIC~Cr to define iodine status in pregnancy in a 
well-nourished iodine sufficient population.  
Methods  
Study design, setting and participants 
A cross-sectional study. We used urine samples collected from pregnant women in South 
Australia participating in the Screening Tests to Identify Poor Outcome in Pregnancy study 





singleton pregnancy of less than 12 weeks of gestation who attended the first antenatal clinic 
were included. Women with known chronic disease were excluded [222]. A random spot 
urine sample was collected from participating pregnant women at 12 weeks of gestation and 
all samples have been stored at -80 degrees Celsius for batched UIC analysis. Data on 
maternal socio-economic and demographic characteristics were collected using a structured 
interviewer-administered questionnaire by research midwives. Height and weight 
measurement and urine sample collection was done by research midwives at the study entry. 
Six hundred pregnant women from the STOP study were randomly selected to assess iodine 
status (see Chapter 6) and 534 of them who had urinary creatinine excretion were included in 
this study.  
 
Assessment of iodine status   
Estimated 24-h UIE, UIC, I/Cr and UIC~Cr were assessed as markers of iodine status. The 
UIC was measured using a modified Sandell-Kolthoff spectrophotometric method (WHO’s 
method B) in the spot urine samples [223]. The urinary creatinine concentration (mmol/L) 
was measured using the kinetic-Jaffe method at the South Australia Pathology Laboratory, an 
accredited diagnostic laboratory. Urine creatinine concentration in mmol/L was converted to 
g/L by dividing it by 8.840 [78]. I/Cr is the ratio of urinary iodine concentration in µg/L and 
urinary creatinine excretion in g/L. The 24-h UIE was calculated based on I/Cr and the 24-h 
urinary creatinine excretion as follows: I/Cr in µg/g x 24-h urinary creatinine excretion in 
g/day [214], the 24-h creatinine was estimated from the creatinine concentration in the spot 
urine sample. The estimated 24-h urinary creatinine value was calculated using two different 
predictive equations by Mage et al. [69] and by Kesteloot and Joosens [68]. While the 
estimated 24-h creatinine values were similar using both equations (Supplemental table 4.1), 
we used the estimated 24-h UIE value based on the Mage et al. method for comparison with 





24-h UIE [72]. The UIC~Cr was calculated by adding the residuals, which were created by 
regressing UIC against urinary creatinine concentration (both log-transformed) [221] to the 
UIC.  
Statistical Analysis   
Data were analysed using Stata 15 (Statacorp LP, College Station, Texas). Iodine status was 
reported as UIC in µg/L, estimated 24-h UIE in µg/day, I/Cr in µg/g and UIC~Cr in µg/L. The 
iodine status of women was categorised using the WHO criteria based on UIC: iodine 
deficiency (<150 μg/L), sufficiency (150-500 μg/L) and excess (≥500 µg/L) based on the WHO 
criteria [12]. We applied the same cut-offs to all markers irrespective of their units for 
comparisons with the literature. The median urinary iodine excretion values (using Wilcoxon 
rank-sum test) and the percentage of pregnant women in the iodine deficiency, iodine 
sufficiency or iodine excess category (using Pearson chi-square test) were compared across all 
markers. As the variables were not normally distributed, they were log-transformed for a 
pairwise correlation test.  
  
Iodine status of the study population was classified using each of the markers. Agreement 
between markers in classifying iodine status of individual pregnant women was assessed 
using the 24-h UIE as a reference marker because it has been shown to better predict the 24-h 
UIE compared with UIC and I/Cr [66, 69]. Agreement between markers to define iodine 
status at individual-level was assessed in three ways. First, sensitivity and specificity of spot 
urinary iodine markers in classifying the iodine status of pregnant women compared with the 
estimated 24-h UIE was determined. Markers which classified iodine deficiency during 
pregnancy (<150 units) consistently with the estimated 24-h UIE marker were categorised as 
true positives while those consistently diagnosing iodine sufficiencies (≥150 units) were 
considered as true negatives. The sensitivity indicates the ability of the urinary iodine markers 





the urinary iodine markers to correctly classify iodine sufficient pregnant women [190]. 
Second, the Kappa Coefficient (K) was used to assess the agreement between each of the 
marker and estimated 24-h UIE to classify iodine status as deficient or sufficient (as 
categorical variables). The agreement between markers was defined as poor if k <0.01, slight 
if K = 0.01-0.20, fair if K = 0.21-0.40, moderate if k = 0.41-0.60, substantial if K = 0.61-0.80, 
almost perfect if K = 0.81-1.0 by using the Kappa statistics [224]. Third, the Bland-Altman 
method was used to determine the mean difference (bias) and limits of agreement (LOA) 
between two markers [225]. The LOA are ± 1.96 SD of the mean difference of two markers. 
The agreement between other urinary iodine markers (I/Cr with UIC or UIC~Cr) was also 
explored. Based on the sample size (n = 534), we had greater than 95% power to compare the 
percentage of women with UIC <150 μg/L and I/Cr <150 μg/g at a 0.05 significance level; 
two-sided [81]. Statistical significance was set at a value of P <0.05. 
Results  
Participant characteristics  
Table 4.1 presents the characteristics of 534 study participants. The mean (± SD) age and 
BMI of participants were 25.7 ± 5.0 years and 28.1 ± 7.3 kg/m2, respectively. The mean  










Table 4. 1 Characteristics of study participants1 
Variables STOP (n = 534) 
Age, y  25.7 ± 5.0 
Married 464 (87%) 
Caucasian race 445 (83%) 
Completed tertiary education  109 (18%) 
SEI 903.9 ± 86.4 
Drunk alcohol during first trimester  75 (14%) 
Smoked during first trimester  98 (18%) 
Took iodine-containing supplements during first trimester  400 (75%) 
BMI, kg/m2  28.1 ± 7.3 
Urine creatinine, g/L  1.2 ± 0.8 
1Values are presented as means ± SDs otherwise specified. BMI, body mass index; SD, 
standard deviation; SEI, Socio Economic Index for areas based on the Index of Relative 
Socio-Economic Disadvantage; STOP, Screening Tests to Identify Poor Outcome in 
Pregnancy; N, sample size; NA, not applicable.  








Iodine status in the study population  
There was a significant difference in the median concentration between UIC and estimated 
24-h UIE (P <0.001) or between UIC and UIC~Cr (P = 0.01) but there was no significant 
difference between UIC and I/Cr (P = 0.40). The median estimated 24-h UIE was different 
from the median I/Cr or UIC~Cr while median I/Cr did not differ from median UIC~Cr  
(P = 0.57). The study population was classified as iodine sufficient based on all urinary iodine 
markers (median values >150). However, as shown in Table 4.2, there was a significant 
difference in the percentage of pregnant women with urinary iodine concentration >150 or 





Table 4. 2 Iodine status of participants using different markers (n=534)1  
 UIC, µg/L  Estimated 24-h UIE, 
µg/day 
I/Cr, µg/g UIC~Cr µg/L  
Median  207.7 (121.7, 335.5)  261.0 (154.9, 466.3) 214.0 (126.9, 343.1) 200.0 (131.8, 332.2)  
Classification of iodine status  
<150 (deficiency) 168 (31%)  124 (23%) 177 (33%) 180 (34%)     
150-499 (sufficiency) 308 (58%)  300 (56%) 300 (56%) 314 (59%) 
≥500 (excess)  58 (11%)  110 (21%) 57 (11%) 40 (7%) 
1Values are presented as medians (IQR) otherwise specified. I/Cr, iodine to creatinine ratio; SD, standard deviation; STOP, Screening Tests to 
Identify Poor Outcome in Pregnancy; UIC, urinary iodine concentration, UIC~Cr, UIC corrected for creatinine by regression method; UIE, 






Agreement between markers of iodine status at an individual level   
The sensitivity and specificity of the markers in classifying iodine status (<150 or ≥150) is 
presented in Table 4.3. When compared with the estimated 24-h UIE, UIC showed lower 
sensitivity and specificity than I/Cr and UIC~Cr. I/Cr had the best sensitivity and specificity 
when compared with the estimated 24-h UIE. A contingency table is presented in 
Supplemental Table 4.2 for the number of pregnant women who were consistently 






Table 4. 3 Sensitivity and specificity of urinary iodine markers to define iodine status in pregnancy1 
1I/Cr, urinary iodine concentration to creatinine ratio; NA, not applicable; UIC, urinary iodine concentration; UIC~Cr, urinary iodine 
concentration corrected for creatinine; UIE, urinary iodine excretion. The sensitivity of a marker was calculated as a/(a + b) where ‘a’ is the 
number of pregnant women classified as iodine deficient by both the test and reference markers and ‘b’ is the number of pregnant women 
classified as iodine deficient by only the test marker. The specificity of a marker was calculated as d/(c + d) where ‘d’ is the number of pregnant 
Reference markers  Test markers  
 UIC Estimated 24-h UIE I/Cr UIC~Cr 
Sensitivity and specificity of markers to define iodine deficiency <150 units2 
Estimated 24-h UIE as the reference      
Sensitivity  0.56 NA 0.98 0.88 
Specificity  0.76 NA 0.87 0.83 
I/Cr as the reference      
Sensitivity  0.49 0.69 NA 0.79 
Specificity  0.77 0.99 NA 0.89 
UIC as the reference     
Sensitivity  NA 0.42 0.52 0.71 
Specificity  NA 0.85 0.75 0.88 
Sensitivity and specificity of markers to define iodine excess ≥500 units2 
Estimated 24-h UIE as the reference     
Sensitivity  0.37 NA 0.49 0.35 
Specificity  0.96 NA 0.99 1.00 
I/Cr as the reference     
Sensitivity  0.42 0.00 NA 0.80 
Specificity  0.93 0.79 NA 0.95 
UIC as the reference     
Sensitivity  NA 0.71 0.41 0.55 





women classified as iodine sufficient by both the test and reference markers and ‘c’ is the number of pregnant women classified as iodine 
sufficient by only the test marker [190].  
2The WHO criteria based on median UIC in µg/L was applied to all markers to define iodine deficiency (<150 units) and excess (≥500 units) 







Based on kappa coefficient, the agreement between markers to classify iodine status as <150 
or ≥150 was ‘substantial’ for estimated 24-h UIE and I/Cr (k =0.74, P <0.001) or estimated 
24-h UIE and UIC~Cr (k = 0.61, P <0.001) but ‘fair’ for estimated 24-h UIE and UIC (k = 
0.30, P <0.001). Furthermore, the agreement between the markers was ‘substantial’ for I/Cr 
and UIC~Cr (k =0.68, P <0.001), ‘Moderate’ for UIC and UIC~Cr (k = 0.60, P <0.001) and 
“fair” for I/Cr and UIC (k = 0.27, P <0.001). 
  
As shown in Figure 4.1, estimated 24-h UIE was 71.8 units (LOA: -118.8 to 262.4 units), 
76.8 units (LOA: -298.2 to 451.8 units) and 86.0 units (LOA: -171.4 to 343.3 units) higher 
than I/Cr, UIC and UIC~Cr, respectively. I/Cr was 5.0 (LOA: -344.7 to 354.6) units higher 



















Figure 4. 1 The Bland-Altman plots for the agreement between estimated 24-h UIE and: A) I/Cr; B) UIC~Cr and C) UIC.  
I/Cr, urinary iodine concentration to creatinine ratio; LL, lower limit of agreement; MD, mean difference; UIE, urinary iodine excretion; UIC, 
urinary iodine concentration; UIC~Cr, urinary iodine concentration corrected for creatinine; UL, upper limit of agreement.  
UL = 262.4 units 
MD = 71.8 units 
LL = -118.8 units 
UL = 343.3 units 
MD = 86.0 units 
LL = -171.4 units 
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Figure 4. 2 The Bland-Altman plot for the agreement between A) I/Cr and UIC~Cr; B) I/Cr and UIC; C) UIC and UIC~Cr.  
I/Cr, urinary iodine concentration to creatinine ratio; LL, lower limit of agreement; MD, mean difference; UIE, urinary iodine excretion; UIC, 
urinary iodine concentration; UIC~Cr, urinary iodine concentration corrected for creatinine; UL, upper limit of agreement. 
A B 
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 UL = 213.0 units 
 MD = 14.2 units 
 LL = -184.7 units 
 
UL = 170.6 units 
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The estimated 24-h UIE had a better correlation with I/Cr (r = 0.94, P <0.001) than UIC~Cr (r 
= 0.85, p <0.001) and UIC (r = 0.57, P <0.001), while I/Cr had a better correlation with 
UIC~Cr (r = 0.86, P <0.001) than UIC (r = 0.52, P <0.001). 
  
Discussion  
The study population was defined as iodine sufficient when the WHO threshold of UIC >150 
(µg/L) was applied to all markers. When considered as a marker of individual iodine status, 
UIC, I/Cr and UIC~Cr underestimated urinary iodine excretion compared with estimated 24-h 
UIE though I/Cr had a better agreement with estimated 24-h UIE compared with the other 
markers. However, the urine samples were obtained from iodine sufficient populations and 
the results may not be generalisable to iodine deficient populations. 
  
Expressing urinary iodine excretion as µg/g of creatinine or as 24-h UIE in µg/day may not 
result in a more accurate assessment of iodine status of populations [74]. Our finding, that 
iodine status classified by spot UIC and I/Cr or UIC~Cr or estimated 24-h UIE was consistent 
in well-nourished pregnant women from iodine sufficient populations, suggests that the use of 
spot UIC as a marker would be appropriate in similar settings. Besides, the cost of measuring 
urine creatinine value that is required to estimate 24-h creatinine excretion would be a 
challenge for surveillance of iodine status by estimated 24-h UIE marker in large populations 
groups. Previous studies on populations of pregnant women also reported a consistent 
classification of iodine status using UIC and I/Cr [65, 67, 77, 78, 80] and using UIC and 
UIC~Cr [64]. However, using estimated 24-h UIE overestimated the percentage of pregnant 
women with iodine excess (≥500 units) and underestimated the percentage of iodine 
deficiency (<150 units) when compared with UIC and other spot urinary iodine markers (I/Cr 
or UIC~Cr). This finding of an overestimated percentage of iodine excess by 24-h UIE has 





current WHO UIC cut-off was established, which was derived from the 24-h UIE studies in 
SAC [41]. The 24-h urine volume is approximately 1.5 L in adults [216] which is higher than 
SAC and the 24-h UIE in adults would overestimate the UIC. There is limited data on the 24-
h urine volume at 12 weeks of gestation, however a study in healthy nulliparous women 
showed a 24-h urine volume of >1.5 L during pre-pregnancy period and at 30-32 weeks of 
pregnancy [227].  Moreover, inconsistent classification of iodine status has also been reported 
by UIC vs I/Cr in populations of pregnant women [64, 71, 81]. The differences in UIC and 
I/Cr may be due to variation in 24-h creatinine excretion [64, 66] or the urine samples were 
collected at a different gestational age in the studies. Unlike the median I/Cr which showed an 
increasing trend from trimester one to trimester three, the median UIC decreased with 
increasing gestational age in several studies [67, 71, 77]. The UIC variations may be caused 
by physiological adaptations of the thyroid gland and an increase in glomerular filtration rate 
as gestational age increases [78, 228]. The increased maternal iodine requirement for thyroid 
hormone synthesis and maternal to fetal iodine transfer may lead to low UIC in late 
pregnancy [78]. Increase in glomerular filtration rate may lead to increased urine output 
which decreases the UIC across the trimesters [67]. Hence, as median UIC is lower in late 
pregnancy, application of the same UIC cut-off across all trimesters may contribute to 
incorrect classification of iodine status in pregnant women. Trimester specific spot UIC cut-
points may be required to more accurately classify population-level iodine status during 
pregnancy [79].   
 
Our results of a poor agreement between UIC and I/Cr or estimated 24-h UIE or UIC~Cr 
show that UIC is not a suitable marker of individual iodine status in pregnant women [12]. 
Expressing UIC per g of creatinine or estimating 24-h UIE from spot UIC reduced within-day 
variation in iodine excretion of individuals [66, 67, 220] but does not address the day-to-day 





samples [62, 63]. Comparison of each of the markers with a gold standard (24-h UIE) is 
required to identify the most appropriate marker to assess individual iodine status of pregnant 
women. Though estimated 24-h UIE showed a better agreement with 24-h UIE than I/Cr in 
adults, Li et al. suggested to use I/Cr over the estimated 24-h UIE as a suitable marker of 
individual iodine status of pregnant women [67]. Li et al. argued that estimating 24-h UIE 
from spot UIC is unnecessary as urine creatinine is not different between individuals in a 
specific population of pregnant women; i.e. reproductive age group and females [67]. As 
shown in our results, the daily estimated creatinine excretion was not the same between 
participants, the mean ± SD of 1.2 ± 0.8 g/L, and I/Cr and estimated 24-h UIE were not 
exchangeable. Besides, the urinary creatinine excretion may vary depending on nutritional 
status, age, and ethnicity [69] which affects the value of I/Cr or estimated 24-h UIE. The 
UIC~Cr marker, which is less affected by creatinine excretion [64], was compared with both 
I/Cr and estimated 24-h UIE in our study. Our results showed a better agreement between 
UIC~Cr and I/Cr than between UIC~Cr and estimated 24-h UIE. No previous study assessed 
agreement between UIC~Cr and 24-h UIE and further research is required to identify the best 
predictor of 24-h UIE in pregnancy among all markers obtained from spot urine samples.  
 
The study has the following limitations: Firstly, we did not collect 24-h urine excretion so 
were unable to compare the agreement between markers from spot urine samples with the 
actual 24-h UIE. Secondly, we only assessed the urinary iodine markers at one time-point (12 
weeks of gestation), and the results may not be generalisable in all trimesters during 
pregnancy [29, 71]. Thirdly, we did not collect data on the type and timing of the spot urine 
collection (first morning urine, fasting or not fasting) as timing and fasting may affect the UIC 
[72]. Lastly, both the Mage et al. and the Kesteloot and Joosens equations to estimate the 24-h 
urinary creatinine excretion were established based on healthy adult populations. The only 





pregnant women is the anthropometric score. Our study was conducted in pregnant women at 
12 weeks of gestation and these women may not significantly differ from the non-pregnant 
women in terms of weight and body mass index.  
 
In conclusion, all markers from spot urine samples defined the study population as iodine 
sufficient according to the WHO criteria for UIC, and correcting iodine for creatinine may not 
increase the accuracy to define population-wide iodine status in pregnancy. UIC shows a low 
agreement with estimated 24-h UIE or I/Cr as a marker of individual-level iodine status in 
pregnant women. Further study comparing the agreement between urinary iodine markers 
from spot urine samples, and UIE measured from 24-h urine samples to define individual-
level iodine status in pregnant women is warranted. 
  
Acknowledgements 
We would like to acknowledge Dylan McCullough for assistance with urine sample selection 
and transporting the samples to the Waite Main Building, Waite Campus for analysis. 
  
Statement of authors’ contributions to the manuscript 
MMW and SJZ designed the study; MMW analysed the UIC and performed the data analyses; 
and MMW drafted the paper with input from all authors. CR contributed to design, 
supervision of data collection and interpretation of results and reviewed the manuscript. SJZ 
oversight the conduct of the study. All authors read and approved the final manuscript. 
 
Conflict of interest  
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Objective: This study aimed to evaluate the effect of mandatory iodine fortification of bread 
on the iodine status of South Australian populations using the newborn thyroid stimulating 
hormone (TSH) concentration as a marker. 
Design: The study used an interrupted time series design. 
Setting: TSH data collected between 2005 and 2016 (n=211,033) were extracted from the 
routine newborn screening program in South Australia for analysis. Iodine deficiency is 
indicated when more than 3% of newborns have TSH >5 mIU/l.  
Subjects: Newborns were classified into three groups: the pre-fortification group (those born 
before October 2009); the transition group (born between October 2009 and June 2010); and 
the post-fortification group (born after June 2010).  
Results: The percentage of newborns with TSH >5 mIU/l was 5.1%, 6.2% and 4.6% in the 
pre-fortification, transition and post-fortification groups, respectively. Based on a segmented 
regression model, newborns in the post-fortification period had a 10% lower risk of having 
TSH >5 mIU/l than newborns in the pre-fortification group [Incidence Rate Ratio (IRR): 0.90; 
95% confidence interval (CI): 0.87, 0.94], while newborns in the transitional period had a 
22% higher risk of having TSH >5 mIU/l compared with newborns in the pre-fortification 
period [IRR: 1.22; 95% CI: 1.13, 1.31].  
Conclusion: Using TSH as a marker, South Australia would be classified as mild iodine 
deficiency post-fortification in contrast to iodine sufficiency using median urinary iodine 
concentration as a population marker. Re-evaluation of the current TSH criteria to define 
iodine status in populations is warranted in this context. 










Iodine is an essential micronutrient required for synthesis of thyroid hormone [20], which is 
important for optimal growth and brain development [1, 2]. Iodine deficiency can affect 
thyroid hormone production, as indicated by altered levels of thyroxine (T4), tri-iodothyronine 
(T3) and thyroid stimulating hormone (TSH) [20]. Newborn TSH concentration is an indicator 
of fetal iodine nutrition prior to birth as iodine deficiency during fetal life can lead to an 
increase in the TSH concentration in the newborn [36, 137].  
 
Methods of monitoring iodine status of populations include measuring TSH concentrations in 
newborns, median urinary iodine concentration (UIC) in school aged children, and prevalence 
of goitre in school aged children [230]. According to the World Health Organization (WHO), 
United Nations Children’s Fund (UNICEF) and International Counsel for Control of Iodine 
Deficiency Disorders (ICCIDD) joint criteria, populations are classified as iodine deficient if 
more than 3% of newborns have TSH concentration >5 mIU/l in whole blood, or median UIC 
<100 μg/L, or goitre prevalence >5% in school aged children [230]. When TSH is used to 
classify population iodine status, the recent WHO recommendation [12] specified to use 
neonatal blood samples taken at 48-96 hours after birth because newborn TSH concentrations 
in the first 24 to 48 hours are higher due to the neonatal TSH surge [45] and are not 
recommended to be used to classify population iodine status.  
 
In Australia, newborn TSH concentration is routinely assessed in whole blood spot samples 
taken by heel-prick as part of the Newborn Screening Test [231]. The test aims to detect 
disorders such as congenital hypothyroidism and newborn errors of metabolism. Iodine 
deficiency re-emerged in Australia [17, 116, 117, 200], and as a result, mandatory iodine 





Australia are also recommended to take an iodine supplement of 150 μg per day since 
January, 2010 [107]. Following iodine fortification, the 2011-2012 National Health Survey 
and other surveys showed Australians are iodine sufficient as assessed by median UIC [29, 
131, 232]. Data on iodine status of the population in Australia using newborn TSH as a 
marker are scarce. A recent study conducted in the Western Australia showed mild iodine 
deficiency using this marker [52] but the population was iodine sufficient based on UIC 
[131]. There is a lack of national data that assessed population iodine status using newborn 
TSH as a marker in the post-fortification period including South Australia.  
 
Monitoring the iodine status of the population post-fortification using multiple markers is 
important to evaluate the efficacy and safety of iodine fortification program as disagreements 
between the TSH marker vs. median UIC or goitre prevalence in classifying iodine status of 
populations have been reported [45, 186]. In this study we use an interrupted time series (ITS) 
design to investigate newborn TSH levels before, during and after the implementation of 
mandatory iodine fortification program [233]. We also explore the impact of the intervention 
on the iodine status of the population using different TSH cut-offs to classify iodine status. 
Based on available evidence, we hypothesised that there will be a reduction in the proportion 




Design, setting and participants: This was an ITS study using population-level data 
collected across the entire state of South Australia from 2005 to 2016 (n=254,156). The TSH 
concentration of all neonates who underwent newborn screening, a routine test in South 
Australia with a screening rate of 98% [234], were extracted from the newborn screening 





blood samples were taken from neonates by heel-prick. Newborn TSH concentration was 
determined using Dissociation-Enhanced Lanthanide Fluorescence Immunoassay (DELFIA). 
The same method was used for the assessment of TSH over the entire study period. Newborns 
with congenital hypothyroidism, defined as newborn TSH concentration ≥13 mIU/l, were 
excluded from the study (n=388).  
 
Outcome:  
The primary outcome of this study was iodine status of the population as defined by the 
percentage of newborns with TSH >5 mIU/l based on the WHO criteria [230]. These criteria 
classify a population as iodine sufficient if the percentage of newborns with TSH >5 mIU/L is 
<3%, and as mildly, moderately and severely iodine deficient if the percentage of newborns 
with TSH >5 mIU/l is 3-19.9%, 20-39.9% and >40%, respectively [230]. Newborn TSH 
concentration declines over the first few days after birth [235, 236] and newborns sampled 
between 48-72 hours after birth had a higher median TSH concentrations than those sampled 
72-96 hours after birth [52]. We considered the percentage of newborns with TSH >6 mIU/l 
as a secondary outcome [179], since the majority of the samples were collected early at 48-72 
hours after birth when TSH concentrations are higher.  
 
Exposure: 
Newborns were classified into three groups based on their exposure to the mandatory iodine 
fortification during their fetal growth period assuming a full-term pregnancy of nine months. 
Since the fortification program was implemented in October 2009, newborns born before 
October 2009 formed the pre-fortification group. Newborns born between October 2009 and 
June 2010 formed the transitional group, as the fetal growth of these children occurred 





the post-fortification group, as these children would have been conceived after the 
fortification program was mandated. 
 
Time varying confounders:  
In this study, time varying confounders are population characteristics that change over time. 
The timing of blood sample collection, birthweight and season at birth were adjusted in the 
analysis as potential time varying confounders. The timing of blood sample collection for 
TSH assessment has been shown to affect the newborn TSH concentration [43, 52, 183], with 
early blood samples collected in the first 24 hours of birth having higher TSH concentration 
due to the surge in neonatal TSH [45]. Low birthweight infants have been shown to have 
higher TSH concentrations [52, 237] and infants born in the spring and winter seasons had a 
higher TSH concentration due to cold atmospheric temperature [238]. Percentage of low 
birthweight infants may vary across time [239]. Use of iodine-containing antiseptics during 
delivery [45], gestational age at birth [47], sex of the newborn [47, 52], organochlorine 
pesticides exposure in perinatal period [50], and mode of delivery [45, 46] have been shown 
to affect TSH concentration, but there was little change in these factors over the study period 
in south Australia [240].   
 
Statistical Analysis:   
The data were analysed using Stata 14 (Statacorp LP, College Station, Texas). Median 
(interquartile range (IQR)) of TSH concentration and percentage of newborns with TSH 
concentration >5 mIU/L were calculated for the overall samples as well as separately by 
fortification group, newborn characteristics and year of sampling. Descriptive analyses were 
repeated for the percentage of newborns with TSH concentration >6 mlU/l. Chi-square tests 
were used to compare newborn characteristics (for categorical variables) and the percentage 





used to compare the median TSH concentration between subpopulations defined by newborn 
characteristics. 
 
A segmented regression analysis [241] was employed to assess the effect of mandatory iodine 
fortification on the percentage of newborns with TSH concentration >5 mIU/l. Newborns with 
heel-prick blood sampled outside of the WHO recommendation of three to four days (48 to 96 
hours) after birth were excluded from the segmented regression analysis. Newborns with 
missing information on time of blood sampling, or birthweight, or improbable values for 
birthweight, defined as <300 gm or >10 kg, were also excluded from the segmented 
regression analysis. Sex and gestational age were not included in the segmented regression 
analysis because data on sex were incomplete for post-fortification groups, while data on 
gestational age were incomplete for pre-fortification groups.   
 
The primary analysis was an unadjusted analysis performed using a Poisson regression model 
with the number of newborns with TSH >5 per month as the outcome, the fortification groups 
as the primary predictor variable and the natural logarithm of the total number of newborns 
per month as an offset. Over-dispersion was handled by estimating the scale parameter by 
Pearson’s chi-square statistic divided by the degrees of freedom. Several exploratory adjusted 
analyses were also performed. Firstly, birthweight and infants’ age at sampling were adjusted 
in the model to control for possible time varying confounding. To allow for changes over time 
in birthweight we used the mean or median birthweight or the percentage of infants with low 
birthweight per month. Both linear and quadratic effects were considered. To examine 
potential changes over time in the infants’ age at sampling we tested the median age at 
sampling or the percentage of infants sampled in each 6-hour period for each month. Akaike 
information criterion (AIC) was used to choose the best way to model the birthweight and 





better model fit. Secondly, season of birth was included to model any seasonal trends in the 
data. Finally, time in months was included as a predictor to allow for a linear trend over time 
and an interaction between time in months and fortification group was included to test for 
possible slope changes between fortification periods. 
 
Global tests were performed to assess whether there was any evidence of a jump in the 
percentage of newborns with TSH >5 mIU/l (fortification group effect) or, in exploratory 
analyses, a slope change (time in months by fortification group interaction effect) between the 
fortification periods. The effect of fortification group on the percentage of newborns with 
TSH concentration >5 mIU/l was reported as the incidence rate ratio (IRR) with a 95% 
confidence interval. A p- value less than 0.05 was considered statistically significant. 
 
Results 
Characteristics of the study population 
Of the 254,156 newborns for whom TSH data were available, 388 were diagnosed with 
congenital hypothyroidism (15 per 10,000 births) and were excluded from the analysis. A heel 
prick blood sample was collected between 48 and 96 hours after birth in 213,642 (84.0%) 
newborns. Of these, 211,033 (98.8%) had data on birthweight and were included in the 
segmented regression analysis (Figure 5.1).  
 
Table 5.1 shows the characteristics of the study population. The majority (91%) of newborns 
were sampled 48-72 hours after birth, both in the pre- and post-fortification periods. The 
percentage of newborns with TSH >5 mIU/l was higher in males than females, higher in 
lower birthweight than normal birthweight infants, higher in preterm than term infants, and 





newborns with TSH >5 mIU/l and median TSH concentrations were highest in newborns 
blood sampled at two days of age and declined afterwards (Figure 5.2).  
Figure 5. 1 Flow chart of participants  





Newborns screened for congenital 
hypothyroidism  
n=254156 
Newborns included in the 
segmented regression analysis 
n= 211033  




- Congenital hypothyroidism: 
TSH ≥13 n=388 
 
Newborns excluded from the 
segmented regression analysis, 
n=42735*   
- Sampled before 48 hours or 
after 96 hours from birth, n= 
40345 
- No birthweight data, 
n=3,485 
- Extreme outliers for 
birthweight (<300 g or 














Abbreviations: n, number of samples; hrs, hours. 
aThe sample size for sex: n 58858;  
b The sample size for gestational age: n 136958  
*The p values were from the Chi-square test for all three groups. 







Neonatal age at blood sampling: 
48-72 hrs 
190997 75850 (90.7) 12200 (89.3) 102947 (90.5) <0.01 
Sex a: Males 30171 19432 (50.9) 3500 (52.0) 7239 (51.8) <0.01 
Birthweight: <2500 g 14720 5438 (6.5) 944 (6.9) 8318 (7.3) <0.01 
Gestational age b: <37 weeks 23456 2383 (15.3) 2021 (15.7) 19052 (17.5) <0.01 
Season         <0.01 
Summer 51736 20115 (24.0) 4457 (32.6) 27164 (23.9) 
Autumn 53591 22037 (26.4) 4686 (34.3) 26868 (23.6) 
Winter 53166 22377 (26.8) 1515 (11.1) 29274 (25.7) 





Iodine status in the pre-fortification, transition and post-fortifications periods   
The median TSH concentration was 2.0 mIU/l (IQR 1.3-2.9) in the post-fortification period, 
2.0 mIU/l (IQR 1.2-3.1) in the transitional period and 1.7 mIU/l (IQR 1.0-2.7) in pre-
fortification period. Figure 5.3 presents the percentage of newborn with TSH concentration 
>5 mIU/l and >6 mIU/l. The percentage of newborns with TSH concentration >5 mIU/l was 
lower in the post-fortification (4.6%) period than the pre-fortification (5.1%) and transition 
(6.2%) periods (P value <0.01) (Figure 5.3). Using samples collected at 72-96 hours after 







Figure 5. 2 Median TSH concentration and % of TSH concentration >5 mIU/L by neonatal age at blood sampling, 2005-2016, South Australia (n 
239 182).  



































Age in days at blood sampling 
% Pre-fortification % Transition % Post-fortification





Table 5. 2 Comparison of the percentage of TSH >5 mIU/L and median TSH concentration of newborns by potential time varying confounders, 











Abbreviations: TSH, thyroid stimulating hormone; IQR, inter quartile range; n, number of samples.  
a Denominator was N=211,033 unless otherwise specified.  
b The Denominator was N=58858  
c The Denominator was N= 136958  
* The p values were from the Chi square test.  
** The p values were from the Kruskal-Wallis test.  
Variables % TSH >5 mIU/L 
n (%)a 
P-value * Median TSH 
(mIU/L) 
IQR (mIU/L) P-value ** 
Neonatal age  <0.01   <0.01 
48-72 hrs 9799 (5.1) 1.9 1.2, 2.9 
72-96 hrs 584 (2.9) 1.6 1.0, 2.4 
Sex  <0.01   <0.01 
Males 1451 (4.8)b 1.8 1.1, 2.7 
Females 1065 (3.7)b 1.6 1.0, 2.5 
Birthweight  <0.01   <0.01 
>2,500g 9345 (4.8) 1.9 1.2, 2.8 
≤2,500g 1308 (7.0) 2.0 1.3, 3.1 
Gestational age  0.01   0.73 
≥37 weeks 5704 (5.0)c 2.0 1.3, 2.9 
<37 weeks 1282 (5.5)c 2.0 1.3, 2.9 
Season  <0.01   <0.01 
Summer 2475 (4.8) 1.9 1.2, 2.8 
Autumn 2512 (4.7) 1.8 1.2, 2.8 
Winter 2741 (5.2) 1.9 1.2, 2.9 





Effect of mandatory iodine fortification of bread on iodine status of the population    
In the primary unadjusted segmented regression analysis, newborns in the post-fortification 
period had a 10% lower risk of having TSH concentration >5 mIU/L than newborns in the 
pre-fortification group [IRR: 0.90, 95% confidence interval (CI): 0.87, 0.94]. Newborns in the 
transitional period had a 22% higher risk of having TSH concentration >5 mIU/L compared 




Figure 5. 3 Percentage of newborns with TSH concentration exceeding different cut-offs, 
2005-2016, South Australia (n 211033).  




























Table 5. 3 The effect of fortification on the proportion of newborns with TSH concentration >5 mIU/L using segmented regression analysis, 
2005-2016, South Australia (n 211033)       
 Pre- fortification Transition Post-fortification 
 IRR(95% CI) IRR(95% CI) P-value IRR(95% CI) P-value 
Unadjusted Model Reference 1.22 (1.13, 1.31) <0.01 0.90 (0.87, 0.94) <0.01 
 
Adjusted Model 1 Reference 1.17 (0.96, 1.43) 0.12 0.88 (0.78, 0.99) 0.04 
 












































1.43 (1.10, 1.85) 
 
0.01 
Abbreviations: IRR, incidence rate ratio; CI, confidence interval. 
Model 1: adjusted for only the linear and quadratic effects for the percentage of infants with low birthweight  
Model 2: adjusted for only the linear and quadratic effects for the percentage of bloods sampled in each six-hour period  
Model 3: adjusted for only season at birth 
Model 4: adjusted for season, linear and quadratic effects for the percentage of bloods sampled in each six-hour period and linear and quadratic 
effects for the percentage of infants with low birthweight 
Model 5: The adjusted model that includes time in months and also adjusted for season, linear and quadratic effects for the percentage of infants’ 





Effect estimates (IRR) were similar in the adjusted exploratory models (models 1-4) except 
model 5 when time in months was included in the adjustment, which changed the direction of 
the effect in the post-fortification period and substantially increased the CIs (Table 5.3). 
There was no evidence of an interaction between the fortification periods and time in months 
(interaction p value= 0.35) and hence the interaction term (fortification groups and time) was 
not included in the final adjusted models. 
 
Based on the predicted values of the exploratory segmented regression including fortification 
group and time in months in the model, there was a jump in the proportion of TSH >5 mIU/L 
at the commencement of the iodine fortification, followed by a decreasing trend throughout 
the post-fortification period which was similar to the trend seen in the pre-fortification period 
(Figure 5.4). Based on the counterfactual model, the proportion of TSH >5 mIU/L would also 
decrease in the post-fortification period even if the mandatory iodine fortification of bread 







Figure 5. 4 Percentage of TSH >5 mIU/L across time in months based on a segmented 
regression model, 2005-2016, South Australia.  
Dotted line, observed data; solid line, predicted values; dashed line, predicted trend without 
introduction of fortification based on an unadjusted regression model including fortification 
group and time. TSH, thyroid stimulating hormone. 
 
Discussion  
The present study assessed the effect of the mandatory iodine fortification program in the 
South Australian population. Using one of the recommended markers of population iodine 
status, the percentage of newborns with TSH concentration >5 mIU/L, South Australia would 
be classified as mild iodine deficiency post-fortification. Our finding of mild iodine 
deficiency in South Australia using newborn TSH as a marker is in contrast to iodine 
sufficiency defined by median UIC among school aged children [131], pregnant women [29] 
and breast-milk iodine concentration [232] in South Australia post-fortification. The majority 





increase the percentage of newborns with TSH concentration >5 mIU/L and contribute to the 
discrepancy in the classification of iodine status between the two markers of population 
iodine status of UIC and newborns TSH. The WHO criteria specify using newborn TSH 
assessed between 48 and 96 hours after birth to classify iodine status of populations. Our data 
showed that TSH concentrations of samples collected 48-72 hours after birth were higher than 
samples collected 72-96 hours after birth. The population became iodine sufficient if samples 
collected between 72 and 96 hours after birth were used. A similar finding has also been 
reported in Western Australia, where the population was iodine sufficient based on the 
median UIC [131] but mildly iodine deficient using TSH as a marker in the post-fortification 
period [52]. In the Western Australian study, the percentage of newborns with TSH 
concentration >5 mIU/L was higher in samples collected 48-72 hours after birth [52] similar 
to our study. Discrepancies in classifying population iodine status using newborns TSH 
concentration versus median UIC have also been reported elsewhere [43, 179, 186]. Evans et 
al [179] and Vandevijvere et al. [186] reported iodine deficiency by median UIC [43, 186] 
though a population study using newborn TSH showed iodine sufficiency. However, TSH 
was measured from blood sampled between 72-120 hours of age, outside the WHO 
recommendation, which may partly explain the difference. Furthermore, the acute perinatal 
stress during the early neonatal period may increase the TSH concentration in a healthy 
newborns with blood sample taken prior to 72 hours compared with newborns sampled after 
72 hours of birth [236, 237].   
 
Many countries have shifted to earlier blood sampling for neonatal screening due to earlier 
discharge from hospitals. This change in the practice may affect the newborns TSH value and 
the percentage with TSH >5 mIU/L at a population-level even that blood samples were 
collected within the WHO recommended 48 to 96 hours’ time frame. In countries with earlier 





birth may not be appropriate since early samples have a higher TSH concentration and this 
may lead to incorrect classification of iodine status. When a higher cut-off of 6 mIU/L for 
TSH was used, we found that South Australia was iodine sufficient post-fortification, 
consistent with finding from the 2011-2012 National Health Survey which indicated iodine 
sufficiency in South Australia [131]. In contrast, Evans et al [179] called for WHO to modify 
its criteria and showed that using a cut-off of 2 mIU/L and 3 mIU/L for samples collected 
from 72 hours after birth was consistent with UIC. Together, these data suggest that in 
countries with earlier blood sampling for newborn TSH, increasing either the cut-off TSH 
value of 5 mIU/L, or the percentage of newborns with TSH concentration >5 mIU/L used to 
define iodine deficiency, or applying specify cut-offs for TSH depending on when the 
newborn blood was sampled may improve the consistency between TSH and median UIC in 
the classification of iodine status. In such countries like Australia, the newborn TSH 
concentration >5 mIU/L at its current cut-off of >3% may not be appropriate marker for 
classifying iodine status of populations.  
 
Different cut-offs have been applied to newborn TSH for estimating population iodine status 
in the literature. Most studies use the 5 mIU/L TSH cut-off [179, 186, 200] while others use 
values rounded to one decimal place (5.0 mIU/L) [52, 54]. The WHO recommends using TSH 
concentration >5 mIU/L [12, 230], however recent sensitive TSH assays make reporting of 
TSH levels to one decimal place possible. It has been shown that using TSH results rounded 
to the nearest whole number and applying a 5 mIU/L cut-off decreased the percentage of 
newborns with elevated TSH concentration compared with using TSH results rounded to one 
decimal place and applying a 5.0 mIU/L cut-off [52]. This discrepancy is due to rounding a 
TSH results between 5.0 mIU/L and 5.5 mIU/L to a whole number (5 mIU/L) and applying a 





TSH concentration to more than one decimal place [52, 242], an update to the TSH cut-off 
value with one decimal place is suggested.  
  
There have been debates over whether the current WHO criteria of newborn TSH 
concentration >5 mIU/L above 3% is appropriate to define iodine deficiency [45, 52, 54, 179, 
186]. Due to the discrepancy between TSH and UIC to classify population iodine status, 
Burns et al [54] and Vandevijvere et al. [186] suggested to use the trend of percentage of TSH 
concentration >5 mIU/L over time to see the change in the iodine status of populations. 
Though the trends are important to observe changes in iodine status over time, the cut-off on 
the percentage of newborn TSH concentration >5 mIU/L is required to classify iodine status 
in populations using this marker.  
 
The post-fortification group had a 10% lower risk of newborn TSH concentration >5 mIU/L 
compared with the pre-fortification group. This indicates the success of both the mandatory 
iodine fortification of bread and the recommendation for routine iodine supplementation in 
pregnancy in Australia to lower the risk of iodine deficiency. This finding is consistent with 
studies in Ireland [54], Armenia [243] and Switzerland [84] that showed a declining trend in 
the percentage of newborn TSH concentration >5 mlU/l after introduction of iodine 
fortification or salt iodisation. However, an exploratory analysis controlling for timing of 
blood sample collection, birthweight, season at birth and the underlying time trend resulted in 
a reversing of the effect estimate and a loss of precision. These seemingly contradictory 
results are due in part to the underlying time trend, which suggests that the percentage of 
newborns with TSH concentration >5 mIU/L was decreasing over time even before 
fortification was introduced. Although the actual percentage of TSH above 5 mIU/L in the 
post-fortification period is lower than the pre-fortification period, it is higher than the 





clear explanation for the decreasing time trend in the pre-fortification periods. Increased 
awareness of the re-emergence of iodine deficiency in Australia from the 2006 national iodine 
nutrition survey may have led to increasing iodised salt use in place of non-iodised salt in the 
population, which may partly explain the decreasing time trend observed in the pre-
fortification [244].  
 
Surprisingly, the percentage of TSH concentration >5 mIU/L and the median TSH 
concentration increased during the transitional period despite that TSH was measured using a 
same method over the entire study period. Our finding of a transient increase in the TSH 
concentration in the transitional period could be explained by the acute Wolf Chaikoff effect 
[26], which refers to a transient inhibition of thyroid function when iodine deficient 
populations exposed to a sudden increase in iodine intake, like in Australia from a 
combination of iodine supplementation in pregnancy and mandatory iodine fortification of 
bread during the transition period. A recent study reported that the mean iodine intake of 
pregnant women in South Australia who took iodine supplements at the recommended dose of 
150 µg/day or above was 377 µg/day, which was well above the Recommended Dietary 
Intake (RDI) for iodine in pregnancy [29]. In addition, based on the median UIC, 20% of 
Australian children aged 2-3 years [245] and 24% of South Australian infants aged 3 months 
[246] had iodine intake above the upper level of safe intake in the post-fortification period 
[245]. A national bread consumption survey [245] conducted in 2010 also indicated that 
iodine content varied in the transitional period, with some as high as 270 µg/100g of bread in 
contrast to the target level of 46 µg/100g of bread [16]. Implementation of both the mandatory 
iodine fortification of bread in October 2009 [247] followed by the recommendation for 
routine iodine supplementation in pregnancy in January 2010 [107] in Australia may have 
resulted in a transient inhibitory effect on thyroid function due to a sudden increase in iodine 





and excess iodine. Elevated newborn TSH concentration of above 17 mIU/L was reported in 
an iodine deficient population exposed to increased intake above requirements, suggesting a 
transient inhibitory effect on the synthesis of thyroid hormones [248]. A transient inhibitory 
effect from a sudden increase in iodine intake during the implementation of the fortification 
and supplementation programs may contribute to a sharp increase in the percentage of TSH 
above 5 mIU/L in the transitional period [26]. In the post-fortification period, the population 
(including childbearing aged women) became iodine sufficient [29, 131]. The same level of 
iodine intake in the post-fortification period is unlikely to cause the acute Wolf Chaikoff 
effect as women entering pregnancy were no longer iodine deficient.  
 
Our study reported seasonal variation in the percentage of newborns with TSH concentration 
>5 mIU/L in the study period and this was slightly higher in winter and spring compared with 
summer and autumn. A similar seasonal pattern was observed in Belgium [238]. Seasonality 
in TSH concentration may due to variation in dietary iodine intake (mainly fish and iodine 
fortified foods) [238] but there are no data on the seasonality of bread consumption in 
Australia. Cold weather conditions can increase thyroid hormone secretion, and this may 
contribute to the higher TSH concentrations observed in winter and spring [249, 250]. 
 
The current study has a number of limitations. Firstly, iodine supplementation for pregnant 
women was recommended by National Health and Medical Research Council in January 
2010, shortly after the implantation of the fortification program. Therefore, it was not possible 
to examine the effect of the fortification separately from the supplementation program. 
Secondly, gestational age was not controlled in the final model due to incomplete information 
but we controlled for birthweight as a proxy which is highly correlated with gestational age 
[239]. Thirdly, we did not adjust the caesarean section rate because the data was not collected 





study period and is unlikely to affect the percentage of TSH >5 mIU/L over the study period 
[240]. Fourthly, due to a move towards earlier discharge of mothers and newborns from 
hospital, a majority of newborns were sampled 48 to 72 hours after birth for newborn 
screening. As a result, there is a difference in the mean timing of blood sampling between the 
three fortification periods which may increase the percentage of newborns with TSH 
concentration >5 mIU/L in the post-fortification period. Although we attempted to control for 
this variation in the timing of blood sample collection in the analysis by considering the 
percentage of infants sampled in each 6-hour period, there may be a residual effect.  
 
Conclusions  
Using newborn TSH as a marker, South Australia would be classified as mild iodine 
deficiency post-fortification in contrast to iodine sufficiency based on the median UIC, the 
most widely used population marker of iodine status. Our study together with the literature 
suggest the newborn TSH concentration >5 mIU/L at its current cut-off of >3% may not be a 
reliable marker for defining the iodine status of populations. There has been a change in 
clinical practice worldwide towards early discharge from hospital and newborn bloods are 
collected early for the newborn screening. Re-evaluation of the current WHO criteria on TSH 
as a marker of population iodine status is warranted in this context.   
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Background: Iodine deficiency re-emerged in Australia and that led to the implementation of 
mandatory iodine fortification of bread in October 2009. There is no study that compared the 
iodine status of pregnant women pre- and post- iodine fortification in pregnant women from 
low socio-economic status (SES).     
Objectives: To assess and compare iodine status before and after the mandatory iodine 
fortification of bread in pregnant women from low SES in South Australia.  
Methods: A comparative study using spot urine samples collected (between 12 to15 weeks of 
gestation) from two pregnancy cohort studies conducted before (n = 600) and after (n = 600) 
the mandatory fortification of bread in pregnant women from low SES. SES was determined 
based on a relative social economic index for areas. Urinary iodine concentration (UIC) was 
measured using a modified Sandell-Kolthoff (S-K) spectrophotometric method. Iodine 
deficiency during pregnancy was defined based on the WHO criteria of median UIC <150 
µg/L.  
Results: The median [Inter Quartile Range (IQR)] UIC of pregnant women was 103 (65 163) 
µg/L in the pre-fortification cohort. In the post-fortification cohort, the median (IQR) UIC 
were 210 (125, 338) µg/L for all pregnant women and 162 (106, 232) µg/L for pregnant 
women who did not take iodine-containing supplements.   
Conclusions: Iodine status of pregnant women from low SES improved from deficiency pre-
fortification to sufficiency post-fortification period regardless of whether iodine-containing 
supplements were consumed. National iodine survey on pregnant women is warranted to 
confirm iodine sufficiency in other states of Australia.  






1. Introduction  
Iodine is an essential micronutrient needed for the synthesis of thyroid hormones, which are 
important for proper growth and development [3]. Iodine requirements increase during 
pregnancy to fulfil the feto-placental demand for thyroid hormone [251]. Iodine deficiency 
during pregnancy can lead to adverse pregnancy outcomes [252] and impaired 
neurodevelopment in children [65, 212]. According to the World Health Organization 
(WHO), pregnant women are classified as iodine deficient if the median UIC is less than 150 
µg/L in a representative sample of pregnant women [178]. 
  
Iodine deficiency re-emerged in Australia [17] and that led to the implementation of 
mandatory fortification of salt used in bread making in October 2009 [16]. Dietary modelling 
suggested that the increased intake from fortified bread was not enough to meet the 
recommended dietary intake in pregnancy and breastfeeding [253]. Hence, the Australian 
National Health and Medical Research Council recommends that pregnant and breastfeeding 
women take iodine supplements of 150 µg/day followed soon after the mandatory iodine 
fortification [107]. The mandatory iodine fortification of bread has been successful in 
preventing iodine deficiency in the general population and reproductive-age women in 
Australia [131], but the impact on the iodine status of pregnant women is uncertain due to a 
lack of nationally representative data. There is only one study that met the WHO 
recommended sample size to assess iodine status in populations of pregnant women [29]. That 
study (n = 783) was conducted in South Australia and showed iodine sufficiency. However, 
one small study in low socio-economic status (SES) (n = 196) in South Australia suggested 
that pregnant women remained iodine deficient post-fortification [39]. 
  
It is well recognised that most individuals from low SES have a low dietary quality with low 





iodine status of populations, particularly in low SES. Pregnant women from low SES may also 
have a higher risk of iodine deficiency as studies showed low compliance with iodine 
supplementation recommendation [255, 256] and low intake of fish and seafood due to the cost 
[254]. Monitoring of iodine status will help to ensure either deficient or excess levels of iodine 
do not widely occur in vulnerable groups of the population. Hence, this study aimed to assess 
and compare the iodine status of pregnant women from low SES in South Australia before and 
after the mandatory iodine fortification of bread.  
2. Methods  
2.1 Study design, setting and participants 
A comparative study. We used urine samples collected from pregnant women participating in 
two pregnancy cohort studies: the SCOPE (screening for pregnancy end points) [257] and 
STOP (screening tests to identify poor outcome in pregnancy) [222]. All pregnant women 
were recruited from the Lyell McEwin Hospital in Elizabeth Vale, northern Adelaide, South 
Australia, and were from the most disadvantaged suburbs in South Australia based on a 
relative social economic index for areas that measures the relative disadvantage [258]. 
Although the relative social economic index for areas summarises the socio-economic 
conditions of population groups within an area, it application to classify SES at individual 
level is limited [226]. Women in the SCOPE study recruited between 2006 and 2008 formed 
the pre-fortification cohort and women in the STOP study recruited between 2015 and 2017 
formed the post-fortification cohort. All women were nulliparous, and the mean gestational 
age was less than 15 weeks at study entry. Women with multiple pregnancy, major fetal 
anomalies, ≥3 terminations of pregnancy or ≥3 miscarriages and known chronic disease were 
excluded in both studies [222, 257]. A random spot urine sample was collected from all 
pregnant women at study entry and all samples were stored at -80 degrees Celsius for 
analysis. Data on socio-economic and demographic characteristics were collected at study 





addition, information on dietary supplement intake at study entry was also collected in the 
post-fortification cohort. Maternal measurements of height and weight, as well as urine 
sample collection, were performed by research midwives. A total of 1,165 nulliparous women 
participated in the SCOPE study in Adelaide, South Australia and 1,373 women in the STOP 



















Figure 6. 1 Selection of participants of the SCOPE and STOP cohorts  
Notes: SCOPE, screening for pregnancy end points; n, number of participants; STOP, 
screening tests to identify poor outcome in pregnancy; UIC, urinary iodine concentration.  
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Based on the WHO recommendation, a sample size of 600 to 900 is sufficient, in most 
instances, to have a reasonable confidence interval around the percentage estimate for iodine 
deficiency [12]. Andersen et al. [63] also suggested the number of spot urine samples required 
to estimate the iodine status in a population with 95% confidence and a 5% precision was 
about 500. Six hundred women were randomly selected from each cohort with a total of 1,200 
pregnant women included in this study.  
2.2 Outcome  
Urinary Iodine Concentration (UIC): Iodine status of pregnant women assessed by median 
UIC. A modified Sandell-Kolthoff spectrophotometric method (WHO’s method B) [223] was 
used to analyse the iodine concentration in the spot urine samples. The SeronormTM (SERO) 
Trace Elements Urine L-2 (LOT 1403081) was used as the external reference. The mean 
iodine concentration of the SeronormTM obtained was 299 (SD 12) μg/L compared with the 
certified reference iodine concentration of 297 (95% CI: 237-356) μg/L. The lower limit of 
detection was 10 μg/L and the limit of quantification of the assay was 30 μg/L. The intra-
assay and inter-assay coefficient of variation (CV) was 5.4% and 3.2%, respectively.  
2.3 Statistical Analysis   
Data were analysed using Stata 15 (Statacorp LP, College Station, Texas). Iodine status was 
reported as median UIC in µg/L. The iodine status of pregnant women was categorised into 
iodine deficiency (<150 μg/L), sufficiency (150-249 μg/L), more than adequate (250-500 µg/L) 
and excess (≥500 µg/L) based on the WHO criteria [12]. Pearson chi-square test was used to 
compare the percentage of pregnant women with UIC <150 μg/L between the cohorts. As UIC 
is not normally distributed, Kruskal wails test, a non-parametric test, was used to compare the 
median UIC between the two cohorts and across maternal characteristics in each cohort. UIC 
was compared between maternal age ≤19 years (young maternal age), 20-34 years and ≥35 





outcomes [259]. A comparison was also made between women who took iodine-containing 
supplements vs. those who did not take the supplements in the post-fortification cohort where 
data on intake of supplements were collected. Statistical significance was set at a value of 
P <0.05. 
3. Results  
3.1 Participant characteristics  
Table 6.1 presents the characteristics of the study participants. The mean ± SD age of 
participants was 25 ± 5 years. More women were Caucasian, smoked, consumed alcohol and 
were obese at study entry in the pre-fortification cohort compared with women in the post-
fortification cohort, while more women completed tertiary education in the post-fortification 
cohort compared with women in the pre-fortification cohort. 
 
Table 6. 1 Characteristics of study participants  




n 1200 600 600 
Age, y  24.6 ± 5.1 23.4 ± 4.9 25.7 ± 5.0 
Age category, y     
≤19 205 (17.1) 141 (23.5) 64 (10.7) 
20-34 945 (78.8) 442 (73.8) 503 (83.8) 
≥35 49 (4.1) 16 (2.7) 33 (5.5) 
Married, n (%)   1034 (86.2) 511 (85.3) 523 (87.2) 
Caucasian race, n (%)    1056 (88.1) 553 (92.3)     503 (83.8) 
Completed tertiary education, n (%)    160 (13.3) 51 (8.5)       109 (18.2) 
Consumed alcohol during first trimester, 
n (%)    
303 (25.3) 213 (35.6) 90 (15.0) 
Smoked during first trimester, n (%)    334 (27.9) 228 (38.1)     106 (17.7) 
Took iodine-containing supplements 
during first trimester, n (%)    
NA NA 450 (75) 
BMI, kg/m2  27.2 ± 6.9 26.6 ± 6.4     27.9 ± 7.2 
Obese, n (%)    332 (27.7) 145 (24.2) 187 (31.2) 
Notes: Values are presented as frequencies (percentages) or means ± SDs. BMI, body mass 
index; SD, standard deviation; SCOPE, screening for pregnancy end points; STOP, screening 






3.2 Iodine status in pregnant women pre- and post- mandatory iodine fortification of 
bread  
As shown in Table 6.2, pregnant women in the pre-fortification cohort were iodine deficient 
while those in the post-fortification cohort were iodine sufficient based on the median UIC. 
The median UIC was higher (210 µg/L vs. 103 µg/L, p <0.001) and the percentage of 
pregnant women with UIC <150 µg/L was lower (31.0% vs. 71.7%, p <0.001) in the post-
fortification cohort than the pre-fortification cohort. However, the percentage of pregnant 
women with UIC >500 µg/L was higher (11.5% vs. 2.0%, P <0.001) in the post-fortification 
cohort than the pre-fortification cohort. In the post-fortification cohort where data on the 
intake of supplements were collected, the median (IQR) UIC was 242 (142, 377) µg/L for 
women who took iodine-containing supplements and 162 (106, 232) µg/L for those who did 
not take supplements, indicating iodine sufficiency regardless of whether women took iodine-
containing supplements.  





P value a 
n 600 600  
Median UIC (IQR), µg/L 103 (65, 163) 210 (125, 338)                     0.0001b 
UIC <50 µg/L, n (%)   99 (16.5) 14 (2.3) <0.0001c 
UIC: 50-149 µg/L, n 
(%)   
331 (55.2) 172 (28.7)  
UIC: 150-299 µg/L, n 
(%)   
117 (19.5) 168 (28.0)  
UIC: 300-499 µg/L, n 
(%)   
41 (6.8) 177 (29.5)  
UIC >500 µg/L, n 
(%)   
12 (2) 69 (11.5)  
 
Notes: Values are presented as frequencies (percentages) or medians (IQR). IQR, inter-
quartile range; SCOPE, screening for pregnancy end points; SD, standard deviation; STOP, 
screening tests to identify poor outcome in pregnancy; UIC, urinary iodine concentration.  
a The p values were for comparison of UIC and iodine status between SCOPE and STOP 
studies.  





c Pearson chi-square test.   
 
3.3 Comparison of iodine status in pregnant women by maternal characteristics  
As depicted in Table 6.3, the median UIC and percentage of women with UIC <150 µg/L 
were not different across maternal characteristics except age and obesity status in both 
SCOPE and STOP. Younger pregnant women aged ≤19 years had lower median UIC in 
STOP when compared with women aged 20-34 years of age or with advanced maternal age 
(≥35). Obese women had a higher median UIC when compared with non-obese women in 





Table 6. 3 Comparison of the median urinary iodine concentration by maternal characteristics  
Variables  SCOPE (Pre-fortification) STOP (Post-fortification) 
 Median UIC 
(IQR), µg/L  




Median UIC (IQR), 
µg/L   
P-value 
a  





n 600    600    
Age, years           
≤19 109 (66, 155) 0.43 104 (17.4) 0.79 168 (119) 0.05 23 (3.8) 0.62 
20-34 102 (65, 163)  314 (52.4)  217 (128, 339)  152 (25.3)  
≥35 71 (43, 164)  12 (2.0)  268 (125, 503)  11 (1.8)  
Obese           
Yes   126 (81, 180) <0.001 87 (14.5) <0.001 237 (142, 377) 0.04 49 (8.2) 0.09 
No  98 (60, 149)  343 (57.3)  200 (119, 322)  137 (22.8)  
Ethnicity         
Caucasian 103 (65, 162) 0.56 400 (66.8) 0.30 202 (125, 322) 0.09 158 (26.3) 0.62 
Others 106 (77, 173)  30 (5.0)  255 (132, 380)  28 (4.7)  
Completed tertiary 
education 
        
No 103 (65, 162) 0.78 397 (66.3) 0.24 202 (122, 321) 0.27 157 (26.2) 0.05 
Yes  112 (51, 182)  33 (5.5)  245 (146, 391)  29 (4.8)  
Consumed alcohol 
during 1st trimester  
        
No  106 (66, 162) 0.30 278 (46.4) 0.86 204 (122, 339) 0.43 164 (27.4) 0.14 
Yes  97 (60.7, 165)  152 (25.4)  237 (152, 336)  22 (3.7)  
Smoked during 1st 
trimester 
        
No  103 (66, 162) 0.80 266 (44.4) 0.95 216 (132, 342) 0.12 145 (24.2) 0.06 
Yes  103 (63, 163)  164 (27.4)  185 (113, 323)  41 (6.8)  
Took iodine-
containing supplement 
at study entry 
        





Variables  SCOPE (Pre-fortification) STOP (Post-fortification) 
 Median UIC 
(IQR), µg/L  




Median UIC (IQR), 
µg/L   
P-value 
a  





n 600    600    
No  NA    162 (106, 232)  63 (10.5)  
Notes: BMI, body mass index; IQR, interquartile range; UIC, urinary iodine concentration.  
a Kruskal wails test was used to compare median UIC across maternal characteristics in the combined cohort.  
bPearson chi-square test was used to compare the percentage of women with <150 µg/L across maternal characteristics in the combined cohort.  





4. Discussion  
Our study is the only study in Australia with a sufficient sample size to assess and compare 
the iodine status of pregnant women from low SES pre- and post-mandatory iodine 
fortification of bread. The study showed that pregnant women from low SES in South 
Australia were iodine deficient in the pre-fortification period but became iodine sufficient in 
the post-fortification period regardless of whether women took iodine-containing 
supplements. 
   
Iodine deficiency in the pre-fortification cohort was consistent with previous studies 
conducted in pregnant women from other states of Australia before the introduction of the 
mandatory iodine fortification of bread [40, 119, 129]. Our finding of iodine sufficiency in 
pregnant women in the post-fortification cohort was consistent with a large study conducted 
in the post-fortification period in South Australia (n = 783) [29] and a small study conducted 
in New South Wales (n = 95) [119] although both studies were not focused on pregnant 
women from low SES. Contrary to our finding of iodine sufficiency post-fortification, a small 
study conducted in pregnant women from low SES in northern Adelaide (n = 196) [39] 
reported iodine deficiency but included pregnant women in the transitional period. Two other 
small studies in the Northern Territory (n = 24) [126] and Victoria’s Gippsland region (n = 
86) [130] also reported iodine deficiency. Findings from these small studies are unlikely to be 
representatives of the iodine status of pregnant women post-fortification. As the studies in 
northern Adelaide and Gippsland were conducted in the transitional period after the 
introduction of mandatory iodine fortification of bread, awareness of the importance of 
adequate iodine intake might be low. The study in the Northern Territory [126], conducted 
between 2013 and 2015, reported a median UIC of 93 µg/L in remote indigenous and non-




small sample (n = 22) of pregnant women in the same region. Mandatory iodine fortification 
of bread and iodine supplementation during pregnancy may be less commonly practised in 
remote communities compared with major cities. The differences in iodine status between the 
pre- and post-fortification cohorts are less likely to be reflective of the changing demographic 
of the general population [260-262] and a changing dietary habit due to difference in the 
ethnic makeup between the two cohorts. 
  
Together with the results of iodine sufficiency from the National Survey in SAC [131] and a 
large pregnancy study in South Australia [29], our finding of iodine sufficiency in pregnant 
women from low SES in the post-fortification cohort during the early pregnancy periods, 
indicated the success of the mandatory fortification of bread. The national survey showed 
bread as the major source of dietary iodine in Australia including in women from low SES 
post-fortification [263]. Although there are no national data on bread intake by SES in 
pregnant women in Australia, reproductive-age women [125, 263] and children [263] in the 
lowest SES had higher iodine intake than those from higher SES. Besides, pregnant women in 
Australia are recommended to follow the National Health and Medical Research Council’s 
recommendation to take iodine supplements of 150 µg/day during pregnancy. Based on data 
from a subgroup of women in our study (n = 150) and the other South Australia study  
(n = 148), pregnant women before 20 weeks of gestation who did not take iodine-containing 
supplements were iodine sufficient. Both our study and the other South Australian study [29] 
suggested iodine intake of pregnant women from low SES is adequate regardless of whether 
they are taking iodine supplements in pregnancy. However, the number of pregnant women 
not taking iodine-containing supplements was small in both studies. Further study assessing 
the iodine status of pregnant women who did not take iodine-containing supplements from a 
large representative sample is warranted. 




The urine samples were collected before 15 weeks of gestation in both cohorts, but whether 
iodine status changes over trimesters of pregnancy is uncertain. There is some evidence 
suggesting a lower median UIC in the second and third trimester compared to first trimester 
[29, 71, 127]. This may be explained by hemodilution and increased iodine requirement in 
late trimesters. Therefore, trimester-specific UIC cut-off may be required to define iodine 
status during pregnancy [79].  
 
The difference in median UIC or percentage of women <150 µg/L in younger and older 
pregnant women may be due to differences in dietary practice. Obese women had a higher 
median UIC compared with non-obese women. This finding was consistent with the National 
Health Survey on adults [131] and the median UIC difference by obesity status may be 
reflective of the differences in dietary patterns of obese and non-obese women. However, this 
finding may not be representative as the number of obese pregnant women was small and 
assessing the iodine status of these women with a larger sample size is warranted. 
  
In conclusion, pregnant women from low SES in South Australia are iodine deficient pre-
fortification but iodine sufficient post-fortification. The mandatory iodine fortification of 
bread improved the iodine status of pregnant women from low SES in South Australia 
irrespective of iodine-containing supplement intake. A representative survey is warranted in 
other states to confirm iodine sufficiency as geographical differences exist in the iodine status 
of pregnant women in Australia. 
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Background: Evidence of an association between newborn thyroid stimulating hormone 
concentration (TSH), a marker of iodine nutrition in early life, and childhood 
neurodevelopment and growth is limited, and findings from previous studies are inconsistent. 
 
Objective: To assess the associations between newborn TSH and childhood 
neurodevelopment and growth using data collected from two pregnancy studies, one in a 
borderline iodine deficient setting and one in an iodine sufficient setting. 
  
Design: TSH data were obtained from routine newborn screening and were analysed as a 
continuous variable or in quartiles. Neurodevelopment was assessed at 18 months using the 
Bayley Scales of Infant and Toddler Development third edition (Bayley-III). Weight, height 
and head circumference were measured at 18 months and anthropometric z scores were 
calculated using the WHO’s Child Growth Standards. Key confounders of neurodevelopment 
and growth were controlled in the analyses. 
 
Results: In total, 1520 children were included in the analysis. Comparing the highest with the 
lowest TSH quartile, the Mean Differences (MDs) in the Bayley-III scores ranged from -2.0 
(95% CI: -4.7, 0.8) to -2.5 (95% CI: -5.9, 0.9) points in a borderline iodine deficient setting 
and 1.2 (95% CI: -1.4, 3.7) to 1.4 (95% CI: -2.0, 4.9) points in an iodine sufficient setting in 
the cognitive, language and motor scales; the MDs in the anthropometric z scores ranged from 
0.04 (95% CI: -0.2, 0.2) to -0.4 (95% CI: -0.8, -0.1) in studies from both settings. 
  
Conclusion: A null association between newborn TSH and neurodevelopment or growth was 
observed but we cannot rule out a different pattern of association in borderline iodine 




and examine neurodevelopmental outcomes at later ages are warranted, as 
neurodevelopmental assessments in older children are more predictive of later achievement. 
 





Iodine is an integral part of thyroid hormone, which in turn is required for normal brain 
development and physical growth during the early critical periods of life [264]. Insufficient 
iodine intake in pregnancy has been linked to poor growth [22, 265] and impaired 
neurodevelopment in children [22, 70, 266] and can result in cretinism if iodine deficiency in 
pregnancy is severe [22]. Because of the concern of potential adverse effects on offspring, 
iodine supplementation in pregnancy has been recommended in many countries, including 
countries with sustained programs to combat iodine deficiency such as Australia with 
mandatory iodine fortification of bread [107]. However, the World Health Organization 
(WHO) does not recommend iodine supplementation during pregnancy in iodine sufficient 
populations with sustained programs to combat iodine deficiency [267]. Evidence from 
randomised controlled trials (RCT) suggested iodine supplementation during pregnancy 
improved child neurodevelopment and growth in severe iodine deficiency settings [174, 265] 
but that there is a lack of benefit in mild iodine deficiency to iodine sufficiency settings based 
on limited data [265, 268, 269]. There is a concern of excess iodine intake in pregnant women 
from iodine sufficient settings who took iodine-containing supplements [132]. Excessive 
iodine intake in pregnancy has been linked with adverse health outcomes and cognitive 
deficits [10]. 
 
Both iodine deficiency [83, 85, 178] and excess [270-272] in pregnancy were associated with 
elevated newborn thyroid stimulating hormone (TSH) concentration. Newborn TSH has been 
suggested as a marker of iodine nutrition in pregnancy [36] and it may be useful to identify 
children at risk of neurodevelopmental or growth delay in countries where newborn screening 
is routinely practised. 




There are several studies that assessed the association between newborn TSH concentration 
and childhood neurodevelopment. Studies in iodine deficient populations showed that 
newborns with higher TSH concentrations of ≥5 mIU/L [86, 166, 167] had an increased risk 
of developmental delay, but the association between newborn TSH and neurodevelopmental 
scores were inconsistent in iodine sufficient populations [142, 161, 162, 273]. Most published 
studies had methodological limitations such as inadequate adjustment for potential 
confounders [86, 167], small sample sizes of <30 participants [163], or subjective assessment 
of the outcome [142, 273]. Only a few studies have examined the association between 
newborn TSH concentration and childhood growth [141, 142, 173]. A cohort study from an 
iodine deficient population showed no correlation between newborn TSH and infant growth 
[173]. In iodine sufficient populations, a higher risk of low birthweight was observed in 
newborns whose TSH was in the highest quartile compared with newborns in the lower three 
TSH quartiles [141], but Cuestas et al. [142] reported no difference in childhood growth 
between newborns with high (≥10 mIU/L) or low (<10 mIU/L) TSH concentrations. 
  
The quality of the studies examining the relationship between newborn TSH concentration 
and neurodevelopment or growth of children was limited, and the findings were inconsistent. 
The objective of the current study was to investigate the associations between newborn TSH 
concentration and neurodevelopment and growth of children at 18 months of age utilising 
data collected from two large pregnancy studies in Australia, one in a borderline iodine 
deficient setting before the implementation of the mandatory iodine fortification of bread, and 








Subjects and Methods 
Study design, setting and participants:  
Participants were children from two pregnancy studies conducted in the same area of 
Australia: the Docosahexaenoic acid to Optimize Mother Infant Outcome (DOMInO) trial 
[274] and the Pregnancy Iodine and Neurodevelopment in Kids (PINK) study [70]. Children 
in the DOMInO study were born before the implementation of the mandatory iodine 
fortification of bread (born between 2005-2008), when the population was defined as 
borderline iodine deficient, and children in the PINK study were conceived and born after the 
implementation of the mandatory fortification (born between 2011-2013), when the 
population was defined as iodine sufficient. Detailed descriptions of DOMInO and PINK are 
reported elsewhere [70, 274]. Briefly, DOMInO was a multicenter randomised controlled trial 
that investigated the effect of docosahexaenoic acid (DHA) supplementation during 
pregnancy on postnatal depression and childhood cognitive and language development. 
Neurodevelopment and growth were assessed in a subset of children at 18 months of age  
(n = 726), consisting of a random sample of children born at term (n = 630) and all children 
born preterm (n = 96) from Adelaide, South Australia. The overall results of the trial showed 
DHA supplementation during pregnancy had no effect on the neurodevelopmental scores of 
children at 18 months, although the DHA treatment group had a lower risk of cognitive delay 
[274]. PINK was a prospective cohort study investigating the relationship between maternal 
iodine intake during pregnancy and the neurodevelopment of children at 18 months of age. 
The results of the PINK study showed that maternal iodine intake during pregnancy in the 
lowest or highest quartiles was associated with poorer Bayley-III scores when compared with 
maternal iodine intake in the middle quartiles [70]. Women were <21 weeks of gestation at 
enrolment in both studies. Women with known fetal abnormalities or the following attributes 
were excluded in both studies: drug or alcohol abuse, English not spoken at home or unable to 




study. The study protocols were approved by the institutional review boards at each 
participating centre in both DOMInO (REC1657/12/2007) and PINK (REC2230/12/15 and 
076.10) and each participant provided informed consent. 
  
Assessment of Outcomes: 
Neurodevelopment of children 
Neurodevelopment of children was assessed at 18 months of age using the Bayley Scales of 
Infant and Toddler Development third edition (Bayley-III) in both studies [70, 274]. The 
Bayley-III Scale consists of cognitive, language, motor, adaptive behaviour and social 
emotional scales. The cognitive scale assesses sensorimotor development, exploration, 
manipulation, object relatedness, concept formation, memory and other aspects of cognitive 
processing. The language scale assesses both receptive and expressive communications. Both 
fine and gross motor skills were assessed using the motor scale. The adaptive behaviour and 
social emotional scales assessed parent reported child behaviours [275]. 
  
Growth of Children  
Weight, length and head circumference were measured at the time of Bayley assessment using 
the standard procedures of the WHO in both studies [276]. Length was measured in a 
lying/supine position using a measuring board and was recorded to the nearest 0.1 centimetre. 
Weight was measured by placing the child on a calibrated weighing scale and was recorded to 
the nearest 10 g. Head circumference (HC) was measured using a non-stretching tape 
positioned above the eyebrows anteriorly and olecranon fossa posteriorly and was recorded to 
the nearest 0.1 centimetre [274]. Weight-for-age z scores (WAZ), weight-for-length z scores 
(WLZ), length-for-age z scores (LAZ) and head circumference-for-age z scores (HCZ) were 





Assessment of Exposure:  
Newborn TSH concentration data were extracted from the routine newborn screening 
database in the South Australian Neonatal Screening Centre [278]. The TSH concentration 
was determined from newborn whole blood samples taken between 3-4 days of infant’s age 
by heel-prick. The method used to measure newborn TSH was consistent between the two 
studies. 
  
Assessment of Confounders:  
The potential confounders of child neurodevelopment and growth were identified based on 
the literature and are presented in Supplemental Figures 7.1 and 7.2. Socio-economic status 
data, including parental education and occupation, were collected using a structured self-
report questionnaire. The Home Screening Questionnaire (HSQ) was completed when a 
parent attended the 18-month Bayley-III appointment to assess the level of cognitive, social 
and emotional support available to the child in the home environment [279]. The HSQ score 
was also used as a proxy for overall maternal care and support during pregnancy [280]. 
Pregnancy related background data on smoking, alcohol consumption, multivitamin intake 
and history of depression were collected during pregnancy by self-report. The mother’s body 
mass index (BMI) was calculated using maternal weight and height measured at enrolment. 
Information on caesarean-section delivery, gestational age at birth, 5-minute Apgar score (a 
proxy for perinatal stress) and birthweight were retrieved from a case note audit at birth. 
Birthweight-for-gestational age z score was calculated using the Australian national 
birthweight percentiles by gestational age data [239].  
 
Statistical analysis  
The data were analysed using Stata 15 (Statacorp LP, College Station, Texas). Multiple 




pattern of missingness was non-monotonic and the data were assumed to be missing at 
random [281]. A total of twenty imputed datasets were generated. The MI model included the 
exposure variable, outcome variables, auxiliary variables (age at TSH assessment, hospital of 
enrolment, maternal height and weight) and potential confounders (parity, ethnicity, 
occupation, education, smoking, alcohol consumption, supplement intake, depression, mode 
of delivery, mothers age, gestational age, sex of the child, Apgar score, HSQ score and 
birthweight-for-gestational age z score). The newborn TSH in quartiles, and the binary 
variables (developmental delay, growth delay and dichotomised TSH as ≤5 mIU/L vs. >5 
mIU/L) were created before the imputation. We compared these variables descriptively 
between the observed dataset and imputed dataset in the DOMInO and PINK studies, and 
they were similar in both studies (Supplemental Table 7.1). All analyses were performed on 
the imputed datasets. 
  
The primary analyses were performed on the DOMInO and PINK data separately for several 
reasons. First, the two studies were conducted over different time periods where the iodine 
status of the population differed. DOMInO was conducted in the borderline iodine deficient 
setting before the implementation of mandatory iodine fortification of bread and 
recommendation of routine iodine supplementation for pregnant women, while PINK was 
conducted in the iodine sufficient setting after those national iodine interventions. Second, the 
two studies may not be directly compatible due to possible changes in the demographic and 
economic characteristics of the general population or the type of antenatal care over time. 
Third, while the participants were from the same geographic area in Australia, the design of 
the studies differed (DOMInO was a RCT while PINK was a cohort study). Finally, the 
direction of the association between TSH and neurodevelopment differed in the two studies. 





To assess the association between newborn TSH and Bayley-III and growth outcomes, the 
exposure variable newborn TSH was treated as a continuous variable and categorised into 
quartiles in separate analyses. The newborn TSH distribution differed between DOMInO and 
PINK studies and hence different TSH quartile cut-offs were applied in each study. 
Sensitivity analyses were conducted to examine the robustness of the main findings by 
examining newborn TSH in tertiles, or quintiles, or applying the DOMInO TSH quartile cut 
points to PINK and vice versa, and using the TSH corrected for an infant’s age at blood 
sampling (TSH~age) because infants in the highest TSH quartile were sampled earlier on 
average than infants in the lowest TSH quartile. It is well recognised that the age at sampling 
affects newborn TSH concentration due to the physiological surge in newborn TSH 
concentration for early infant blood sampling [45]. The TSH~age variable was created by 
regressing TSH on age at blood sampling. The residuals of the models, which represent the 
differences between each infant’s actual TSH and the TSH concentration predicted by age at 
sampling, were added to the mean TSH. TSH and age at blood sampling were log-
transformed for the analysis and back transformed to the original scales [64, 221]. TSH was 
also dichotomised based on the commonly reported categories in literature (>5 mIU/L vs. ≤5 
mIU/L) to facilitate comparison with previous studies [12]. 
 
There are no well-designed studies on which to base power calculations for the assessment of 
childhood neurodevelopment and growth outcomes between children in the lowest and 
highest TSH quartiles. However, a five point difference on average in the cognitive and 
psychomotor development between children with adequate vs. deficient iodine or iron intake 
was considered clinically significant [70, 154]. With the sample sizes available in DOMInO 
(n = 726; all singleton) and PINK (n = 794; 11 twins), a mean Bayley-III score of 100 and a 
SD of 15, the studies have 89% and 91% power to detect a difference of five points in the 




   
The neurodevelopment and growth outcomes of children were analysed as both continuous 
and categorical outcomes. For the categorical outcomes, developmental delay was defined as 
Bayley-III scores below 85 and growth delay was defined as anthropometric z scores below -1 
(i.e. more than 1 SD below the mean). 
  
A linear regression model was used to analyse continuous outcomes and a log Poisson 
regression model with robust variance estimation was used to analyse binary outcomes [282]. 
Both unadjusted and adjusted analyses were performed, with adjusted analyses considered to 
be the primary analysis. In DOMInO, we adjusted for DHA treatment group to investigate 
potential confounding as DHA may influence child development [283], though there is no 
known biological mechanism for an effect of DHA supplementation on iodine metabolism 
and newborn TSH concentration. The following confounders were controlled in the adjusted 
analyses for neurodevelopmental and growth outcomes in both DOMInO and PINK: parity, 
ethnicity, parents’ occupation, parents’ education, maternal smoking and alcohol consumption 
during and before pregnancy (Yes or No), maternal multivitamin intake (Yes or No) during 
pregnancy, maternal depression during and before pregnancy (Yes or No), mother’s BMI, 
HSQ score, delivery by caesarean section (Yes or No), mother’s age, gestational age at birth, 
5 minute Apgar score, sex and birthweight-for-gestational age z score. Twins in the PINK 
study were not excluded in the analysis as the number of twins was small (n = 11) and the 
impact of clustering would not be a concern [284]. The mean differences (MDs) in Bayley-III 
scores with the 95% confidence intervals (CIs) estimated from the linear regression model 
and the Relative Risks (RRs) and 95% CIs estimated from the log Poisson regression model 
were reported to indicate the magnitude and direction of the associations. In line with current 
best practice [285-288], we have not used p values to interpret the associations. The STATA 




heterogeneity between the two studies. Heterogeneity between the results was classified as 
low (I2 : <25%), moderate (I2: 25-75%) and high (I2: >75%) [147, 148]. A random effects 
model was applied due to the heterogeneity between the two studies. The pooled effect sizes 
were calculated to see the magnitude and direction of the associations between newborn TSH 
and neurodevelopment and growth. The pooled effect sizes were reported using forest plots.  
 
Results  
Maternal and infant characteristics  
A total of 726 children in DOMInO and 794 children in PINK were included in the analysis 
(Figure 7.1). Table 7.1 shows the characteristics of the DOMInO and PINK participants. The 
two studies differed in some socio-demographic characteristics. There were more Caucasian 
women, smokers and alcohol consumers in DOMInO compared with PINK. As a result of the 
study design that included a subset of randomly selected term infants and all preterm infants 
[274], there was a higher percentage of preterm infants in DOMInO. More PINK mothers 
completed secondary education and took multivitamin supplements during pregnancy 
compared with DOMInO mothers. The two studies had similar mean HSQ scores and 














































Figure 7. 1 Selection of participants from the DOMInO and PINK studies  
  
DOMInO study  
2399 Pregnant women consented 
726 Children (all singleton) selected 
for Bayley-III and growth 
assessment (630 randomly selected 
term infants and 96 all preterm 
infants)  
PINK study 
794 Pregnant women consented  
766 Children (11 twins) live births  
 
726 Imputed cases included in the 
analysis  
 
794 Imputed cases included in the 
analysis  
 
694 Completed Bayley-III assessment 
685 Completed Growth assessment 
590 Newborn TSH data available 
699 Completed Bayley-III assessment 
683 Completed Growth assessment 
679 Newborn TSH data available  
30 Lost to follow-up or 
withdrew consent  
2 Death 
9 Growth assessment 
not completed  
 
39 Withdrew 
before birth    
 
66 Lost to follow-up or   
withdrew consent  
1 Death 






Table 7. 1 Characteristics of the participants1  
 DOMInO (n = 726) PINK (n = 794) 
Mother characteristics    
Caucasian ethnicity 663 (91.3) 668 (84.1) 
Age, y 28.8 ± 5.8 30.0 ± 5.1 
BMI, kg/m2 27.3 ± 5.9 26.1 ± 5.4 
Nulliparous 405 (55.8) 427 (53.8) 
Completed secondary education 450 (62.0) 659 (83.0) 
HSQ score 33.4 ± 3.6 33.0 ± 2.9 
Smoking during second trimester 113 (15.6) 45 (5.7) 
Previous smoking 227 (31.3) 102 (12.9) 
Alcohol consumption during second trimester 76 (10.5) 41 (5.2) 
Previous alcohol consumption 445 (61.3) 526 (66.3) 
Supplement intake during second trimester 352 (48.5) 708 (89.2) 
Depression during second trimester 48 (6.6) 48 (6.1) 
Previous depression 159 (21.9) 169 (21.3) 
Caesarean Section 203 (28.0) 222 (28.0) 
Child characteristics     
Female sex 361 (49.7) 382 (48.1) 
Gestational age, wk 38.7 ± 2.2 38.9 ± 1.8 
Birthweight-for-gestational age z score 0.2 ± 1.0 0.0 ± 1.0 
Preterm 90 (12.4) 61 (7.7) 
5 minute APGAR score 9.0 ± 0.9 8.9 ± 0.7 
Newborn TSH2, mIU/L 1.7 (1.0, 2.9) 2.2 (1.4, 3.3) 
Age at TSH assessment, h 58.7 ± 9.2 57.5 ± 9.0 
Newborns with TSH >5 mIU/L 33 (4.6) 43 (5.4) 
Age at Bayley assessment, mo 18.8 ± 1.8 19.5 ± 4.8 
1Data are mean ± SD or n (%) unless otherwise specified. DOMInO, DHA to Optimize 
Mother Infant Outcome; HSQ, home screening questionnaire; n, number of participants, 
PINK, Pregnancy Iodine and Neurodevelopment in Kids; TSH, thyroid-stimulating hormone. 
2Median (Inter Quartile Range). 
 
As shown in Table 7.1, the median (IQR) newborn TSH concentration was 1.7 (1.0, 2.9) 
mIU/L in DOMInO and 2.2 (1.4, 3.3) mIU/L in PINK. The percentage of newborns with TSH 
concentration >5 mIU/L was lower in DOMInO (4.6%) than PINK (5.4%). Newborn heel 
prick blood samples were collected between 48-96 hours of age in both studies and the 
median age at the TSH assessment was 57.5 hours in PINK, which was 1.2 hours earlier than 
DOMInO. In DOMInO, the median age at sampling was 1.5 hours earlier in preterm than 
term infants, but the median newborn TSH was comparable between these subgroups (1.8 




    
TSH concentration and Bayley-III scores at 18 months of age    
Table 7.2 reports the Bayley-III scores of children in the DOMInO and PINK studies. The 
mean Bayley-III scores were 3 to 6 points higher in DOMInO than PINK across all domains 
except the adaptive behaviour domain, which had similar mean scores in both studies. For 
example, the mean ± SD cognitive scores were 102 ± 12 points in DOMInO and 96 ± 12 
points in PINK. The percentage of children with cognitive or language delay was lower in 
DOMInO than PINK. Children in the highest TSH quartile had the lowest mean Bayley-III 
score in the DOMInO study but the highest mean score in PINK study when compared with 


























 DOMInO PINK 
 n Bayley-III Score Developmental delay n Bayley-III Score Developmental delay 
Cognitive scale        
All children 726 101.7 ± 11.9 36 (4.9) 794 96.3 ± 11.9 80 (10.0) 
Quartile 1 184 103.3 ± 12.2 7 (4.0) 200 96.2 ± 11.7 21 (10.0) 
Quartile 2 176 101.6 ± 11.5 6 (4.0) 196 96.1 ± 12.2 20 (10.0) 
Quartile 3 185 101.8 ± 12.2 10 (6.0) 201 95.0 ± 11.8 25 (13.0) 
Quartile 4 181 100.2 ± 11.9 12 (7.0) 197 97.8 ± 11.9 14 (7.0) 
Language scale        
All children 726 97.2 ± 14.7 127 (17.4) 794 93.9 ± 18.1 234 (29.4) 
Quartile 1 184 98.8 ± 14.8 23 (13.0) 200 93.7 ± 18.1 56 (28.0) 
Quartile 2 176 98.2 ± 14.6 29 (17.0) 196 92.5 ± 6.3 56 (28.0) 
Quartile 3 185 96.9 ± 14.9 36 (19.0) 201 94.0 ± 19.5 63 (31.0) 
Quartile 4 181 94.7 ± 14.4 38 (21.0) 197 95.5 ± 18.2 59 (30.0) 
Motor scale        
All children 726 102.5 ± 11.2 37 (5.1) 794 98.9 ± 11.2 35 (4.4) 
Quartile 1 184 103.8 ± 10.6 6 (3.0) 200 99.5 ± 9.9 11 (5.0) 
Quartile 2 176 102.6 ± 10.6 8 (5.0) 196 98.2 ± 11.6 8 (4.0) 
Quartile 3 185 102.6 ± 11.4 8 (4.0) 201 97.6 ± 13.1 10 (5.0) 
Quartile 4 181 101.0 ± 12.2 15 (8.0) 197 100.4 ± 9.6 6 (3.0) 
Social emotional scale       
All children 726 106.8 ± 17.8 36 (4.9) 794 103.7 ± 14.7 44 (5.5) 
Quartile 1 184 107.9 ± 18.4 10 (5.0) 200 102.7 ± 14.3 9 (5.0) 
Quartile 2 176 107.5 ± 18.0 8 (5.0) 196 103.4 ± 15.2 13 (7.0) 
Quartile 3 185 107.5 ± 18.0 8 (5.0) 201 103.9 ± 15.4 13 (6.0) 
Quartile 4 181 104.6 ± 16.9 9 (5.0) 197 104.8 ± 13.7 9 (4.0) 
Adaptive behaviour scale       
All children 726 100.0 ± 14.4 87 (12.1) 794 100.1 ± 14.0 87 (11.0) 
Quartile 1 184 100.3 ± 15.1 19 (10.0) 200 100.3 ± 13.9 18 (9.0) 
Quartile 2 176 100.2 ± 14.4 21 (12.0) 196 98.4 ± 14.3 29 (15.0) 
Quartile 3 185 100.2 ± 13.6 21 (11.0) 201 100.6 ± 14.5 23 (11.0) 




1Data are mean ± SD or n (%). Developmental delay was defined as Bayley-III scores below 85. TSH was categorised into quartiles in both 
DOMInO and PINK. DOMInO quartile 1 (Lowest): <1.1 mIU/L; quartile 2: 1.1-1.7 mIU/L; quartile 3: 1.8-2.9 mIU/L; quartile 4 (Highest): ≥3.0 
mIU/L. PINK quartile 1 (Lowest): <1.5 mIU/L; quartile 2: 1.5-2.2 mIU/L; quartile 3: 2.3-3.3 mIU/L; quartile 4 (Highest): ≥3.4 mIU/L. 





There was a null association between newborn TSH and neurodevelopment. For example, 
when TSH was treated as a continuous exposure (Table 7.3), a 1 mIU/L increase in TSH was 
associated with a -0.3 point (95% CI: -1.0, 0.3) change in the mean cognitive score in 
DOMInO, compared with a 0.2 point (95% CI: -0.4, 0.7) change in PINK, and a RR of 1.1 
(95% CI: 0.9, 1.3) for cognitive delay in DOMInO compared with a RR of 0.9 (95% CI: 0.8, 
1.0) in PINK. When TSH was categorised into quartiles, the MD for children in the highest 
TSH quartile compared with the lowest quartile was -2.2 points (95% CI: -5.0, 0.7) for the 
cognitive score in DOMInO compared with 1.2 points (95% CI: -1.4, 3.7) in PINK, and the 
RR was 2.0 (95% CI: 0.6, 6.1) for cognitive delay in DOMInO compared with 0.7 (95% CI: 













Table 7. 3 Adjusted associations between newborn TSH concentration and Bayley-III outcomes at 18 months of age1     
 DOMInO PINK 
 n Bayley-III Score  Developmental delay2  n Bayley-III Score  Developmental delay2  
  MD (95% CI)3 RR (95% CI)4  MD (95% CIs)3 RR (95% CI)4 
Cognitive scale         
1 mIU/L increase in TSH5 726 -0.3 (-1.0, 0.3) 1.1 (0.9, 1.3) 794 0.2 (-0.4, 0.7) 0.9 (0.8, 1.0) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -1.3 (-4.0, 1.4) 1.1 (0.3, 4.3) 196 -0.7 (-3.1, 1.8) 1.1 (0.5, 2.1) 
Quartile 3 185 -1.6 (-4.4, 1.2) 2.3 (0.7, 7.2) 201 -0.9 (-3.4, 1.5) 1.1 (0.6, 2.1) 
Quartile 4 181 -2.2 (-5.0, 0.7) 2.0 (0.6, 6.1) 197 1.2 (-1.4, 3.7) 0.7 (0.3, 1.4) 
Language scale         
1 mIU/L increase in TSH5 726 -0.4 (-1.2, 0.3) 1.1 (1.0, 1.2) 794 0.5 (-0.2, 1.3) 1.0 (1.0, 1.1) 
TSH in quartiles6        
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -0.1 (-3.4, 3.2) 1.3 (0.7, 2.2) 196 -2.0 (-5.4, 1.3) 1.1 (0.8, 1.5) 
Quartile 3 185 -1.4 (-4.8, 2.0) 1.5 (0.9, 2.7) 201 0.6 (-3.2, 4.5) 1.1 (0.8, 1.6) 
Quartile 4 181 -2.5 (-5.9, 0.9) 1.4 (0.8, 2.4) 197 1.4 (-2.0, 4.9) 1.1 (0.7, 1.5) 
Motor scale       
1 mIU/L increase in TSH5 726 -0.3 (-0.9, 0.4) 1.2 (1.0, 1.4) 794 0.3 (-0.2, 0.8) 0.9 (0.7, 1.2) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -1.0 (-3.5, 1.6) 1.6 (0.5, 5.3) 196 -1.3 (-3.6, 1.0) 0.7 (0.2, 2.0) 
Quartile 3 185 -1.4 (-4.1, 1.3) 1.6 (0.5, 5.2) 201 1.5 (-3.9, 1.0) 0.8 (0.3, 2.2) 
Quartile 4 181 -2.0 (-4.7, 0.8) 2.3 (0.8, 7.1) 197 1.3 (-0.7, 3.4) 0.5 (0.1, 1.8) 
Social emotional scale         
1 mIU/L increase in TSH5 726 0.0 (-1.0, 1.0) 0.9 (0.7, 1.2) 794 0.4 (-0.2, 1.1) 1.0 (0.8, 1.2) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -0.7 (-4.8, 3.4) 1.2 (0.4, 3.6) 196 0.7 (-2.5, 4.0) 1.6 (0.6, 4.6) 
Quartile 3 185 -0.2 (-4.4, 4.0) 0.8 (0.2, 2.5) 201 1.6 (-1.8, 4.9) 1.8 (0.6, 5.0) 
Quartile 4 181 -2.5 (-6.8, 1.7) 0.9 (0.3, 2.6) 197 2.9 (-0.3, 6.1) 1.1 (0.3, 3.9) 




 DOMInO PINK 
 n Bayley-III Score  Developmental delay2  n Bayley-III Score  Developmental delay2  
  MD (95% CI)3 RR (95% CI)4  MD (95% CIs)3 RR (95% CI)4 
1 mIU/L increase in TSH5 726 0.0 (-0.8, 0.8) 1.0 (0.9, 1.2) 794 0.1 (-0.6, 0.8) 1.0 (0.8, 1.2) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 0.0 (-3.4, 3.3) 1.2 (0.6, 2.2) 196 -2.0 (-5.1, 1.1) 1.6 (0.8, 3.0) 
Quartile 3 185 -0.1 (-3.3, 3.5) 1.0 (0.5, 2.1) 201 1.1 (-2.0, 4.1) 0.9 (0.4, 1.9) 
Quartile 4 181 -0.5 (-4.0, 3.1) 1.3 (0.7, 2.5) 197 0.9 (-2.0, 3.8) 0.8 (0.4, 1.7) 
1The regression models were adjusted for sex, parity, ethnicity, occupation, education, smoking during second trimester, previous smoking, 
alcohol consumption during second trimester, previous alcohol consumption, supplement intake during second trimester, previous depression, 
depression during second trimester, mode of delivery, mothers age, gestational age at birth, 5 minute Apgar score, mothers BMI, home screening 
questionnaire score and birthweight-for-gestational age z score in both DOMInO and PINK studies. In addition, treatment group in the DOMInO 
study was also added to the adjusted models when analysing the DOMInO data. CI, confidence interval; DOMInO, DHA to Optimize Mother 
Infant Outcome; MD, mean difference; n, number of participants, PINK, Pregnancy Iodine and Neurodevelopment in Kids; ref, reference 
category; RR, relative risk; TSH, thyroid-stimulating hormone.  
2Developmental delay was defined as Bayley-III scores below 85. 
3The Mean Differences (95% CIs) were estimated with multivariable linear regression model.  
4The Relative Risks (95% CIs) were estimated with multivariable log Poisson regression model with robust variance estimation. 
5TSH is modelled continuously. 
6TSH was categorised into quartiles separately in DOMInO and PINK. DOMInO quartile 1 (Lowest): <1.1 mIU/L; quartile 2: 1.1-1.7 mIU/L; 
quartile 3: 1.8-2.9 mIU/L; quartile 4 (Highest): ≥3.0 mIU/L. PINK quartile 1 (Lowest): <1.5 mIU/L; quartile 2: 1.5-2.2 mIU/L; quartile 3: 2.3-3.3 




A similar pattern of null association was observed between newborn TSH and 
neurodevelopment in both studies regardless of whether TSH was categorised into tertiles 
(Supplemental Table 7.2), quintiles (Supplemental Table 7.3) or dichotomised at 5 mIU/L 
(Supplemental Table 7.4), or when the quartile cut points from the PINK study were applied 
to DOMInO and vice versa (Supplemental Table 7.5), or when TSH was corrected for age at 
sampling (Supplemental Table 7.6). Null association was also observed in the unadjusted 
analyses (Supplemental Table 7.7).  
 
TSH concentration and growth at 18 months of age   
As shown in Table 7.4, the mean WLZ, LAZ, WAZ and HCZ scores were mostly greater 
than zero for both DOMInO and PINK, indicating children were larger on average than the 
populations used to define the WHO growth standards. The percentage of children with z 

















1Data are mean ± SD or n (%). Growth delay was defined as z scores below 1 SD. TSH was categorised into quartiles in both DOMInO and 
PINK. DOMInO quartile 1 (Lowest): <1.1 mIU/l; quartile 2: 1.1-1.7 mIU/l; quartile 3: 1.8-2.9 mIU/L; quartile 4 (Highest): ≥3.0 mIU/L. PINK 
quartile 1 (Lowest): <1.5 mIU/L; quartile 2: 1.5-2.2 mIU/L; quartile 3: 2.3-3.3 mIU/L; quartile 4 (Highest): ≥3.4 mIU/L. cm, centimetre; 
 DOMInO PINK 
 n Anthropometric z score Growth delay n Anthropometric z score  Growth delay 
WLZ       
All children 726 0.7 ± 1.0 25 (3.5) 794 0.6 ± 1.3 41 (5.2) 
Quartile 1 184 0.7 ± 1.0 6 (3.0) 200 0.8 ± 1.1 7 (3.0) 
Quartile 2 176 0.6 ± 1.0 5 (3.0) 196 0.6 ± 1.1 10 (5.0) 
Quartile 3 185 0.6 ± 1.1 10 (5.0) 201 0.6 ± 1.1 13 (6.0) 
Quartile 4 181 0.7 ± 1.0 5 (3.0) 197 0.6 ±1.8 12 (6.0) 
LAZ       
All children 726 0.1 ± 1.1 113 (15.6) 794 -0.1 ± 0.2 123 (15.5) 
Quartile 1 184 0.2 ± 1.1 24 (13.0) 200 0.0 ± 1.0 23 (11.0) 
Quartile 2 176 0.1 ± 1.0 26 (15.0) 196 0.1 ± 1.2 27 (14.0) 
Quartile 3 185 0.1 ± 1.1 26 (14.0) 201 -0.1 ± 0.3 42 (21.0) 
Quartile 4 181 -0.1 ± 1.2 37 (20.0) 197 -0.2 ± 0.4 31 (16.0) 
WAZ       
All children 726 0.5 ± 1.0 38 (5.3) 794 0.5 ± 1.4 56 (7.0) 
Quartile 1 184 0.6 ± 1.0 12 (6.0) 200 0.8 ± 1.7 9 (4.0) 
Quartile 2 176 0.5 ± 1.0 5 (3.0) 196 0.6 ± 1.6 12 (6.0) 
Quartile 3 185 0.5 ± 1.1 7 (4.0) 201 0.3 ± 1.1 18 (9.0) 
Quartile 4 181 0.5 ± 1.0 15 (8.0) 197 0.3 ± 1.1 17 (9.0) 
HCZ       
All children 726 0.7 ± 1.0 30 (4.1) 794 0.9 ± 1.9 33 (4.2) 
Quartile 1 184 0.8 ± 1.0 5 (3.0) 200 1.0 ± 1.3 7 (7.0) 
Quartile 2 176 0.6 ± 0.9 5 (3.0) 196 0.9 ± 1.7 8 (10.0) 
Quartile 3 185 0.7 ± 1.0 9 (5.0) 201 0.7 ± 1.4 12 (13.0) 




DOMInO, DHA to Optimize Mother Infant Outcome; HAZ, length-for-age z score; HCZ, head circumference-for-age z score; n, number of 
participants; PINK, Pregnancy Iodine and Neurodevelopment in Kids; SD, standard deviation; TSH, thyroid-stimulating hormone; WAZ, weight-




The associations between newborn TSH and growth outcomes were similar in both PINK and 
DOMInO. Null associations were observed between newborn TSH and growth outcomes in 
both studies regardless of whether TSH was treated as a continuous variable or categorised 
into quartiles (Table 7.5), tertiles or quintiles (data not shown) or when TSH was 
dichotomised at 5 mIU/L (Supplemental Table 7.8), or when TSH was corrected for age at 
sampling (Supplemental Table 7.9). A similar pattern of null association was also observed 




Table 7. 5 Adjusted associations between newborn TSH and growth outcomes at 18 months of age1     
   DOMInO PINK 
 n Anthropometric z score  Growth delay2  n Anthropometric z score  Growth delay2  
  MD (95% CI)3 RR (95% CI)4  MD (95% CIs)3 RR (95% CI)4 
WLZ       
1 mIU/L increase in TSH5  726 0.01 (-0.04, 0.05) 0.8 (0.6, 1.1) 794 -0.02 (-0.09, 0.03) 1.0 (0.9, 1.2) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -0.2 (-0.4, 0.0) 1.6 (0.3, 10.0) 196 -0.2 (-0.4, 0.1) 1.3 (0.4, 4.4) 
Quartile 3 185 -0.1 (-0.3, 0.1) 2.2 (0.5, 9.8) 201 -0.2 (-0.5, 0.0) 1.4 (0.4, 4.7) 
Quartile 4 181 -0.04 (-0.2, 0.2) 0.6 (0.1, 4.6) 197 -0.1 (-0.5, 0.2) 1.2 (0.4, 4.1) 
LAZ       
1 mIU/L increase in TSH5 726 -0.01 (-0.05, 0.06) 1.0 (0.9, 1.1) 794 -0.01 (-0.07, 0.04) 1.0 (0.9, 1.1) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -0.1 (-0.3, 0.1) 1.2 (0.7, 2.1) 196 0.1 (-0.1, 0.4) 1.1 (0.6, 2.1) 
Quartile 3 185 -0.1 (-0.3, 0.1) 1.1 (0.6, 2.0) 201 0.0 (-0.3, 0.2) 1.5 (0.8, 2.6) 
Quartile 4 181 -0.2 (-0.4, 0.1) 1.4 (0.8, 2.4) 197 -0.1 (-0.3, 0.2) 1.1 (0.6, 2.1) 
WAZ       
1 mIU/L increase in TSH5 726 0.01 (-0.04, 0.05) 1.0 (0.8, 1.2) 794 -0.09 (-0.16, -0.01) 1.1 (0.9, 1.2) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -0.2 (-0.4, 0.0) 0.6 (0.2, 2.5) 196 -0.2 (-0.5, 0.1) 1.2 (0.4, 3.7) 
Quartile 3 185 -0.1 (-0.3, 0.1) 0.8 (0.2, 2.6) 201 -0.4 (-0.8, -0.1) 1.8 (0.7, 4.6) 
Quartile 4 181 -0.1 (-0.3, 0.1) 1.2 (0.5, 3.3) 197 -0.4 (-0.8, -0.1) 1.5 (0.5, 4.2) 
HCZ       
1 mIU/L increase in TSH5 726 -0.01 (-0.06, 0.03) 1.1 (0.9, 1.3) 794 0.00 (-0.12, 0.06) 0.8 (0.7, 1.1) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -0.2 (-0.4, 0.1) 1.8 (0.4, 7.4) 196 -0.1 (-0.4, 0.3) 1.2 (0.3, 4.6) 
Quartile 3 185 -0.1 (-0.3, 0.1) 2.8 (0.8, 9.6) 201 -0.2 (-0.6, 0.1) 1.3 (0.4, 5.0) 




1The regression models were adjusted for sex, parity, ethnicity, occupation, education, smoking during second trimester, previous smoking, 
alcohol consumption during second trimester, previous alcohol consumption, supplement intake during second trimester, previous depression, 
depression during second trimester, mode of delivery, mothers age, gestational age at birth, 5 minute Apgar score, mothers BMI, home screening 
questionnaire score and birthweight-for-gestational age z score in both DOMInO and PINK studies. In addition, treatment group in the DOMInO 
study was also added to the adjusted models when analysing the DOMInO data. CI, confidence interval; DOMInO, DHA to Optimize Mother 
Infant Outcome; HAZ, length-for-age z score; HCZ, head circumference-for-age z score; MD, mean difference; n, number of participants, PINK, 
Pregnancy Iodine and Neurodevelopment in Kids; ref, reference category; RR, relative risks; TSH, thyroid-stimulating hormone; WAZ, weight-
for-age z score; WLZ, weight-for-length z score. 
2Growth delay was defined as z scores below 1 SD 
3The Mean Differences (95% CIs) were estimated with multivariable linear regression model.  
4The Relative Risks (95% CIs) were estimated with multivariable log Poisson regression model with robust variance estimation. 
5TSH is modelled continuously. 
6TSH was categorised into quartiles in both DOMInO and PINK. DOMInO quartile 1 (Lowest): <1.1 mIU/L; quartile 2: 1.1-1.7 mIU/L; quartile 
3: 1.8-2.9 mIU/L; quartile 4 (Highest): ≥3.0 mIU/L. PINK quartile 1 (Lowest): <1.5 mIU/L; quartile 2: 1.5- 2.2 mIU/L; quartile 3: 2.3-3.3 




Meta-analysis combined the DOMInO and PINK studies   
As shown in Supplemental Figures 7.3 and 7.4, there was high heterogeneity between the 
DOMInO and PINK studies in the developmental outcomes, but low heterogeneity in the 




Our study showed a null association between newborn TSH and both childhood 
neurodevelopment and growth in the DOMInO and PINK studies. However, children in the 
highest TSH quartile had the lowest mean Bayley-III score in the DOMInO study but the 
highest mean score in PINK study. We cannot rule out a different pattern of association 
between newborn TSH and neurodevelopmental outcomes in the two studies where the iodine 
status of the study populations differed because of the wide CIs around the effect estimates, as 
well as possible residual confounding. Similarly, we cannot rule out a poorer growth outcome 
of children in the highest TSH quartile compared with children in the lowest quartile in both 
studies.  
 
Newborn TSH as an indicator of iodine nutrition during pregnancy may depend on maternal 
iodine intake, as either too little [83, 85, 178] or too much [270, 271] iodine during pregnancy 
may lead to high TSH. Excess iodine intake may also lead to lower TSH in iodine induced 
hyperthyroidism during pregnancy [290]. DOMInO was conducted in a borderline iodine 
deficient population before the mandatory iodine fortification of bread in Australia while 
PINK was conducted in an iodine sufficient population after the introduction of fortification. 
In studies from iodine deficient populations, like DOMInO, high newborn TSH may be due to 
inadequate maternal iodine intake during pregnancy. Iodine deficiency during pregnancy can 
lead to lower maternal free thyroxine concentration [291] and shifts the intra-thyroidal 




to a lower transfer of thyroid hormones, primarily thyroxine, to the foetus and may cause 
impaired neurodevelopment in early childhood. Although a majority of studies conducted in 
iodine deficient populations showed a negative association between newborn TSH and 
childhood neurodevelopment [86, 167, 169, 170], all except one study [86], had a small 
sample size (ranged from 61 to 250 participants), and did not account for key confounders 
including maternal socio-economic status, gestational age at birth and home environment. Our 
finding of a null association in DOMInO was consistent with a large study (n = 691) in a 
mildly iodine deficient population that controlled for key confounders including maternal 
socio-economic status and infants age at blood sampling for TSH assessment [160]. Similar to 
DOMInO, Murcia et al. [160] used Bayley scales to assess neurodevelopment of offspring 
under two years of age. Participants in DOMInO and Murcia et al. [160] were healthy 
children from population-based cohorts unlike a study in Italy from hospitalised children 
[169] where the cause for a higher TSH may differ. Furthermore, outcome assessors were not 
blinded to the exposure variable and maternal characteristics in a prospective cohort study by 
Costeira et al. [170], which may lead to bias. All of the studies in iodine deficient populations 
assessed neurodevelopment in toddlers and pre-schoolers except a large Australian study [86] 
that assessed educational performance at a median age of 10 years. In that Australian study 
[86], infants without congenital hypothyroidism whose TSH concentration was above the 99th 
percentile (TSH 12.4-20 mIU/L) had a higher risk of poorer school achievement than infants 
with TSH <75th percentile (TSH concentration ≤4 mIU/L). Neurodevelopmental assessments 
at later ages may be more stable and a better indication of cognitive function [293].  
 
In contrast to the DOMInO study, the higher TSH concentration in PINK may be due to a 
high iodine intake as a result of mandatory iodine fortification and routine iodine 
supplementation in a previously iodine deficient population [82]. This is partially explained 




thyroid hormones and resulted in elevated TSH [270]. Our finding of a null association 
between newborn TSH and Bayley-III scores in PINK study is consistent with the 
PsychoTSH study (n = 315) [161, 162, 273] in an iodine sufficient population in Belgium, 
which is a prospective cohort study designed to assess the association between newborn TSH 
and neurodevelopmental outcomes in pre-schoolers. Similar to PINK, children who 
participated in the PsychoTSH study were born during a transitional period when Belgium 
introduced a voluntary program to use iodised salt in bread-making in 2009 [202], and the 
higher TSH may be due to the transient excess in iodine intake. Although the PsychoTSH 
study reported no association between TSH level and most of the neurodevelopmental scales 
[161, 162, 273], it showed higher mean verbal IQ scores in children with TSH concentration 
in the range 5-9 mIU/L compared with children whose TSH concentration <5 mIU/L [161]. 
We cannot rule out a higher neurodevelopmental score in children with TSH in the highest 
quartile (median TSH of 4.5 mIU/L) in the PINK study due to the wide CIs around the 
estimates. In contrast, though not directly compatible to our study, a smaller (n = 250) 
prospective cohort study by Cuestas et al. [142] in the iodine sufficient population in 
Argentina showed a higher odds of developmental delay in SAC with newborn TSH ≥10 
mIU/L compared with TSH <10 mIU/L at birth, however, the developmental outcome 
assessment was by parents’ evaluation of developmental status, and TSH was sampled earlier 
at 2-3 days of age outside the WHO recommendation. Prospective cohorts or population data 
linkage studies using exposure data from newborn screening and cognitive function at later 
ages may help to evaluate long-term effect of the newborn TSH concentration on cognition. 
    
The newborn TSH level is influenced by the timing of blood sampling due to physiological 
surge within 48 hours after birth. Higher TSH level may also be a reflection of earlier blood 
sampling in newborn screening [45]. Although the median age at blood sampling was earlier 




sampling compared with the other quartiles in both the DOMInO and PINK studies. 
Therefore, age at the newborn TSH assessment is unlikely to explain the different patterns of 
associations observed between newborn TSH and neurodevelopmental outcomes in the two 
studies. 
  
There is only one study (n = 250) [142], which examined the association between newborn 
TSH in full-term infants and childhood growth, which was conducted in Argentina, in an 
iodine sufficient population. It showed no difference in the weight and height at 6 years of age 
between children with newborn TSH ≥10 mIU/L and those with newborn TSH <10 mIU/L at 
birth though no adjustment was made for potential confounding variables. While the 
Argentina study is not directly compatible to our study, both suggested no difference in the 
growth of children between newborns with high or low TSH in populations of mild iodine 
deficiency or iodine sufficiency. 
  
The WHO defines iodine deficiency in populations when >3% of newborns have TSH 
concentration >5 mIU/L [12]. Several studies examining the association between newborn 
TSH and developmental outcomes dichotomised TSH into ≤5 mIU/L or >5 mIU/L [167, 273], 
but it is important to note that TSH >5 mIU/L alone is not a criterion in classifying iodine 
deficiency either in populations or individuals. Further research is warranted to establish a 
newborn TSH cut-off associated with impaired neurodevelopment to identify children at risk 
of developmental delay for monitoring and early intervention as appropriate. 
  
Our results should be interpreted with caution because our study is a secondary analysis 
utilising data from the DOMInO and PINK studies that differed in the distribution of several 
confounders. In the DOMInO study, for instance, there was an over-representation of preterm 




Bayley-III scores were assessed based on the child’s corrected age, preterm birth may 
increase TSH concentration and confound the association. The timing of newborn screening 
was earlier in PINK, as there was a shift towards earlier discharge from hospitals after birth. 
We attempted to address this through correcting TSH for an infant’s age at blood sampling 
but residual confounding may still present. 
 
Conclusion  
Our study shows a null association between newborn TSH and both childhood 
neurodevelopment and growth. However, we cannot exclude the possibility of poorer 
neurodevelopment or growth in infants with high TSH in a borderline iodine deficient setting, 
and better neurodevelopment in infants with high TSH in an iodine sufficient setting, due to 
the wide CIs around the estimated effects. Follow-up studies that utilise newborn TSH data 
obtained from routine newborn screening and examines neurodevelopmental outcomes at a 
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CHAPTER 8 GENERAL DISCUSSION  
8.1 Discussion of key findings and overall significance of the work  
Iodine deficiency remains a public health problem worldwide [7]. There is a re-emergence of 
iodine deficiency even in countries that were previously iodine sufficient like Australia. 
Therefore, it would seem prudent to have regular monitoring of iodine status using 
appropriate markers of iodine status to prevent iodine deficiency or excess in general 
populations and at-risk population such as pregnant women. 
 
My thesis is the first to systematically investigate the agreement between different markers of 
iodine status in populations. I have shown there is a discrepancy between these markers in 
classifying population iodine status. The iodine status of South Australians was sufficient by 
the UIC marker but classified as mildly iodine sufficient by the TSH marker. This suggests a 
need to use multiple markers of iodine status in populations as markers are conducted in 
different population groups. The WHO, UNICEF and ICCIDD jointly recommended using 
the median UIC in SAC, goitre prevalence in SAC, or proportion of newborns with TSH 
concentration >5 mIU/L to define iodine status in populations [12]. 
 
Choosing an appropriate marker is the important first step in monitoring iodine status of 
populations and early identification of iodine deficiency or excess in high-risk populations 
such as neonates and pregnant women. However, there is not a gold standard marker to define 
iodine status in populations that can be applied in all settings. The results from the systematic 
review presented in this thesis showed that these markers might not consistently classify the 
iodine status of populations [15]. The results showed that a population that is iodine sufficient 
by one marker may be classified as iodine deficient by another marker. In South Australia, 
there has been an inconsistent classification of iodine status when using different markers of 




SAC [118] but iodine deficiency by the TSH marker [229]. This kind of discrepancy may 
affect the decision-making process towards monitoring and controlling IDD.  
  
Several factors may contribute to the observed discrepancies among different markers to 
define the iodine status of populations. For instance, the length of time when populations were 
exposed to a low or high iodine environment may affect the choice of a marker. Markers of 
population iodine status differ in their application to monitor iodine status as the UIC marker 
may be preferable to assess iodine status shortly after an iodine supplementation or 
fortification program, while goitre and newborn TSH may be used to monitor long-term 
changes following iodine interventions [12]. Therefore, using multiple markers may give 
better representation for the iodine status of populations. Furthermore, the cut-off applied for 
different markers may not be appropriate and could be a source of disagreement in classifying 
iodine status. The current UIC cut-offs for SAC, adults and pregnant women, and the current 
newborn TSH cut-off recommended by the WHO have been criticised. The concern about the 
UIC marker is that it may overestimate iodine intake in SAC [294, 295] while 
underestimating iodine intake in adults [217]. In the recent WHO recommendation of UIC 
>100 µg /L to define iodine sufficiency [12], it was assumed that SAC had an average urine 
volume of 1 L irrespective of their age, though urine volume may be less than 1 L in many 
SAC [295] and UIC would be higher than 24-h UIE [296]. In adults, however, their daily 
urinary excretion 1.5 L and UIC would be lower than the 24-h UIE. As measuring 24-h UIE 
in a population survey is impractical, prone to errors in urine collection, and imposes burdens 
to participants [12], revision of the UIC criteria to define iodine status in adults needs to be 
considered. As the original WHO classification of iodine status using the median UIC was 
based from a functional assessment of goitre in SAC, the current newborn TSH cut-off also 
needs to be re-evaluated by either a functional outcome like childhood neurodevelopment or 




intervention programs, re-evaluation of the current cut-offs for UIC and TSH markers has 
been suggested to define the iodine status of populations correctly.  
 
The main concern with the newborn TSH marker is due to a recent move towards early 
discharge of mothers and newborns from hospitals, as the age at which TSH sampling for 
newborn screening is younger in recent surveys [52]. Early discharge results in artificially 
higher newborn TSH concentrations and higher proportions of newborns with TSH >5 
mIU/L. Using the median UIC as a reference marker, the systematic review presented in my 
thesis suggested iodine sufficiency in populations when more than 5% of newborns have 
TSH >5 mIU/L [15]. The increased percentage cut-off in the proposed criterion may be due to 
the increasing number of studies with early blood sampling before three days of age for TSH 
assessment. This criterion is likely to be applicable in countries like Australia with the early 
discharge of infants that leads to early blood sampling for TSH assessment. Re-evaluation of 
the current TSH cut-off may improve the sensitivity and accuracy of the TSH marker to 
define and monitor the iodine status of populations. However, using the TSH marker is 
feasible only in countries that practise newborn screening for CH.  
 
Exposure to a deficient or an excess iodine environment during pregnancy has been 
associated with adverse birth outcomes and neurodevelopmental deficits in childhood. 
Although UIC is not recommended for defining the iodine status of individuals due to a day-
to-day or within-day variability in the iodine intake and hydration [12], measurement of 
urinary iodine remained a better biomarker to assess exposure to poor iodine nutrition 
compared with goitre and thyroid hormones [36]. However, discrepancies in urinary iodine 
markers (UIC, I/Cr and UIE) to classify individual iodine status in pregnancy, is a challenge 
to evaluate the associations between iodine nutrition in pregnancy and health, and 




as a marker of population-level iodine status, the dichotomised median UIC (<150 vs ≥150 
µg/L) from spot urine samples has been widely used to assess iodine status in individual 
pregnant women. However, UIC is highly variable during pregnancy due to hemodilution and 
iodine excretion [297, 298]. Whilst the 24-h UIE reduces within-day variation in iodine 
excretion, assessing the actual 24-h UIE is not practical and also does not address the day-to-
day variation in iodine excretion. I/Cr and the estimated 24-h UIE, which are estimated from 
spot UIC and estimated 24-h urinary creatinine excretion, have been used as surrogates of 
actual 24-h UIE in healthy adults to assess iodine status in individuals [72, 214]. My thesis is 
the first to assess the agreement between spot UIC and other urinary iodine markers 
(estimated 24-h UIE, I/Cr and UIC~Cr) in pregnancy from iodine sufficient populations. The 
results showed that the spot UIC was not comparable with the estimated 24-h UIE nor I/Cr as 
the spot UIC underestimated iodine excess and overestimated iodine deficiency in pregnancy.   
 
The results of my study that assessed the agreement between the urinary iodine markers 
during pregnancy showed that I/Cr and UIC~Cr had a better agreement with the estimated  
24-h UIE than spot UIC. However, the agreement between each of these markers and the 
actual 24-h UIE is not known during pregnancy, and this could be the subject of future 
research. If the estimated 24-h UIE is a good predictor of actual 24-h UIE, obtaining socio-
demographic variables (maternal age, ethnicity, height, weight and BMI) required to estimate 
24-h creatinine excretion [69] would not be a challenge as these variables are commonly 
reported in many cohort studies during pregnancy. However, these variables may not be 
available in population-wide surveys that are designed to monitor the iodine status of 
populations. Therefore, continued use of the current UIC criterion >150 µg/L to define iodine 





This thesis also examines the iodine status of general populations and populations of pregnant 
women who were from areas of low SES in South Australia. Based on findings from this 
thesis, the mandatory iodine fortification of bread implemented in October 2009 was 
successful in improving the iodine status of pregnant women from low SES areas in South 
Australia. Although the South Australians would be classified as mildly iodine deficient post-
fortification using TSH as a marker in contrast to iodine sufficiency by UIC, the decreasing 
trend in the percentage of TSH >5 mIU/L in this large population study indicated 
improvement in iodine status of populations following the mandatory fortification of bread 
[229]. Moreover, the iodine status of the general population in South Australia would be 
improved from mild iodine deficiency to iodine sufficiency if the new proposed cut-off at the 
percentage of TSH >5 mIU/L greater than 5% from this thesis has been applied in classifying 
iodine status in the post-fortification period.  
 
The results of my study on the iodine status of pregnant women showed that pregnant women 
in low SES areas of South Australia were iodine sufficient irrespective of iodine supplement 
intake. The WHO recommends iodine supplements in pregnancy when the median UIC was 
<100 µg/L in SAC [267] with sustained iodine prevention program. The median UIC was 
greater than 100 µg/L in SAC in the Australian Health Survey conducted three to four years 
post-fortification [118]. Therefore, based on the WHO’s recommendation, routine iodine 
supplementation may not be required in Australia, for an iodine sufficient population [267, 
299]. The routine iodine supplementation for pregnant and breastfeeding women was 
introduced in Australia without evidence from double-blind RCTs on the value of iodine 
supplementation in borderline iodine deficient or iodine sufficient population. Instead, pre-
emptive recommendations were mainly based on the increasing concerns of negative 
consequences on the offspring following mild iodine deficiency in pregnancy. The 




supplementation in pregnancy in an iodine sufficient population may lead to excessive iodine 
intake [70]. Iodine excess during pregnancy may be associated with thyroid hormone 
disorders [13, 132, 300] and subsequent impaired neurodevelopment in children [70]. 
Therefore, a double-blind RCT on the impacts of iodine supplementation on the iodine status 
of pregnant women, as well as on the general health outcomes, is warranted in iodine 
sufficient settings. However, conducting such a trial would not be practical in Australia, as 
routine iodine supplementation is recommended for pregnancy [269]. However, a national 
survey of iodine status in a representative sample of pregnant women would be informative in 
helping to understand the impact of both mandatory iodine fortification and routine iodine 
supplementation in improving the iodine status of pregnant women. Moreover, the 
supplementation strategy may be expensive and not a feasible intervention for women from 
low SES, as they may not be able to adhere to the recommendation. The fact that both iodine 
deficiency and excess are associated with impaired neurodevelopment further underscores the 
need for an iodine monitoring program, particularly among high-risk populations like 
pregnant women in Australia.   
   
Even though the mandatory iodine fortification of bread was successful in improving iodine 
status among SAC and pregnant women in South Australia, public health strategies to reduce 
salt intake may be an issue for ongoing success in the prevention of iodine deficiency [301, 
302]. For example, there was a significant reduction in the sodium content of bread from 2009 
to 2013 in Australia [303], which may have a significant impact on the iodine content of 
bread. Whilst salt reduction is a very important measure to reduce cardiovascular disease risk, 
the implications of low iodine intake of individuals on impaired growth and development 
should not be overlooked even in iodine sufficient populations. Therefore, the two public 
health measures need to be balanced [106, 304] with a shared goal of achieving salt reduction 




sources of iodine and a major contributor of calories in Australians, including pregnant 
women, the public health message on bread choices and quantity to prevent iodine deficiency 
needs to be advocated. 
 
This thesis also examined whether newborn TSH is a suitable biomarker to identify children 
at risk of impaired childhood neurodevelopment in both borderline iodine deficient and iodine 
sufficient settings. The results showed a null association between newborn TSH and 
neurodevelopment in both settings. However, previous studies showed a lower 
neurodevelopmental score in infants with high TSH in iodine deficient population [86, 165-
167, 169, 170] and no association in iodine sufficient population [162, 168]. Therefore, the 
associations between newborn TSH and child neurodevelopment might vary depending on the 
iodine status of populations. However, most of the previous studies collected newborn TSH 
samples outside of the recommended age range of 3-4 days after birth, did not control key 
confounders and had assessed neurodevelopmental outcomes at early ages [167, 169, 170]. 
Neurodevelopmental assessment at early ages may not be conclusive for long-term 
neurodevelopmental consequences [293]. There was no study that examined the association 
between newborn TSH and neurodevelopmental outcomes assessed at later ages using 
standard scales from a large population-based data in both iodine deficient and sufficient 
settings. Assessment of neurodevelopmental outcomes in older children has been suggested as 
more precise, reliable and a better predictor of long-term mental function and adulthood 
productivity [293]. Therefore, long-term follow up studies that assess the associations 
between newborn TSH and neurodevelopment outcomes in later ages are warranted to use 
newborn TSH as a screening tool to identify children at risk of neurodevelopmental deficits.  
 
As thyroid hormones are essential for normal physical growth in early life, newborn TSH 




examined the association between newborn TSH and childhood anthropometry in healthy 
well-nourished populations using an adequate sample size and appropriate age at TSH 
sampling that controlled for key confounders of child growth. The results showed a null 
association between newborn TSH and anthropometry in both borderline iodine deficient and 
iodine sufficient settings. However, there were only a few children with anthropometric z 
scores <-1 SD with a mean anthropometric z score of 0 SD in participating children. A study 
in healthy infants from iodine sufficient populations also showed no association between 
newborn TSH and child anthropometry though the study did not adjust for key confounders of 
child growth [142]. It might not be worthwhile using TSH as a marker of child anthropometry 
in borderline iodine deficient or iodine sufficient well-nourished populations.  
 
The use of newborn TSH as a biomarker to screen children at increased risk of impaired 
neurodevelopment or growth has multiple benefits. First, as newborn TSH data is available 
from routine newborn screenings, there will be no additional cost for the determination of the 
biomarker. Second, newborn TSH can identify children exposed to both iodine deficiency and 
iodine excess in pregnancy. Third, as the marker is collected at birth, children identified as 
having a higher risk of impaired neurodevelopment are able to access the available treatments 
as early as possible.  
 
8.2 Potential future works    
The following areas of future research work have been suggested based on the results of this 
thesis.   
 Re-evaluation of the current TSH cut-off to improve the accuracy and sensitivity of 
the TSH marker to define iodine status in populations appropriately. 
 A double-blind RCT on the health and neurodevelopmental impacts of iodine 




 A program for monitoring iodine status in pregnant women across all states in 
Australia as both iodine deficiency and excess may be associated with impaired 
neurodevelopment.  
 Ways of integrating public health programs that recommend cutting salt intake with 
the national program that encourages to increase iodine in bread-making. Whether 
increasing the level of iodine in the salt, from its current range of 25-65 mg of iodine 
per kg of salt to higher acceptable thresholds that will align with a lower amount of 
salt, is technically achievable and safe remains an area of further research.  
 Assessment of the agreement between actual 24-h UIE and estimated 24-h UIE as well 
as the agreement between spot UIC and I/Cr with actual 24-h UIE in pregnant women 
from all settings.  
 Population-based data linkage studies that assess the associations between newborn 
TSH and neurodevelopment outcomes at later ages.  
 Continuous monitoring and appropriate intervention for infants with mildly elevated 
TSH >5 mIU/L at birth to prevent later childhood cognitive impairment.  
 Utilising newborn TSH data from newborn screening as a potential biomarker to 
identify children at risk of impaired development or growth in different settings. 
 
8.3 Conclusions  
Regular monitoring of iodine status using an appropriate measure of population-level and 
individual-level iodine status helps to identify populations or individuals at increased risk of 
IDD such as impaired neurodevelopment. The disagreement between markers to classify 
iodine status in South Australia may affect measures to prevent and control iodine deficiency. 
Re-evaluation of the current TSH criteria for classifying iodine status in populations, but 
continued use of median UIC from spot UIC in populations of pregnant women, is suggested. 




pregnant women in South Australia regardless of iodine supplement intake. However, more 
data is required on the iodine status of pregnant women by way of a national representative 
survey. Newborn TSH may be a potential marker for identifying children at risk of poor 
neurodevelopmental scores at 18 months because infants with higher TSH may have poor 
cognitive scores, but future research should focus on neurodevelopmental outcomes at a later 
age for evaluating long-term neurodevelopmental consequences in countries where routine 
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Supplemental Table 2. 1 Search strategy in different databases 
PUBMED: 
Iodine [mh:noexp] OR iodides 
[TIAB] OR iodates [TIAB] OR 
Iodine status [TW] OR 
Urinary iodi* [TW] OR 
iodine nutritional status [TW] OR  
iodide status [TW] OR goiter 
[Mesh] OR  
Iodine Deficienc*[TW] OR   
 
Thyroid function [tiab] OR Thyroid 
stimulating hormone [TW] OR TSH 
[TIAB] OR 
Thyrotropin [MH:noexp] OR  
Thyrotropin [TIAB] OR 
Thyrotrophin [TW] OR 
Thyreotropin [TW] OR 
Hypothyroidism [TIAB] OR 
hypothyroxin* [TW] OR thyroid 
hormones [TIAB] OR thyroxine [TW] 
OR Triiodothyronine [TW] 
child development 
[mh:noexp] OR cognition 
[mh:noexp] OR cognition 
[TIAB] OR intelligence 
[TIAB] OR motor skills 
[TIAB] OR psychomotor 
performance [TIAB] OR 
intelligence quotient [TIAB] 
OR IQ [TIAB] OR 
neurological development 
[TIAB] OR cognition 
disorders [TIAB] OR 
cognitive function [TIAB] 
OR neural development 
[TIAB] OR intellectual 
disability [TW] OR post-natal 
development [TIAB] OR 
memory [TIAB] OR 
executive function [TIAB] 
OR mental process [TIAB] 
physical development [TIAB] 
OR growth [TIAB] OR Head 
circumference [TIAB] OR 
Length [TIAB] OR Height 
[TIAB] OR stature [TIAB] OR 
Weight [TIAB] OR Mid upper 
arm circumference [TIAB] OR 
MUAC [TIAB] OR 
Anthropometric status [TIAB] 
OR Z-score [TW] OR Body 
mass index [TW] OR BMI 
[TW] OR Underweight [TIAB] 
OR Obesity [TIAB] OR 
Stunting [TIAB] OR wasting 





OR learning [TIAB] OR 
child behaviour [Mesh] OR 
brain development [TIAB] 
OR language [TIAB] OR 
language development 
[mh:noexp] OR child 
language [mh:noexp] OR 
child language [TIAB] OR 
language development 
[TIAB] 
(((Iodine [mh:noexp] OR iodides [TIAB] OR iodates [TIAB] OR Iodine status [TW] OR Urinary iodi* [TW] OR iodine nutritional status 
[TW] OR iodide status [TW] OR goiter [Mesh] OR Iodine Deficienc*[TW] OR Thyroid function [tiab] OR Thyroid stimulating hormone 
[TW] OR TSH [TIAB] OR Thyrotropin [MH:noexp] OR Thyrotropin [TIAB] OR Thyrotrophin [TW] OR Thyreotropin [TW] OR 
Hypothyroidism [TIAB] OR hypothyroxin* [TW] OR thyroid hormones [TIAB] OR thyroxine [TW] OR Triiodothyronine [TW])) AND (child 
development [mh:noexp] OR cognition [mh:noexp] OR cognition [TIAB] OR intelligence[TIAB] OR motor skills [TIAB] OR psychomotor 
performance [TIAB] OR intelligence quotient [TIAB] OR IQ [TIAB] OR neurological development[TIAB] OR cognition disorders [TIAB] 
OR cognitive function [TIAB] OR neural development [TIAB] OR intellectual disability [TW] OR post-natal development [TIAB] OR 
memory [TIAB] OR executive function [TIAB] OR mental process [TIAB] OR learning [TIAB] OR child behaviour [Mesh] OR brain 
development [TIAB] OR language [TIAB] OR language development [mh:noexp] OR child language [mh:noexp] OR child language [TIAB] 
OR language development [TIAB] OR physical development [TIAB] OR growth [TIAB] OR Head circumference [TIAB] OR Length [TIAB] 
OR Height [TIAB] OR stature [TIAB] OR Weight [TIAB] OR Mid upper arm circumference [TIAB] OR MUAC [TIAB] OR Anthropometric 
status [TIAB] OR Z-score [TW] OR Body mass index [TW] OR BMI [TW] OR Underweight [TIAB] OR Obesity [TIAB] OR Stunting 




adolescent[Mesh] OR baby[TW] OR babies[TW] or toddler[TW] or preschool children[TW] OR School age [TW] children [TW] OR school 
child [TW] OR teenager [TW]) 
Embase:  
Iodine OR iodides OR iodates OR 
'Iodine status' OR 'Urinary iodi*' 
OR 'iodine nutritional status' OR 
'iodide status' OR goiter OR 
'Iodine Deficienc*' OR 'Thyroid 
function' OR 'Thyroid stimulating 
hormone' OR TSH OR 
Thyrotropin OR Thyrotropin OR 
Thyrotrophin OR Thyreotropin 
OR Hypothyroidism OR 
hypothyroxin* OR 'thyroid 
hormones' OR thyroxine OR 
Triiodothyronine 
'child development' OR cognition OR 
intelligence OR 'motor skills' OR 
'psychomotor performance' OR 
'intelligence quotient' OR IQ OR 
'neurological development' OR 
'cognition disorders' OR 'cognitive 
function' OR 'neural development' OR 
'intellectual disability' OR 'post-natal 
development' OR memory OR 
'executive function' OR 'mental 
process' OR learning OR 'child 
behaviour' OR 'brain development' OR 
language OR 'language development' 
OR 'child language' OR 'language 
development' OR 'physical 
development' OR growth OR 'Head 
circumference' OR Length OR Height 
Infant OR Neonat* OR 
Newborn* OR Child* OR 
adolescent OR baby OR 
babies or toddler or 
'preschool children' OR 
'School age children' OR 





OR stature OR Weight OR 'Mid upper 
arm circumference' OR MUAC OR 
'Anthropometric status' OR 'Z-score' 
OR 'Body mass index' OR BMI OR 
Underweight OR Obesity OR Stunting 
OR wasting OR 'Child growth rate'  
 
('thyroid stimulating hormone' OR thyrotropin OR tsh OR thyrotrophin OR thyreotropin OR hypothyroidism OR 'iodine deficienc*' OR Goiter 
OR 'Thyroid volume' OR hypothyroxin* OR 'iodine/deficiency' OR 'iodine status' OR 'urinary iodi*' OR 'iodine nutritional status' OR 'iodide 
status') AND (infant OR newborn OR neonat* OR newborn*) AND (child*) AND humans  
Scopus: 
A B C D 
Iodine OR iodides OR iodates OR 
“Iodine status” OR “Urinary 
iodi*” OR “iodine nutritional 
status” OR “iodide status” OR 
goiter OR “Iodine Deficienc*” 
OR “Thyroid function” OR 
“Thyroid stimulating hormone” 
OR TSH OR Thyrotropin OR  
Thyrotropin OR Thyrotrophin OR 
Thyreotropin OR Hypothyroidism 
OR hypothyroxin* OR “thyroid 
 
“child development” OR cognition OR 
intelligence OR “motor skills” OR 
“psychomotor performance” OR 
“intelligence quotient” OR IQ OR 
“neurological development” OR 
“cognition disorders” OR “cognitive 
function” OR “neural development” 
OR “intellectual disability” OR 
“postnatal development” OR memory 
OR “executive function” OR “mental 
Infant OR Neonat* OR 
Newborn* OR Child* OR 
adolescent OR baby OR 
babies or toddler or 
“preschool children” OR 
“School age children” OR 






hormones” OR thyroxine OR 
Triiodothyronine 
process” OR learning OR “child 
behaviour” OR “brain development” 
OR language OR “language 
development” OR “child language” 
OR “physical development” OR 
growth OR “Head circumference” OR 
Length OR Height OR stature OR 
Weight OR “Mid upper arm 
circumference” OR MUAC OR 
“Anthropometric status” OR “Z score” 
OR “Body mass index” OR BMI OR 
Underweight OR Obesity OR Stunting 
OR wasting OR “Child growth rate” 
Title (A AND B AND C) 
CINAHL:   
Iodine OR iodides OR iodates OR 
“Iodine status” OR “Urinary 
iodi*” OR “iodine nutritional 
status” OR “iodide status” OR 
goiter OR “Iodine Deficienc*” 
OR “Thyroid function” OR 
“Thyroid stimulating hormone” 
OR TSH OR Thyrotropin OR  
(“child development” OR cognition 
OR intelligence OR “motor skills” OR 
“psychomotor performance” OR 
“intelligence quotient” OR IQ OR 
“neurological development” OR 
“cognition disorders” OR “cognitive 
function” OR “neural development” 
OR “intellectualdisability” OR “post-
(Infant OR Neonat* OR Newborn* OR Child* OR adolescent 
OR baby OR babies or toddler or “preschool children” OR 





Thyrotropin OR Thyrotrophin OR 
Thyreotropin OR Hypothyroidism 
OR hypothyroxin* OR “thyroid 
hormones” OR thyroxine OR 
Triiodothyronine) AND 
natal development” OR memory OR 
“executive function” OR “mental 
process” OR learning OR “child 
behaviour” OR “brain development” 
OR language OR “language 
development” OR “child language” 
OR “language development” OR 
“physical development” OR growth 
OR “Head circumference” OR Length 
OR Height OR stature OR Weight OR 
“Mid upper arm circumference” OR 
MUAC OR “Anthropometric status” 
OR “Z-score” OR “Body mass index” 
OR BMI OR Underweight OR Obesity 
OR Stunting OR wasting OR “Child 
growth rate”) 
(Iodine OR iodides OR iodates OR “Iodine status” OR “Urinary iodi*” OR “iodine nutritional status” OR “iodide status” OR goiter OR 
“Iodine Deficienc*” OR “Thyroid function” OR “Thyroid stimulating hormone” OR TSH OR Thyrotropin OR Thyrotropin OR Thyrotrophin 
OR Thyreotropin OR Hypothyroidism OR hypothyroxin* OR “thyroid hormones” OR thyroxine OR Triiodothyronine) AND (“child 
development” OR cognition OR intelligence OR “motor skills” OR “psychomotor performance” OR “intelligence quotient” OR IQ OR 
“neurological development” OR “cognition disorders” OR “cognitive function” OR “neural development” OR “intellectualdisability” OR 
“post-natal development” OR memory OR “executive function” OR “mental process” OR learning OR “child behaviour” OR “brain 




growth OR “Head circumference” OR Length OR Height OR stature OR Weight OR “Mid upper arm circumference” OR MUAC OR 
“Anthropometric status” OR “Z-score” OR “Body mass index” OR BMI OR Underweight OR Obesity OR Stunting OR wasting OR “Child 
growth rate”) AND (Infant OR Neonat* OR Newborn* OR Child* OR adolescent OR baby OR babies or toddler or “preschool children” OR 
“School age children” OR “school child” OR teenager) 
PsycINFO: 
(Iodine OR iodides OR iodates OR Iodine status OR Urinary iodine OR iodine nutritional status OR iodide status OR goiter OR Iodine 
Deficiency OR Thyroid function OR Thyroid stimulating hormone OR TSH OR Thyrotropin OR Thyrotropin OR Thyrotrophin OR 
Thyreotropin OR Hypothyroidism OR hypothyroxin OR thyroid hormones OR thyroxine OR Triiodothyronine) AND (child development OR 
cognition OR intelligence OR motor skills OR psychomotor performance OR intelligence quotient OR IQ OR neurological development OR 
cognition disorders OR cognitive function OR neural development OR intellectual disability OR post-natal development OR memory OR 
executive function OR mental process OR learning OR child behaviour OR brain development OR language OR language development OR 
child language OR language development OR physical development OR growth OR Head circumference OR Length OR Height OR stature 
OR Weight OR Mid upper arm circumference OR MUAC OR Anthropometric status OR Z-score OR Body mass index OR BMI OR 
Underweight OR Obesity OR Stunting OR wasting OR Child growth rate) AND (Infant OR Neonate OR Newborn OR Child OR Children OR 
adolescent OR baby OR babies or toddler or preschool children OR School age children OR school child OR teenager) 
Web of Science  
(Title (Iodine OR iodides OR iodates OR Iodine status OR Urinary iodine OR iodine nutritional status OR iodide status OR goiter OR Iodine 
Deficiency OR Thyroid function OR Thyroid stimulating hormone OR TSH OR Thyrotropin OR Thyrotropin OR Thyrotrophin OR 
Thyreotropin OR Hypothyroidism OR hypothyroxin OR thyroid hormones OR thyroxine OR Triiodothyronine) AND (child development OR 
cognition OR intelligence OR motor skills OR psychomotor performance OR intelligence quotient OR IQ OR neurological development OR 
cognition disorders OR cognitive function OR neural development OR intellectual disability OR post-natal development OR memory OR 
executive function OR mental process OR learning OR child behaviour OR brain development OR language OR language development OR 




OR Weight OR Mid upper arm circumference OR MUAC OR Anthropometric status OR Z-score OR Body mass index OR BMI OR 
Underweight OR Obesity OR Stunting OR wasting OR Child growth rate) AND (Infant OR Neonate OR Newborn OR Child OR Children OR 







Supplemental Table 2. 2 The risk of bias in non-randomized studies of interventions (ROBINS-I) assessment tool for assessing quality of the 
studies1  
 Signalling questions Description Response options 
Bias due to confounding 
 1.1 Is there potential for confounding of the effect of intervention in this study? 
If N/PN to 1.1: the study can be considered to be at low risk of bias due to confounding and no 
further signalling questions need be considered 
 Y / PY / PN / N 
If Y/PY to 1.1: determine whether there is a need to assess time-varying confounding:   
1.2. Was the analysis based on splitting participants’ follow up time according to 
intervention received? 
If N/PN, answer questions relating to baseline confounding (1.4 to 1.6)  
If Y/PY, go to question 1.3. 
 NA / Y / PY / PN / N / NI 
1.3. Were intervention discontinuations or switches likely to be related to factors that are 
prognostic for the outcome? 
If N/PN, answer questions relating to baseline confounding (1.4 to 1.6) 
If Y/PY, answer questions relating to both baseline and time-varying confounding (1.7 
and 1.8)  
 NA / Y / PY / PN / N / NI 
 
 Questions relating to baseline confounding only 
1.4. Did the authors use an appropriate analysis method that controlled for all the important 
confounding domains? 
 NA / Y / PY / PN / N / NI 
1.5. If Y/PY to 1.4: Were confounding domains that were controlled for measured validly 
and reliably by the variables available in this study? 
 NA / Y / PY / PN / N / NI 
1.6. Did the authors control for any post-intervention variables that could have been affected 
by the intervention? 
 NA / Y / PY / PN / N / NI 
 Questions relating to baseline and time-varying confounding  
1.7. Did the authors use an appropriate analysis method that controlled for all the important 
confounding domains and for time-varying confounding? 
 NA / Y / PY / PN / N / NI 
1.8. If Y/PY to 1.7: Were confounding domains that were controlled for measured validly 
and reliably by the variables available in this study? 
 NA / Y / PY / PN / N / NI 
 Risk of bias judgement  Low / Moderate / Serious / 




Optional: What is the predicted direction of bias due to confounding?  Favours experimental / 
Favours comparator / 
Unpredictable 
 
Bias in selection of participants into the study 
 2.1. Was selection of participants into the study (or into the analysis) based on participant 
characteristics observed after the start of intervention? 
If N/PN to 2.1: go to 2.4 
 Y / PY / PN / N / NI 
2.2. If Y/PY to 2.1: Were the post-intervention variables that influenced selection likely to 
be associated with intervention? 
2.3 If Y/PY to 2.2: Were the post-intervention variables that influenced selection likely to 
be influenced by the outcome or a cause of the outcome? 
 NA / Y / PY / PN / N / NI 
 
 
NA / Y / PY / PN / N / NI 
 
2.4. Do start of follow-up and start of intervention coincide for most participants?  Y / PY / PN / N / NI 
2.5. If Y/PY to 2.2 and 2.3, or N/PN to 2.4: Were adjustment techniques used that are likely to 
correct for the presence of selection biases? 
 NA / Y / PY / PN / N / NI 
Risk of bias judgement  Low / Moderate / Serious / 
Critical / NI 
Optional: What is the predicted direction of bias due to selection of participants into the study?  Favours experimental / 
Favours comparator / 
Towards null /Away from 
null / Unpredictable 
 
Bias in classification of interventions  
 3.1 Were intervention groups clearly defined?   Y / PY / PN / N / NI 
3.2 Was the information used to define intervention groups recorded at the start of the 
intervention? 
 Y / PY / PN / N / NI 
3.3 Could classification of intervention status have been affected by knowledge of the outcome 
or risk of the outcome? 
 Y / PY / PN / N / NI 
Risk of bias judgement  Low / Moderate / Serious / 




Optional: What is the predicted direction of bias due to classification of interventions?  Favours experimental / 
Favours comparator / 
Towards null /Away from 
null / Unpredictable 
Bias due to deviations from intended interventions 
 If your aim for this study is to assess the effect of assignment to intervention, answer questions 4.1 and 4.2  
4.1. Were there deviations from the intended intervention beyond what would be expected in 
usual practice? 
 Y / PY / PN / N / NI 
4.2. If Y/PY to 4.1: Were these deviations from intended intervention unbalanced between 
groups and likely to have affected the outcome? 
 NA / Y / PY / PN / N / NI 
If your aim for this study is to assess the effect of starting and adhering to intervention, answer questions 4.3 
to 4.6 
 
4.3. Were important co-interventions balanced across intervention groups?  Y / PY / PN / N / NI 
4.4. Was the intervention implemented successfully for most participants?  Y / PY / PN / N / NI 
4.5. Did study participants adhere to the assigned intervention regimen?  Y / PY / PN / N / NI 
4.6. If N/PN to 4.3, 4.4 or 4.5: Was an appropriate analysis used to estimate the effect of 
starting and adhering to the intervention? 
 NA / Y / PY / PN / N / NI 
Risk of bias judgement  Low / Moderate / Serious / 
Critical / NI 
Optional: What is the predicted direction of bias due to deviations from the intended 
interventions? 
 Favours experimental / 
Favours comparator / 
Towards null /Away from 
null / Unpredictable 
 
Bias due to missing data 
 5.1 Were outcome data available for all, or nearly all, participants?  Y / PY / PN / N / NI 
5.2 Were participants excluded due to missing data on intervention status?   
Y / PY / PN / N / NI 
5.3 Were participants excluded due to missing data on other variables needed for the analysis?   
Y / PY / PN / N / NI 
5.4 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Are the proportion of participants and reasons for 
missing data similar across interventions? 




5.5 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Is there evidence that results were robust to the 
presence of missing data? 
 NA / Y / PY / PN / N / NI 
Risk of bias judgement  Low / Moderate / Serious / 
Critical / NI 
Optional: What is the predicted direction of bias due to missing data?  Favours experimental / 
Favours comparator / 
Towards null /Away from 
null / Unpredictable 
 
Bias in measurement of outcomes  
 6.1 Could the outcome measure have been influenced by knowledge of the intervention 
received? 
 Y / PY / PN / N / NI 
6.2 Were outcome assessors aware of the intervention received by study participants?  Y / PY / PN / N / NI 
6.3 Were the methods of outcome assessment comparable across intervention groups?  Y / PY / PN / N / NI 
6.4 Were any systematic errors in measurement of the outcome related to intervention 
received? 
 Y / PY / PN / N / NI 
Risk of bias judgement  Low / Moderate / Serious / 
Critical / NI 
Optional: What is the predicted direction of bias due to measurement of outcomes?  Favours experimental / 
Favours comparator / 
Towards null /Away from 
null / Unpredictable 
 
Bias in selection of the reported result 
 Is the reported effect estimate likely to be selected, on the basis of the results, from...   
7.1. ... multiple outcome measurements within the outcome domain?   Y / PY / PN / N / NI 
7.2 ... multiple analyses of the intervention-outcome relationship?  Y / PY / PN / N / NI 
7.3 ... different subgroups?  Y / PY / PN / N / NI 
Risk of bias judgement  Low / Moderate / Serious / 
Critical / NI 
Optional: What is the predicted direction of bias due to selection of the reported result?  Favours experimental / 
Favours comparator / 
Towards null /Away from 






 Risk of bias judgement  Low / Moderate / Serious / 
Critical / NI 
Optional: What is the overall predicted direction of bias for this outcome?  Favours experimental / 
Favours comparator / 
Towards null /Away from 
null / Unpredictable 
1Responses underlined in green are potential markers for low risk of bias, and responses in red/bold are potential markers for a risk of bias. No 
formatting is used for questions 1.2 and 1.3 because these questions are only sign posts to other questions. NA, not applicable; NI, no 
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Supplemental Table 3. 1 Search strategy in different databases 
PUBMED:   
Thyroid stimulating hormone[TW] OR 
Thyrotropin[MH:noexp] OR 
Thyrotropin[TIAB] OR TSH[TW] OR 
Thyrotrophin[TW] OR Thyreotropin[TW] 
OR Hypothyroidism[TW] OR Iodine 
Deficienc*[TW] OR Goiter[TW] OR Thyroid 
volume [TW] OR Hypothyroxin* [TW] OR 
"Iodine/deficiency"[Mesh] OR Iodine 
status[TW] OR Urinary iodi* [TW] OR 








(Thyroid stimulating hormone[TW] OR Thyrotropin[MH:noexp] OR Thyrotropin[TIAB] 
OR TSH[TW] OR Thyrotrophin[TW] OR Thyreotropin[TW] OR Hypothyroidism[TW] OR 
Iodine Deficienc*[TW] OR hypothyroxin* [TW] OR "Iodine/deficiency"[Mesh] OR 
Goiter[TW] OR Thyroid volume [TW] OR Iodine status[TW] OR Urinary iodi* [TW] OR 
iodine nutritional status [TW] OR iodide status[TW]) AND (Infant, Newborn[MH:noexp] 
OR Neonat*[TW] OR Newborn*[TW]) AND Child*[TW] 
Embase: 
“Thyroid stimulating hormone” OR 
Thyrotropin OR  
Thyrotropin OR TSH OR 
Thyrotrophin OR Thyreotropin OR 
Hypothyroidism OR 
“Iodine Deficienc*” OR 









"Iodine/deficiency" OR Goiter OR “Thyroid 
volume” OR 
“Iodine status” OR 
“Urinary iodi*” OR 
“iodine nutritional status” OR  
“iodide status” 
('thyroid stimulating hormone' OR thyrotropin OR tsh OR thyrotrophin OR thyreotropin 
OR hypothyroidism OR 'iodine deficienc*' OR Goiter OR 'Thyroid volume' OR 
hypothyroxin* OR 'iodine/deficiency' OR 'iodine status' OR 'urinary iodi*' OR 'iodine 
nutritional status' OR 'iodide status') AND (infant OR newborn OR neonat* OR newborn*) 
AND (child*) AND humans  
Scopus: 
A B C D 
“Thyroid stimulating hormone” OR 
Thyrotropin OR Thyrotropin OR TSH OR 
Thyrotrophin OR 
Thyreotropin OR Hypothyroidism OR 
“Iodine Deficiency” OR Goiter OR “Thyroid 
volume” OR hypothyroxine OR 
"Iodine deficiency" OR “Iodine status” OR 
“Urinary iodine” OR “iodine nutritional 
status” OR “iodide status” 
Infant OR Newborn 
OR Neonate OR 
Newborn 
Child  Humans 
ABS (“Thyroid stimulating hormone” OR Thyrotropin OR Thyrotropin OR TSH OR 
Thyrotrophin OR Thyreotropin OR Hypothyroidism OR “Iodine Deficiency” OR Goiter 




“Urinary iodine” OR “iodine nutritional status” OR “iodide status”) AND (Infant OR 
Newborn OR Neonate OR Newborn) AND (Child) AND (humans) 
ABS (A AND B AND C AND D) 
CINAHL:     
“Thyroid stimulating hormone” OR  
Thyrotropin OR Thyrotropin OR 
TSH OR Thyrotrophin OR 
Thyreotropin OR Hypothyroidism OR 
“Iodine Deficiency” OR Goiter OR “Thyroid 
volume” OR  
hypothyroxine OR "Iodine deficiency" OR 
“Iodine status” OR 
“Urinary iodine” OR “iodine nutritional 
status” OR “iodide status” 
Infant OR Newborn 
OR Neonate OR 
Newborn 
Child or children 
or “school age 
children” 
PsycINFO:    
Thyroid stimulating hormone OR  
Thyrotropin OR Thyrotropin OR 
TSH OR Thyrotrophin OR 
Thyreotropin OR Hypothyroidism OR Iodine 
Deficiency OR Goiter OR Thyroid volume 
OR  
hypothyroxine OR Iodine deficiency OR 
Iodine status OR 
Urinary iodine OR iodine nutritional status 
OR iodide status 
Infant OR Newborn 
OR Neonate OR 
Newborn 
Child or children 





(Thyroid stimulating hormone OR Thyrotropin OR Thyrotropin OR TSH OR Thyrotrophin 
OR Thyreotropin OR Hypothyroidism OR Iodine Deficiency OR hypothyroxine OR Iodine 
deficiency OR Goiter OR Thyroid volume OR Iodine status OR Urinary iodine OR iodine 
nutritional status OR iodide status) AND (Infant OR Newborn OR Neonate OR Newborn) 





Supplemental Table 3. 2 Check list for assessing quality of the studies1  
REVIEWER________________________________________ DATE_______________ 
AUTHOR__________________________________________ YEAR______ RECORD 
NUMBER_____ 
 
ITEMS  QUALITY ASSESSMENT QUESTIONS  YES  NO  UNCLEAR  NA 
1 Was the research question clearly stated?  
1.1 Was the outcome clearly indicated? 
1.2 Were the target population and setting 
specified?   
    
22 Was the selection of study subjects free from bias?  
2.1 Were inclusion/exclusion criteria specified and 
with sufficient detail and without omitting criteria 
critical to the study? 
2.2 were health, demographics and other 
characteristics of subjects described?  
2.3 Were the subjects/patients a representative 
sample of the relevant population? 
    
32 Were study groups comparable?  
3.1 Were groups comparable on important 
confounding factors, period of outcome (TSH vs 
UIC vs goitre) assessment and/or were pre-existing 
differences accounted for by using appropriate 
adjustments in statistical analysis? 
    
4 Was methods of handling withdrawals described? 
4.1 Was the number, characteristics of response rate 
described for each group?  
4.2 Were all enrolled subjects/patients (in the 
original sample) accounted for? 
    
5 Was blinding used to prevent introduction of bias?  
5.1 Were data collectors blinded for outcome 
assessment? (If outcome is measured using an 
objective test, these criteria is assumed to be met)  
5.2 were measurements of outcomes and risk 
factors blinded?  
    
62 Were exposure factor described in detail? 
6.1 was the study setting and exposure factor 
described? 
 
    
72 Were outcomes clearly defined and the 
measurements valid and reliable? 
7.1 Were the observations and measurements based 
on standard, valid, and reliable data collection 
instruments/tests/procedures? 
    
8 Was the statistical analysis appropriate for the study 
design and type of outcome indicators?  
8.1 were the statistical analysis adequately 
described?  
8.2 were correct statistical tests were used and 
assumptions of the test not violated?  




8.3 were statistics reported with levels of 
significance and or confidence intervals?  
 
9 Are conclusions supported by the results with 
biases and limitations taken into consideration?  
9.1 Is there a discussion of findings?  
9.2 Are biases and study limitations identified and 
discussed?  
    
10 Is bias due to study’s funding or sponsorship 
unlikely?  
10.1 were sources of funding and investigators 
affiliations described?  
10.2 was there no apparent conflict of interest?  
    
 Rate of the overall quality   
 
1The checklist was modified by authors from American Dietetic Association (ADA) quality 
assessment checklist to be used for cross sectional studies[189].   
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Yes  Yes No Yes  Unclear  No Yes Yes Yes  Yes  Ø 
Simsek [60] Yes Yes Yes3 Yes Yes Yes Yes  Yes  Yes Yes + 
Simsek [60] Yes Yes Yes3 Yes Yes Yes Yes  Yes  Yes Yes + 
Simsek [60] Yes Yes Yes3 Yes Yes Yes Yes  Yes  Yes Yes + 
Simsek [60] Yes Yes Yes3 Yes Yes Yes Yes  Yes  Yes Yes + 
Costante 
[196] 
Yes  Yes Yes3 Yes  Yes  Yes  Yes Yes Yes  Yes  + 
Costante 
[196] 
Yes  Yes Yes3 Yes  Yes  Yes  Yes Yes Yes  Yes  + 
Dalili [197] Yes Yes Yes3 Yes Yes Yes No Yes  Yes Yes Ø 
Dalili [197] Yes Yes Yes3 Yes Yes Yes No Yes  Yes Yes Ø 
Dalili [197] Yes Yes Yes3 Yes Yes Yes No Yes  Yes Yes Ø 
Dalili [197] Yes Yes Yes3 Yes Yes Yes No Yes  Yes Yes Ø 
Dalili [197] Yes Yes Yes3 Yes Yes Yes No Yes  Yes Yes Ø 
Fuse [198] Yes No No3 Yes No Yes Yes Yes Yes Yes Ø 
Fuse[198] Yes No No3 Yes No Yes Yes Yes Yes Yes Ø 
Konrade 
[199] 
Yes Yes Yes Yes Yes Yes Yes Yes  Yes Yes + 
Svinaryov 
[201] 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes + 
Wachter 
[188] 
Yes  No No3 Yes No Yes  Yes  Yes  Yes  Yes  Ø 
Wachter 
[188] 
Yes  No No3 Yes No Yes  Yes  Yes  Yes  Yes  Ø 
Wachter 
[188] 
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Yes  No No3 Yes No Yes  Yes  Yes  Yes  Yes  Ø 
Yamada 
[203] 
Yes Yes Yes3 Yes Yes Yes No Yes Yes Yes Ø 
Yamada 
[203] 
Yes Yes Yes3 Yes Yes Yes No Yes Yes Yes Ø 
Yamada 
[203] 
Yes Yes Yes3 Yes Yes Yes No Yes Yes Yes Ø 
Yamada 
[203] 
Yes Yes Yes3 Yes Yes Yes No Yes Yes Yes Ø 
Yamada 
[203] 
Yes Yes Yes3 Yes Yes Yes No Yes Yes Yes Ø 
Zimmerman 
[84] 
Yes Yes Yes3 Yes Yes Yes Yes Yes  Yes Yes + 
Zimmerman 
[84] 
Yes Yes Yes3 Yes Yes Yes Yes Yes  Yes Yes + 
Costante 
[195] 








Yes No Yes3 Yes Yes Yes No Yes  Yes Yes Ø 
Kapil [85] Yes Yes Yes3 Yes Yes Yes No Yes Yes Yes Ø 
Kapil [85] Yes Yes Yes3 Yes Yes Yes No Yes Yes Yes Ø 
Kapil [85] Yes Yes Yes3 Yes Yes Yes No Yes Yes Yes Ø 
Copeland 
[182] 
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Yes Yes Yes3 Yes Yes Yes Yes Yes  Yes Yes + 
Copeland 
[182] 
Yes Yes Yes3 Yes Yes Yes Yes Yes  Yes Yes + 
Sareen [83] Yes Yes Yes3 Yes Yes Yes Yes Yes Yes Yes + 
Sareen [83] Yes Yes Yes3 Yes Yes Yes Yes Yes Yes Yes + 
Sareen [83] Yes Yes Yes3 Yes Yes Yes Yes Yes Yes Yes + 
Sullivan 
[184] 
Yes Yes Unclear 3 Unclear Yes Yes No Yes  Yes Yes Ø 
Sullivan 
[184] 
Yes Yes Unclear 3 Unclear Yes Yes No Yes  Yes Yes Ø 
Sullivan 
[184] 


















p [180]  
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Yes  No Yes4 No Yes  Yes  No Yes  Yes  Yes  Ø 
Wilcken 
[116] and Li 
[17] 
Yes No Yes4 Yes Yes  Yes No Yes Yes Yes Ø 
Mikelsaar  
[57] 
Yes  No No Unclear Yes  Yes  Yes  Yes  Yes  Yes  Ø 
Mikelsaar 
[57] 
Yes  No No Unclear Yes  Yes  Yes  Yes  Yes  Yes  Ø 
Mikelsaar 
[57] 
Yes  No No Unclear Yes  Yes  Yes  Yes  Yes  Yes  Ø 
Rahman 
[200] and Li 
[17] 
Yes  Yes Yes4 Yes  Yes  Yes  No  Yes Yes  Yes  Ø 
Vandevijver
e [186] and 
Vandevijver
e [202]   
Yes Yes Yes4 Yes  Yes  Yes  Yes  Yes  Yes  Yes  + 
Vandevijver
e [186] and 
Vandevijver
e [202]   
Yes Yes Yes4 Yes  Yes  Yes  Yes  Yes  Yes  Yes  + 
Vandevijver
e [186] and 
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e [202]   
Mehran 
[205] 
Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  + 
 
1The important items to assess the quality of cross-sectional studies.  
2The quality of included studies was assessed based on the American Dietetic Association’s study quality analysis manual [189]. Studies with + 
sign were considered as high quality/low risk of bias, studies with Ø sign were considered as neutral and studies with – sign were considered as 
low quality/high risk of bias. 
3Two or more studies were reported in a single publication. 
4The Data on iodine status based on the different markers were extracted from different publications of the same country/region conducted in the 





Supplemental Table 3. 4 The World Health Organization’s criteria in classifying population 
iodine status1  







Newborn TSH >5 mIU/L, % 0-3 > 3-19.9 20-39.9 ≥40 
MUIC in SAC, µg/L ≥100 50-99 20-49 <20 
Goitre in SAC, % 0-4.9 5-19.9 20-29.9 ≥30 
 
1TSH, thyroid stimulating hormone; MUIC, median urinary iodine concentration; SAC, 
school age children.  





Supplemental Table 3. 5 Characteristics of the included studies1  




% GOITRE BY 
PALPATION (N) 
% TVOL > 97TH 
PERCENTILE (N) 
AGE AT TSH ASSESSMENT:3-4 DAYS3 
Yamada, 2000, Mongolia [203]  Study (Ulaanbaatar) 18.0 (128) 160.4 (210) 30.7 (1,209) NA 
Study (Uvurkhangai) 30.4 (112) 45.0 (300) 19 (1,200) NA 
Study (Huvsgol) 13.3 (207) 126 (140) 29.5 (516) NA 
Study (Dornod) 12.2 (368) 40.6 (110) 36.9 (428) NA 
Study (Hovd) 28.3 (99) 39.1 (150) 28.5 (302) NA 









1.7 (218,665) 141 (386) NA NA 
Clapin, 2014, [52]; ABS report, 
2013, Western Australia [131]  
Single study  5.7 261.3 (NA) NA NA 
Evans, 2014, [179]; 
Vanderpump, 2011, Wales, UK 
[180]  
Single study  1.5 (535) 80.1 (737)4 NA NA 
Rahman, 2010, [200]; Li, 2005, 
Victoria, Australia [17]  
Single study  9.26 (NA) 
 
73.5 (348)4 NA NA 
Fuse, 2003, Ulaan Baatar, 
Mongolia [198]  
Study (1996), 1996 17.8 (129) 152.5 (300) 49.4 (1,203) 43.3 (300) 
Study (1996-1999)  17.8 (129) 160.4 (198) NA 29.8 (205) 
Wilcken, 2011, [116]; Li , 2005, 
NSW, Australia [17]  
Single study  
 
5.02 (NA) 89.0 (427)4 NA NA 
AGE AT TSH ASSESSMENT: < 3 DAYS OR > 4 DAYS5 
Gruneiro- Papendieck, 2004, 
Argentina [183]  
Single study  3.6 (112) 143 (100) 4.5(500) NA 
Al-Hosani, 2003, United Arab 
Emirates [181] 
Single study  2.6 (23,116) 
 










% GOITRE BY 
PALPATION (N) 
% TVOL > 97TH 
PERCENTILE (N) 
Wachter,1985, Tanzania [188]  




2.7 (150) 17.6 (23)6 
 




0 (74) 93.3 (13)6 NA NA 
Evans,2014 [179]; 
Vanderpump, 2011, Wales, UK 
[180]  
Single study  0.9 (41,809) 80.1 (737)4 NA NA 
AGE AT TSH ASSESSMENT: 3-4 DAYS AND < 3 DAYS OR > 4 DAYS7 
Mehran, 2016, Iran [205]  Single study  2.8 (128,8237) 145 (11280) NA NA 
Dalili, 2012, Iran [197]  Study (2006) 1.7 (9,251) 270.2 (240) NA NA 
Study (2007) 1.4 (23,529) 200.4 (240) NA NA 
Study (2008) 2.1 (27,427) 200.1 (240) NA NA 
Study (2009) 1.8 (29,511) 200 (240) NA NA 
Study (2010) 1.9 (29,983) 200.2 (240) NA NA 





14.8 (9,957) 53.8 (191) 41.3 (10243) NA 
Study (Sea level 
territory) 
14.1 (11,121) 89.6 (93) 17.4 (3741) NA 
Costante,1997, Italy [195]  Single study  14.4 (21,078) 65.6 (284) 37 (13,984)  
Burns, 2008 [54]; Vanderpump, 
2011, Ireland [180]  
Single study  
 
2.35 80.1 (737) NA NA 
Mikelsaar, 1999; Not cited, 
Estonia,[57] 
 
Study (North) 16.4 61.54 NA NA 
Study (Central) 21 714 NA NA 
Study (South) 17.2 53.54 NA NA 
Vandevijvere, 2012 [186]; 
Vandevijvere, 2012, Belgium 
[202]   
Study (2009-2011) 2.6 (81,107) 113 (1,541)4 7.2 (1,541) NA 
Study (2010-2011) 3.0 (92,961) 113 (1,541)4 7.2 (1,541) NA 
Study (2011) 3.3 (81,511) 113 (1,541)4 7.2 (1,541) NA 
Simsek, 2003, Turkey [60]  Study (Turkey) 26.7 (18,606) NA 52 (1,046) NA 
Study (Bolu) 32.1 (5,210) 31 (342) 76 (342) 79 (342) 








% GOITRE BY 
PALPATION (N) 
% TVOL > 97TH 
PERCENTILE (N) 
Study (Zongulda) 23.2 (7,256) 23.2 (320) 9 (320) 17 (320) 
Konrade, 2014, Latvia [199]  Single study  8.2 and 
9.3 (31,274) 
107.3 (913)6 NA NA 
Svinaryov, 2003, Russia [201]  Single study  37.4 (95,657) 38.2 (654) 35.8 (2,040) 25.8 (2040) 
Wachter, 1985, Tanzania [188]  




45 (69) 17.6 (23)6 
 




21 (117) 93.3 (13)6 NA NA 
Gruneiro- Papendieck,, 2004, 
Argentina [183]  
Single study  2.7 (1500) 143 (100) 4.5 (500) NA 
Gyurjyan, 2006[187]; Selga, 
2000, Latvia [204] 
Single study  
 
16.5 (NA) 59 (NA)4 NA NA 
TSH ASSESSED IN CORD BLOOD SAMPLES  
Kapil, 2015, India 
[85]  
  
Study (Kangra) 73.4 (613) 200 (463) 15.8 (1,864) NA 
Study (Kullu)  79.8 (638) 175 (532) 23.4 (1,986)  
Study (Solan)  63.2 (683) 62.5 (513) 15.4 (1,898)  
Copeland, 2002, Bangladesh 
[182]  
Single study  
 
84 (208) 73 (400) 27 (3,99) 
 
26 (351) 
Copeland, 2002, Guatemala 
[182]  
Single study  58 (141) 181 (458) 15 (518) NA 
Copeland, 2002, USA [182]  Single study  82 (243) 282 (284) 2 (305) 0 (300) 
Sareen, 2016, India[83]  
 
  






13.2 (NA) NA 
Study (Nainital) 76.4 (670) 125 (2,269) 15.9 (NA)  
Study (Pauri Garhwal) 72.8 (694) 115 (2,067) 16.8 (NA)  
Sullivan, 1997, Kyrgyzstan 
[184]   
Study (Bishkek) 74 (90) 30 (NA) 49 (NA) 39 (NA) 
Study (OSH) 47 (92) 30 (NA) 49 (NA) 39 (NA) 
Sullivan,1997, Philippines [184]  Single study  32 (750) 40 (NA) 2 (NA) NA 
Gruneiro-Papendieck, 2004, 
Argentina [183]  





1NA, not applicable; N, number of children; TSH, thyroid stimulating hormone; Tvol, thyroid volume; MUIC, median urinary iodine 
concentration 
2Studies conducted at different regions or different periods within the same publication were classified as separate studies, with the region /time 
period in the brackets. “Single study” denotes that the publication(s) reported a study that was conducted in only one region or one time point. 
3Studies where the newborns’ heel prick samples were collected within the World Health Organization’s recommended age (at 3-4 days of 
infant’s age). 
4MUIC or goitre results from the same country/region conducted in the same time period were extracted from different publications.  
5Studies where the newborns’ heel prick samples were collected outside the World Health Organization’s recommended age (at < 3 or > 4 days 
of infant’s age). 
6Urinary iodine concertation as µg iodine per gram of creatinine. 
7Studies where the newborns’ heel prick samples were collected within (3-4 days of infant age) and outside (< 3 and > 4 days of infants age) the 

















Supplemental Table 3. 6 Classification of the iodine status of the included studies based on TSH, MUIC and goitre prevalence1  
PUBLICATIONS, COUNTRY   STUDY2 IODINE STATUS BY POPULATION MARKERS3 




AGE AT TSH ASSESSMENT:3-4 DAYS4 
Yamada, 2000, Mongolia [203]  Study (Ulaanbaatar) Mild  Sufficiency Severe  NA 
Study (Uvurkhangai) Moderate Moderate  Moderate  NA 
Study (Huvsgol) Mild  Sufficiency Moderate NA 
Study (Dornod) Mild  Moderate Severe NA 
Study (Hovd) Moderate  Moderate Moderate NA 









Sufficiency Sufficiency NA NA 
Clapin, 2014, [52]; ABS report, 
2013, Western Australia [131]  
Single study  Mild Sufficiency NA NA 
Evans, 2014, [179]; 
Vanderpump, 2011, Wales, UK 
[180]  
Single study  Sufficiency  Mild  NA NA 
Rahman, 2010, [200]; Li, 2005, 
Victoria, Australia [17]  
Single study  Mild Mild NA NA 
Fuse, 2003, Ulaan Baatar, 
Mongolia [198]  
Study (1996), 1996 Mild Sufficiency Severe Severe 
Study (1996-1999)  Mild Sufficiency NA Moderate 
Wilcken, 2011, [116]; Li , 2005, 
NSW, Australia [17]  
Single study  
 
Mild  Mild  NA NA 
AGE AT TSH ASSESSMENT: < 3 DAYS OR > 4 DAYS5 
Gruneiro- Papendieck, 2004, 
Argentina [183]  
Single study  Mild  Sufficiency Sufficiency  NA 
Al-Hosani, 2003, United Arab 
Emirates [181] 




PUBLICATIONS, COUNTRY   STUDY2 IODINE STATUS BY POPULATION MARKERS3 




Wachter,1985, Tanzania [188]  










Sufficiency Mild NA NA 
Evans,2014 [179]; 
Vanderpump, 2011, Wales, UK 
[180]  
Single study  Sufficiency Mild NA NA 
AGE AT TSH ASSESSMENT: 3-4 DAYS AND < 3 DAYS OR > 4 DAYS6  
Mehran, 2016, Iran [205]  Single study  Sufficiency Sufficiency NA NA 
Dalili, 2012, Iran [197]  Study (2006) Sufficiency Sufficiency NA NA 
Study (2007) Sufficiency Sufficiency NA NA 
Study (2008) Sufficiency Sufficiency NA NA 
Study (2009) Sufficiency Sufficiency NA NA 
Study (2010) Sufficiency Sufficiency NA NA 





Mild  Mild Severe NA 
Study (Sea level 
territory) 
Mild Mild Mild  NA 
Costante,1997, Italy [195]  Single study  Mild Mild Severe  
Burns, 2008 [54]; Vanderpump, 
2011, Ireland [180]  
Single study  
 
Sufficiency  Mild NA NA 
Mikelsaar, 1999; Not cited, 
Estonia,[57] 
 
Study (North) Mild Mild NA NA 
Study (Central) Mild Mild NA NA 
Study (South) Mild Mild NA NA 
Vandevijvere, 2012 [186]; 
Vandevijvere, 2012, Belgium 
[202]   
Study (2009-2011) Sufficiency  Sufficiency Mild NA 
Study (2010-2011) Mild Sufficiency Mild NA 
Study (2011) Mild Sufficiency Mild NA 
Simsek, 2003, Turkey [60]  Study (Turkey) Moderate  NA Severe NA 




PUBLICATIONS, COUNTRY   STUDY2 IODINE STATUS BY POPULATION MARKERS3 




Study (Duzce) Moderate Moderate Severe Severe 
Study (Zongulda) Moderate Moderate Mild Mild 
Konrade, 2014, Latvia [199]  Single study  Mild   Sufficiency NA NA 
Svinaryov, 2003, Russia [201]  Single study  Moderate  Moderate Severe Moderate 
Wachter, 1985, Tanzania [188]  










Moderate  Mild NA NA 
Gruneiro- Papendieck,, 2004, 
Argentina [183]  
Single study  Sufficiency  Sufficiency  Sufficiency NA 
Gyurjyan, 2006[187]; Selga, 2000, 
Latvia [204] 
Single study  
 
Mild  Mild NA NA 
TSH ASSESSED IN CORD BLOOD SAMPLES    
Kapil, 2015, India 
[85]  
  
Study (Kangra) Severe Sufficiency Mild NA 
Study (Kullu)  Severe Sufficiency Moderate   
Study (Solan)  Severe Mild Mild  
Copeland, 2002, Bangladesh [182]  Single study  
 
Severe Mild Moderate  Moderate 
Copeland, 2002, Guatemala [182]  Single study  Severe Sufficiency Mild NA 
Copeland, 2002, USA [182]  Single study  Severe Sufficiency Sufficiency Sufficiency  
Sareen, 2016, India[83]  
 
  
Study (Udham Singh 
Nagar) 
Severe Sufficiency Mild NA 
Study (Nainital) Severe Sufficiency Mild  
Study (Pauri Garhwal) Severe Sufficiency Mild  
Sullivan, 1997, Kyrgyzstan [184]   Study (Bishkek) Severe Moderate Severe Severe 
Study (OSH) Severe  Moderate Severe Severe 




PUBLICATIONS, COUNTRY   STUDY2 IODINE STATUS BY POPULATION MARKERS3 





Argentina [183]  
Single study  Mild  Sufficiency Sufficiency  
 
1NA, not applicable; TSH, thyroid stimulating hormone; Tvol, thyroid volume; MUIC, median urinary iodine concentration 
2Studies conducted at different regions or different periods within the same publication were classified as separate studies, with the region /time 
period in the brackets. “Single study” denotes that the publication(s) reported a study that was conducted in only one region or one time point. 
3The Iodine status was defined according to the WHO criteria [12, 178] using the results of MUIC, percentage of TSH >5 mIU/L and goitre 
prevalence reported in the included studies.  
4Studies where the newborns’ heel prick samples were collected within the World Health Organization’s recommended age (at 3-4 days of 
infant’s age). 
5Studies where the newborns’ heel prick samples were collected outside the World Health Organization’s recommended age (at < 3 or > 4 days 
of infant’s age). 
6Studies where the newborns’ heel prick samples were collected within (3-4 days of infant age) and outside (< 3 and > 4 days of infants age) the 




Supplemental Table 3. 7 Summary of the number of studies and publications included in the systematic review   
References  Number of 
publications 
Number of studies per 
publication 
Total number of 
studies 
Publication contained > 1 study    
Dalili [197], Yamada [203] Two 5 10 
Simsek [60], Wachter [188] Two 4 8 
Copeland [182], Gruneiro-
Papendieck [183], Kapil 
[85], Mikelsaar [57], Sareen 
[83], Sullivan [184] 
Six 3 18 
Costante [196], Evans [179] 
Fuse [198], Zimmermann 
[84] 
Four 2 8 
Al-Hosani [181], Costante 
[195], Konrade [199], 
Rahman [200], Svinaryov 
[201], Mehran [205] 
Seven 1 6 
One study from two publications    
Burns [54] Clapin [52], 
Gyurjyan [187], Li[17], 
Vanderpump [180] 
Wilcken [116], Selga [204] 
Australian Health Survey 
[131]  
Eight  4 
Three studies from two publications    
Vandevijvere [186], 
Vandevijvere [202] 
Two  3 









Supplemental Table 3. 8 Comparison of the agreement between markers from the same or different publications1 
 Agreement between TSH and MUIC Agreement between TSH and goitre 
 Yes No Total Yes No Total 
Studies from the same publication  24 (73%) 9 (27%) 33 (100%) 17 (85%) 3 (15%) 20 (100%) 
Studies from the different publications  4 (40%) 6 (60%) 10 (100%) 2 (67%) 1 (33%) 3 (100%) 
 



























1TSH, thyroid stimulating hormone; MUIC, median urinary iodine concentration 





  Iodine deficiency by MUIC2 Iodine deficiency by goitre2 
Iodine deficiency by TSH2 No Yes No Yes 
No 10 6 1 3 




Supplemental Table 3. 10 The agreement between newborn TSH and MUIC in pregnant women in classifying population iodine status1  





TSH and MUIC 
Sareen, 2016, India [83]  
 
Udham Singh Nagar: 2013-2014 3,4 53.3(649) 124(532) Yes 
Nainital: 2013-2014 3,4 76.4(670) 117.5(468) Yes 
Pauri Garhwal: 2013-2014 3,4 72.8(694) 110(404) Yes 
 
Zimmerman, 2005, Switzerland [84]  
1992-19983,19994 2.9 (259,035) 138(511) No 
1999-20043, 20044 1.7(218,665) 249(279) Yes 
Kapil, 2015, India [85]  
 
Kangra: 201443,4 73.4 (613) 200 (368) No 
Kullu:20143,4 79.8 (638) 149 (439) Yes 
Solan:20143,4 63.2 (683) 130 (311) Yes 
 
1TSH, thyroid stimulating hormone; MUIC, median urinary iodine concentration.  
2Agreement between newborn TSH and MUIC to classify iodine status. Iodine status is defined as deficiency if ≥ 3% of the population with 
newborn TSH >5 mIU/L, or MUIC < 150µg/L during pregnancy [12, 178]. 
3Year of data collection for newborn TSH concentration. 




Supplemental Table 3. 11 Coordinates of the receiver operating curve for TSH >5 mIU/L vs 
UIC <100 µg/L1 
Test result variable: proportion of TSH>5 mIU/L  
State variable: median UIC <100 µg/L 
Iodine sufficient if 
proportion greater than or 
equal to2 Sensitivity 1 - Specificity 
-1.0000 1.000 1.000 
0.4500 0.958 1.000 
1.1500 0.917 1.000 
1.4500 0.917 0.947 
1.6000 0.875 0.947 
1.7500 0.833 0.842 
1.8500 0.833 0.789 
2.0000 0.833 0.737 
2.2250 0.833 0.684 
2.4750 0.792 0.684 
2.6500 0.792 0.632 
2.7500 0.750 0.579 
2.8500 0.750 0.526 
2.9500 0.750 0.474 
3.1500 0.750 0.421 
3.4500 0.750 0.368 
4.3100 0.750 0.316 
5.3600 0.708 0.316 
7.4800 0.708 0.263 
9.2800 0.667 0.263 
10.7500 0.667 0.211 
12.7500 0.625 0.211 
13.7000 0.625 0.158 
14.2500 0.583 0.158 
14.6000 0.542 0.158 
15.6000 0.500 0.158 
16.4500 0.458 0.158 
16.8500 0.417 0.158 
17.5000 0.375 0.158 
17.9000 0.375 0.053 
19.5000 0.375 0.000 
22.1000 0.292 0.000 
24.6000 0.250 0.000 
27.1500 0.208 0.000 
29.3500 0.167 0.000 
31.2500 0.125 0.000 
34.7500 0.083 0.000 
41.2000 0.042 0.000 
1TSH, thyroid stimulating hormone; UIC, urinary iodine concentration 
2The smallest cut-off value is the minimum observed test value minus 1, and the largest cut-
off value is the maximum observed test value plus 1. All the other cut-off values are the 





Supplemental Table 3. 12 Coordinates of the receiver operating curve for TSH >5 mIU/L vs 
prevalence of goitre >5%1 
Test result variable(s): proportion of TSH >5 mIU/L   
State variable: prevalence of goitre >5% 
Iodine sufficient if 
proportion greater than or 
equal to2 Sensitivity 1 - Specificity 
0.7000 1.000 1.000 
2.1500 0.952 1.000 
2.6500 0.905 1.000 
2.8500 0.857 0.500 
3.1500 0.810 0.500 
3.4500 0.762 0.500 
7.9000 0.762 0.000 
12.7500 0.714 0.000 
13.7000 0.667 0.000 
14.2500 0.619 0.000 
14.6000 0.571 0.000 
16.3000 0.524 0.000 
17.9000 0.429 0.000 
20.6000 0.381 0.000 
24.6000 0.333 0.000 
26.3500 0.286 0.000 
27.5000 0.238 0.000 
29.3500 0.190 0.000 
31.2500 0.143 0.000 
34.7500 0.095 0.000 
41.2000 0.048 0.000 
46.0000 0.000 0.000 
 
1TSH, thyroid stimulating hormone 
2The smallest cut-off value is the minimum observed test value minus 1, and the largest cut-
off value is the maximum observed test value plus 1. All the other cut-off values are the 




Supplemental Table 4. 1 Iodine status of participants classified using different markers 
(n=534)1.  
 Estimated 24-h UIE, µg/day 
 Mage et al. Kesteloot and Joosens 
Median  261.0 (154.9, 466.3) 259.0 (153.6, 415.8) 
Broad classification of iodine status    
<150 (deficiency) 124 (23.2) 128 (24.0) 
150-499 (sufficiency) 300 (56.2) 315 (59.0) 
≥500 (excess)  110 (20.6) 91 (17.0) 
1 Values are presented as frequencies (percentages) unless otherwise specified. UIE, urinary 
iodine excretion.  





Supplemental Table 4. 2 A contingency table of the number of pregnant women with urinary 
iodine value <150 (yes or no) or ≥500 (yes or no) based on estimated 24-h UIE and other 
urinary iodine markers1  
1I/Cr, urinary iodine concentration to creatinine ratio; NA, not applicable; UIC, urinary iodine 
concentration; UIC~Cr, urinary iodine concentration corrected for creatinine; UIE, urinary 
iodine excretion.  
  Test markers   
Reference markers UIC Estimated 24-h UIE I/Cr UIC~Cr 
 Yes  No Yes  No Yes No Yes No 
Comparison of markers to define iodine deficiency at <150 units2 
Estimated 24-h UIE as the 
reference 
        
        Yes  70 54 NA NA 122 2 109 15 
        No 98 312 NA NA 55 355 71 339 
I/Cr as the reference         
         Yes 87 90 122 55 NA NA 140 37 
         No 81 276 2 355 NA NA 40 317 
UIC as the reference         
         Yes  NA NA 70 98 87 81 127 41 
         No NA NA 54 312 90 276 53 313 
Comparison of markers to define iodine excess at ≥500 units2 
Estimated 24-h UIE as the 
reference 
        
        Yes  41 69 NA NA 
54 56 38 72 
        No 17 407 NA NA 
3 421 2 422 
I/Cr as the reference         
         Yes 
24 33 0 3 
NA NA 
32 8 
         No 
34 443 110 421 
NA NA 
25 469 
UIC as the reference         
         Yes  NA NA 
41 17 24 34 32 26 
         No NA NA 




2The WHO criteria based on median UIC in µg/L was applied in all markers to define iodine 
deficiency (<150) or excess (≥500) including I/Cr in µg/g and UIC~Cr in µg/L and estimated 






















Supplemental Table 7. 1 Comparison of observed vs. imputed values1  
Variables DOMInO PINK 
 n Observed cases n Imputed cases2 n Observed cases n Imputed cases2 
Mother characteristics          
Age at enrolment, y   726     28.8 ± 5.8 726 NA 792 30.0 ± 5.1 794 30.0 ± 5.1 
Weight, kg  720 73.7 ± 16.3 726 73.7 ± 16.3 789 70.8 ± 16.0 794 70.8 ± 16.0 
Height, cm 726     1.6 ± 0.1 726 NA 788 1.6 ± 0.1 794 1.6 ± 0.0 
BMI, kg/m2 720 27.3 ± 5.9 726 27.3 ± 5.9 787 26.1 ± 5.4 794 26.1 ± 0.4 
HSQ score   687 33.7 ± 3.6 726 33.4 ± 3.6 685 33.0 ± 2.9 794 33.0 ± 2.9 
Hospital 726  726  794  794  
    FMC  257 (35.4)  NA  402 (50.6)  NA 
   WCH  469 (64.6)  NA  392 (49.4)  NA 
Parity 726  726  794  794  
   0  405 (55.8)  NA  427 (53.8)  NA 
   ≥1  321 (44.2)  NA  367 (46.2)  NA 
Race 726  726  794  794  
   Caucasian   663 (91.3)  NA  668 (84.1)  NA 
   Others   63 (8.7)  NA  126 (15.9)  NA 
Occupation  726  726  794  794  
   Managers           165 (22.7)  NA  44 (5.5)  NA 
   Professionals            165 (22.7)  NA  266 (33.5)  NA 
   Sales, trades person, clerical service            201 (27.7)  NA  333 (41.9)  NA 
   Labourers  0  NA  16 (2.0)  NA 
   Unemployed/pension            24 (3.3)  NA  14 (1.8)  NA 
   Student            29 (4.0)  NA  25 (3.2)  NA 
   Home duties       142 (19.6)  NA  96 (12.1)  NA 
   Secondary education 726 450 (62.0) 726 NA 794 659 (83.0) 794 NA 
Qualification 726  726  794  794  
   Certificate or Diploma         317 (43.7)  NA  274 (34.5)  NA 
   Degree              142 (19.6)  NA  330 (41.6)  NA 
   Higher Degree            25 (3.4)  NA  79 (9.9)  NA 
   None            242 (33.3)  NA  111 (14.0)  NA 




Variables DOMInO PINK 
 n Observed cases n Imputed cases2 n Observed cases n Imputed cases2 
Previous smoking 726 227 (31.3) 726 NA 794 102 (12.9) 794 NA 
Alcohol consumption during second trimester 726 76 (10.5) 726 NA 794 41 (5.2) 794 NA 
Previous alcohol consumption 726 445 (61.3) 726 NA 794 526 (66.3) 794 NA 
Supplement intake during second trimester 726 352 (48.5) 726 NA 794 708 (89.2) 794 NA 
Previous depression 726 159 (21.9) 726 NA 794 169 (21.3) 794 NA 
Depression during second trimester  726 48 (6.6) 726 NA 794 48 (6.1) 794 NA 
Caesarean section 726 203 (28.0) 726 NA 765 213 (27.8) 794 222 (28.0) 
Father characteristics         
Secondary education 726 389 (53.6) 726 NA 785 587 (74.8) 794 592 (74.5) 
Qualification 691  726  793  794  
   Certificate/Diploma           313 (45.3)  327 (45.0)  315 (39.7)  315 (39.7) 
   Degree           107 (15.5)  112 (15.4)  218 (27.5)  218 (27.5) 
   Higher Degree            27 (3.9)  29 (4.0)  74 (9.3)  74 (9.3) 
   None         244 (35.3)  258 (35.6)  186 (23.5)  187 (23.5) 
Occupation  694  726  784  794  
   Managers                  127 (18.3)  131 (18.1)  92 (11.7)  93 (11.7) 
   Professionals            300 (43.2)  313 (43.1)  234 (29.9)  235 (29.7) 
   Sales, trades person, clerical service            207 (29.8)  218 (30.0)  352 (44.9)  357 (45.0) 
   Labourers                     2 (0.3)  2 (0.3)  75 (9.8)  77 (9.7) 
   Unemployed/pension            33 (0.8)  35 (4.9)  16 (2.0)  17 (2.1) 
   Student           21 (3.0)  23 (3.1)  9 (1.2)  9 (1.2) 
   Home duties            4 (0.6)  4 (0.6)  6 (0.8)  6 (0.8) 
Child characteristics         
Sex 726  726  765  794  
   Female         361 (49.7)  NA  371 (48.5)  382 (48.1) 
   Male           365 (50.3)  NA  394 (51.5)  412 (51.9) 
Gestational age at birth, weeks 726 38.7 ± 2.2 726 NA 765 39.0 ± 1.8 794 39.0 ± 1.8 
Birthweight, gm   725 3392.2 ± 607.2 726 3391.5 ± 607.1 764 3380.4 ± 548.7 794 3379.5 ± 549.0 
Birthweight-for-gestational age z score  725 0.2 ± 1.0 726 0.2 ± 1.0 764 0.0 ± 1.0 794 0.0 ± 1.0 
Birth Length, cm   722 49.5 ± 3.0 726 49.5 ± 3.0 744 49.8 ± 2.6 794 49.8 ± 2.6 
Birth Head circumference, cm   717 34.5 ± 2.0 726 34.5 ± 2.0 737 34.5 ± 1.6 794 34.5 ± 1.6 




Variables DOMInO PINK 
 n Observed cases n Imputed cases2 n Observed cases n Imputed cases2 
1 minute APGAR score  721 8.2 ± 1.4 726 8.2 ± 1.4 760 8.2 ± 1.4 794 8.2 ± 1.4 
5 minute APGAR score 721 9.0 ± 0.9 726 9.0 ± 0.9 760 8.9 ± 0.7 794 8.9 ± 0.7 
Newborn TSH3, mIU/L 590 1.7 (1.0, 2.9) 726  679 2.2 (1.4, 3.3) 794 2.2 (1.4, 3.3) 
Newborn TSH quartiles 590  726  679  794  
   First   148 (25.1)  184 (25.3)  170 (25.0)  200 (25.2) 
   Second           147 (24.9)  176 (24.3)  170 (25.0)  196 (24.7) 
   Third            148 (25.1)  185 (25.5)  170 (25.0)  201 (25.3) 
   Fourth           147 (24.9)  181 (24.9)  169 (24.9)  197 (24.9) 
Newborn TSH category  590  726  679  794  
   >5 mIU/L  29 (4.9)  33 (4.6)  37 (5.5)  43 (5.4) 
   ≤5 mIU/L  561 (95.1)  693 (95.4)  642 (94.6)  751 (94.6) 
Weight, kg   684 11.5 ± 1.5 726 11.5 ± 1.5 683 11.6 ± 1.5 794 11.6 ± 0.5 
Length, cm 685 82.4 ± 3.4 726 82.5 ± 3.4 672 83.0 ± 3.9 794 83.0 ± 4.0 
Head circumference, cm  685 47.8 ± 1.5 726 47.8 ± 1.5 660 48.2 ± 2.1 794 48.2 ± 2.2 
WLZ 682 0.7 ± 1.0 726 0.7 ± 1.0 669 0.6 ± 1.2 794 0.6 ± 1.3 
LAZ 685 0.1 ± 1.1 726 0.1 ± 1.1 670 -0.1 ± 1.2 794 -0.1 ± 1.2 
WAZ 684 0.5 ± 1.0 726 0.5 ± 1.0 681 0.5 ± 1.4 794 0.5 ± 1.4 
HCZ 685 0.7 ± 1.0 726 0.7 ± 1.0 657 0.9 ± 1.4 794 0.9 ± 1.9 
WLZ < - 1 682 23 (3.4) 726 25 (3.5) 669 31 (4.6) 794 41 (5.2) 
LAZ < - 1 685 104 (15.2) 726 113 (15.6) 670 100 (14.9) 794 123 (15.5) 
WAZ < - 1 684 35 (5.1) 726 38 (5.3) 681 43 (6.3 794 56 (7.0) 
HCZ < - 1 685 28 (4.1) 726 30 (4.1) 657 21 (3.2) 794 33 (4.2) 
Cognitive score    694 102.0 ± 11.8 726 101.7 ± 12.0 699 96.6 ± 11.6 794 96.3 ± 11.9 
Language score  692 97.4 ± 14.5 726 97.2 ± 14.7 698 94.5 ± 17.8 794 93.9 ± 18.1 
Motor score  694 102.6 ± 11.1 726 102.5 ± 11.2 698 99.4 ± 10.6 794 98.9 ± 11.2 
Social emotional score  681 107.0 ± 17.5 726 106.8 ± 17.8 698 104.1 ± 14.3 794 103.7 ± 14.7 
Adaptive behaviour score    680 100.0 ± 14.3 726 100.0 ± 14.4 699 100.3 ± 13.6 794 100.1 ± 14.0 
Cognitive delay (<85)  694 31 (4.5) 726 36 (4.9) 699 63 (9.0) 794 80 (10.0) 
Language delay (<85)   692 118 (17.1) 726 127 (17.4) 698 196 (28.1) 794 234 (29.4) 
Motor delay (<85)   694 33 (4.8) 726 37 (5.1) 698 24 (3.4) 794 35 (4.4) 
Social emotional delay (<85) 681 31 (4.6) 726 36 (4.9) 698 34 (4.9) 794 44 (5.5) 





1Data are mean ± SD or n (%) unless otherwise specified. Developmental delay was defined as Bayley-III scores below 85 and low growth 
indices were defined as z scores below 1 SD. BMI, body mass index; DOMInO, DHA to Optimize Mother Infant Outcome; HCZ, head 
circumference-for-age z score; HSQ, home screening questionnaire; LAZ, length-for-age z score; n, total sample size; NA, not applicable; PINK, 
Pregnancy Iodine and Neurodevelopment in Kids; SD, standard deviation; TSH, thyroid-stimulating hormone; WAZ, weight-for-age z score; 
WLZ, weight-for-length z score.  














Supplemental Table 7. 2 Adjusted associations between newborn TSH tertiles and Bayley-III outcomes at 18 months of age1    
 DOMInO PINK 
 n Bayley-III score  Developmental delay2  n Bayley-II score Developmental delay2 
  MD (95% CI)3 RR (95% CI)4  MD (95% CIs)3 RR (95% CI)4 
Cognitive scale        
Tertile 1 278 ref ref 257 ref ref 
Tertile 2 210 -1.8 (-4.1, 0.5) 1.8 (0.7, 4.9) 256 -0.3 (-2.5, 1.9) 0.8 (0.5, 1.5) 
Tertile 3 238 -1.8 (-4.3, 0.6) 1.6 (0.6, 4.3) 281 1.0 (-1.2, 3.1) 0.6 (0.4, 1.1) 
Language scale        
Tertile 1 278 ref ref 257 ref ref 
Tertile 2 210 -1.0 (-3.8, 1.8) 1.4 (0.9, 2.3) 256 0.5 (-2.7, 3.6) 1.0 (0.7, 1.3) 
Tertile 3 238 -1.6 (-4.4, 1.2) 1.4 (0.9, 2.2) 281 2.5 (-0.5, 5.4) 1.0 (0.7, 1.4) 
Motor scale        
Tertile 1 278 ref ref 257 ref ref 
Tertile 2 210 -1.6 (-4.0, 0.7) 2.6 (1.0, 6.2) 256 -1.1 (-3.4, 1.1) 1.0 (0.4, 2.4) 
Tertile 3 238 -1.6 (-4.1, 0.8) 2.1 (0.8, 5.6) 281 1.0 (-0.9, 3.0) 0.6 (0.2, 1.7) 
Social emotional scale       
Tertile 1 278 ref ref 257 ref ref 
Tertile 2 210 -0.8 (-4.2, 2.6) 0.8 (0.3, 2.2) 256 1.3 (-1.6, 4.2) 1.2 (0.5, 2.9) 
Tertile 3 238 -1.3 (-5.0, 2.3) 0.8 (0.3, 2.2) 281 2.3 (-0.5, 5.1) 1.1 (0.4, 3.0) 
Adaptive behaviour scale       
Tertile 1 278 ref ref 257 ref ref 
Tertile 2 210 -0.9 (-3.7, 1.8) 1.5 (0.9, 2.6) 256 0.6 (-2.1, 3.4) 0.9 (0.5, 1.6) 
Tertile 3 238 -0.2 (-3.3, 2.8) 1.2 (0.6, 2.2) 281 1.7 (-0.8, 4.2) 0.7 (0.4, 1.3) 
 
1 TSH was categorised into tertiles in both DOMInO and PINK. DOMInO tertile 1 (Lowest): <1.3 mIU/L; tertile 2: 1.4-2.5 mIU/L; tertile 3 
(Highest): ≥2.6 mIU/L. PINK tertile 1 (Lowest): <1.6 mIU/L; tertile 2: 1.7-2.7 mIU/L; tertile 3 (Highest): ≥2.8 mIU/L. The regression models 
were adjusted for sex, parity, race, occupation, education, qualification, smoking during second trimester, previous smoking, alcohol 
consumption during second trimester, previous alcohol consumption, supplement intake during second trimester, previous depression, depression 




questionnaire score and birthweight-for-gestational age z score in both DOMInO and PINK studies. In addition, treatment group in the DOMInO 
study was also added to the adjusted models when analysing the DOMInO data. CI, confidence interval; DOMInO, DHA to Optimize Mother 
Infant Outcome; MD, mean difference; n, number of participants, PINK, Pregnancy Iodine and Neurodevelopment in Kids; ref, reference 
category; RR, relative risks; TSH, thyroid-stimulating hormone.  
2Developmental delay was defined as Bayley-III scores below 85. 
3The Mean Differences (95% CIs) were estimated with multivariable linear regression model.  










Supplemental Table 7. 3 Adjusted associations between newborn TSH quintile and Bayley-III outcomes at 18 months of age1    
 DOMInO PINK 
 n Bayley-III score Developmental delay2 n Bayley-III score  Developmental delay2 
  MD (95% CI)3 RR (95% CI)4  MD (95% CIs)3 RR (95% CI)4 
Cognitive scale       
Quintile 1 167 ref ref 173 ref ref 
Quintile 2 149 -0.8 (-3.6, 2.0) 1.0 (0.2, 4.6) 140 -1.2 (-4.0, 1.7) 1.4 (0.7, 3.0) 
Quintile 3 114 -1.9 (-5.1, 1.4) 2.2 (0.6, 7.7) 143 -2.0 (-4.8, 0.9) 1.1 (0.5, 2.4) 
Quintile 4 143 -1.3(-4.4, 1.8) 1.4 (0.3, 5.3) 173 -1.0 (-3.7, 1.7) 1.1 (0.5, 2.3) 
Quintile 5 153 -2.4 (-5.4, 0.6) 2.0 (0.6, 7.0) 165 0.6 (-2.2, 3.4) 0.6 (0.3, 1.5) 
Language scale       
Quintile 1 167 ref ref  173 ref ref 
Quintile 2 149 -0.3 (-3.7, 3.0) 1.2 (0.7, 2.2) 140 -3.6 (-7.4, 0.2) 1.3 (0.9, 1.9) 
Quintile 3 114 -1.3 (-5.1, 2.5) 1.5 (0.9, 2.8) 143 -1.2 (-5.2, 2.9) 1.0 (0.7, 1.5) 
Quintile 4 143 -0.6 (-4.2, 3.1) 1.4 (0.8, 2.6) 173 0.4 (-3.6, 4.3) 1.2 (0.8, 1.8) 
Quintile 5 153 -2.7 (-6.2, 0.8) 1.4 (0.8, 2.6) 165 1.6 (-2.0, 5.4) 1.1 (0.7, 1.5) 
Motor scale       
Quintile 1 167 ref ref  173 ref ref 
Quintile 2 149 -0.5 (-3.0, 2.0) 1.1 (0.3, 4.0) 140 -0.8 (-3.5, 1.8) 0.6 (0.1, 2.3) 
Quintile 3 114 -2.4 (-5.5, 0.7) 2.6 (0.9, 7.7) 143 -2.2 (-5.3, 0.9) 0.8 (0.3, 2.5) 
Quintile 4 143 -1.1 (-4.2, 2.0) 1.0 (0.2, 4.2) 173 -0.6 (-3.0, 1.9) 0.7 (0.2, 2.1) 
Quintile 5 153 -2.3(-5.3, 0.6) 2.7 (0.9, 8.1) 165 1.3 (1.0, -3.8) 0.4 (0.1, 1.8) 
Social emotional scale       
Quintile 1 167 ref ref  173 ref ref 
Quintile 2 149 0.7 (-2.8, 4.3) 1.0 (0.3, 3.1) 140 -1.0 (-5.0, 2.9) 2.1 (0.6, 6.8) 
Quintile 3 114 -1.1 (-4.6, 2.6)  0.7 (0.2, 2.6) 143 2.1 (-1.8, 5.9) 1.3 (0.3, 4.9) 
Quintile 4 143 -0.2 (-3.9, 3.6) 0.7 (0.2, 2.1) 173 0.1 (-3.5, 3.6) 2.7 (0.8, 9.0) 
Quintile 5 153 0.0 (-3.8, 3.8) 0.7 (0.2, 2.5) 165 2.8 (-0.6, 6.2) 0.9 (0.2, 4.0) 
Adaptive behaviour scale       
Quintile 1 167 ref ref  173 ref ref  
Quintile 2 149 -0.9 (-5.2, 3.3) 0.9 (0.4, 1.8) 140 -3.5 (-6.9, -0.1) 1.7 (0.8, 3.7) 
Quintile 3 114 -2.4 (-7.2, 2.3) 1.5 (0.7, 2.9) 143 0.0 (-3.7, 3.8) 1.0 (0.4, 2.3) 
Quintile 4 143 -0.3 (-4.7, 4.0) 1.0 (0.5, 2.0) 173 0.0(-3.1, 3.2) 1.0 (0.5, 2.2) 





1TSH was categorised into quintiles in both DOMInO and PINK. DOMInO quintile 1 (Lowest): <0.9 mIU/L; quintile 2: 1.0-1.5 mIU/L; quintile 
3: 1.6-2.1 mIU/L; quintile 4 : 2.2-3.0 mIU/L, quintile 5 (Highest): ≥3.1 mIU/L. PINK quintile 1 (Lowest): <1.3 mIU/L; quintile 2: 0.4-1.8 
mIU/L; quintile 3: 1.9-2.4 mIU/L; quintile 4 : 2.5-3.4 mIU/L, quintile 5 (Highest): ≥3.5 mIU/L. The regression models were adjusted for sex, 
parity, race, occupation, education, qualification, smoking during second trimester, previous smoking, alcohol consumption during second 
trimester, previous alcohol consumption, supplement intake during second trimester, previous depression, depression during second trimester, 
mode of delivery, mothers age, gestational age at birth, 5 minute Apgar score, mothers BMI, home screening questionnaire score and 
birthweight-for-gestational age z score in both DOMInO and PINK studies. In addition, treatment group in the DOMInO study was also added to 
the adjusted models when analysing the DOMInO data. CI, confidence interval; DOMInO, DHA to Optimize Mother Infant Outcome; MD, mean 
difference; n, number of participants, PINK, Pregnancy Iodine and Neurodevelopment in Kids; ref, reference category; RR, relative risks; TSH, 
thyroid-stimulating hormone. 
2Developmental delay was defined as Bayley-III scores below 85.   
3The Mean Differences (95% CIs) were estimated with multivariable linear regression model.  








Supplemental Table 7. 4 Adjusted associations between newborn TSH dichotomised at 5 mIU/L and Bayley-III outcomes at 18 months of age1     
 DOMInO PINK 
  Bayley-III score Developmental delay2  Bayley-III score Developmental delay2 
 n MD (95% CI)3 RR (95% CI)4 n MD (95% CI)3 RR (95% CI)4 
Cognitive scale        
TSH ≤5 mIU/L 693 ref ref 751 ref  
TSH >5 mIU/L 33 0.2 (-4.6, 5.0) 0.8 (0.1, 7.2) 43 -0.3 (-3.6, 3.0) 0.3 (0.1, 1.6) 
Language scale        
TSH ≤5 mIU/L 693 ref ref 751 ref  
TSH >5 mIU/L 33 -1.6 (-7.2, 4.0) 1.3 (0.6, 2.5) 43 0.8 (-4.5, 6.1) 1.1 (0.7, 1.6) 
Motor scale         
TSH ≤5 mIU/L 693 ref ref 751 ref  
TSH >5 mIU/L 33 0.7 (-5.4, 6.7) 3.4 (1.0, 13.9) 43 1.9 (-1.4, 5.2) 0.8 (0.1, 4.8) 
Social emotional scale         
TSH ≤5 mIU/L 693 ref ref 751 ref  
TSH >5 mIU/L 33 -0.1 (-7.0, 6.7) 0.7 (0.2, 3.0) 43 -0.1 (-4.2, 4.0) 1.0 (0.2, 4.8) 
Adaptive behaviour scale         
TSH ≤5 mIU/L 693 ref ref 751 ref  
TSH >5 mIU/L 33 0.2 (-6.2, 6.6) 1.0 (0.3, 3.3) 43 -1.3 (-6.4, 3.9) 1.4 (0.6, 3.6) 
 
1The TSH classification was based on the World Health Organization‘s recommendation to classify population iodine status based on the 
percentage of TSH >5 mIU/L. The regression models were adjusted for sex, parity, race, occupation, education, qualification, smoking during 
second trimester, previous smoking, alcohol consumption during second trimester, previous alcohol consumption, supplement intake during 
second trimester, previous depression, depression during second trimester, mode of delivery, mothers age, gestational age at birth, 5 minute 
Apgar score, mothers BMI, home screening questionnaire score and birthweight-for-gestational age z score in both DOMInO and PINK studies. 
In addition, treatment group in the DOMInO study was also added to the adjusted models when analysing the DOMInO data. CI, confidence 
interval; DOMInO, DHA to Optimize Mother Infant Outcome; MD; mean difference; n, number of participants, PINK, Pregnancy Iodine and 




2Developmental delay was defined as Bayley-III scores below 85. 
3The Mean Differences (95% CIs) were estimated with Univariable and multivariable linear regression model. 






Supplemental Table 7. 5 Adjusted associations between newborn TSH quartiles, Bayley-III outcomes at 18 months of age1     
  DOMInO  PINK 
 n Bayley –III score  Developmental delay2  n Bayley –III score  Developmental delay2  
  MD (95% CI)3 RR (95% CI)4  MD (95% CI)3 RR (95% CI)4 
Cognitive scale       
Quartile 1 127 ref ref 127 ref ref 
Quartile 2 155 -1.3 (-3.9, 1.3) 1.1 (0.2, 4.3)    155 -0.9 (-4.0, 2.0) 1.9 (0.8, 4.4)    
Quartile 3 262 -1.3 (-4.1, 1.5)   2.3 (0.7, 7.2)    262 -1.5 (-4.1, 1.2)   1.3 (0.6, 2.9)    
Quartile 4 250 -2.0 (-4.5, 0.7) 1.9 (0.6, 6.1)    250 0.4 (-2.2, 3.1) 0.9 (0.4, 2.0)    
Language scale       
Quartile 1 127 ref ref 127 ref ref 
Quartile 2 155 -1.0 (-4.1, 2.0) 1.4 (0.9, 2.2) 155 -2.3 (-6.7, 2.1) 1.7 (1.1, 2.6) 
Quartile 3 262 -1.1 (-4.1, 2.0) 1.2 (0.7, 2.0)  262 -0.7 (-4.7, 3.3) 1.3 (0.9, 1.9)  
Quartile 4 250 -2.3 (-5.5, 1.0) 1.3 (0.8, 2.2) 250 1.8 (-2.1, 5.7) 1.3 (0.8, 1.9) 
Motor scale       
Quartile 1 127 ref ref 127 ref ref 
Quartile 2 155 -2.4 (-5.0, 0.1) 3.0 (1.2, 7.3)    155 -0.5 (-3.2, 2.1) 1.2 (0.4, 4.0)    
Quartile 3 262 -0.9 (-3.6, 1.7) 0.9 (0.2, 3.3) 262 -1.4 (-4.0, 1.3) 1.0 (0.3, 3.2) 
Quartile 4 250 -1.8 (-4.6, 1.0) 2.3 (0.9, 6.3) 250 0.7 (-1.7, 3.2) 0.6 (0.2, 2.2) 
Social emotional scale       
Quartile 1 127 ref ref 127 ref ref 
Quartile 2 155 -1.5 (-5.6, 2.6) 0.7 (0.2, 2.0)    155 -1.2 (-5.0, 2.7) 2.1 (0.6, 7.1)    
Quartile 3 262 -0.8 (-4.9, 3.2) 0.6 (0.2, 1.8)    262 1.0 (-2.4, 4.5) 1.5 (0.5 , 4.7)    
Quartile 4 250 -1.4 (-5.7, 2.8) 0.8 (0.3, 2.3)    250 1.4 (-2.0, 4.9) 1.5 (0.4, 5.3)    
Adaptive behaviour scale       
Quartile 1 127 ref ref 127 ref ref 
Quartile 2 155 -1.2 (-4.3, 1.8) 1.6 (0.9, 2.8)    155 -3.3 (-6.9, 0.3) 1.6 (0.7, 34)    
Quartile 3 262 -0.7 (-4.1, 2.5) 1.1 (0.6, 2.0)   262 -0.6 (-4.0, 2.8) 1.0 (0.5, 2.2)   
Quartile 4 250 0.0 (-3.7, 3.6) 1.2 (0.6, 2.4)    250 0.1 (-3.1, 3.3) 0.8 (0.4, 1.8)    
 
1TSH in the DOMInO study was categorised into quartiles based on the PINK quartile cut-points (quartile 1 (Lowest): <1.5 mIU/L; quartile 2: 




DOMInO quartile cut-points (quartile 1 (Lowest): <1.1 mIU/L; quartile 2: 1.1-1.7 mIU/L; quartile 3: 1.8-2.9 mIU/L; quartile 4 (Highest): ≥3.0 
mIU/L). The regression models were adjusted for sex, parity, race, occupation, education, qualification, smoking during second trimester, 
previous smoking, alcohol consumption during second trimester, previous alcohol consumption, supplement intake during second trimester, 
previous depression, depression during second trimester, mode of delivery, mothers age, gestational age at birth, 5 minute Apgar score, mothers 
BMI, home screening questionnaire score, birthweight-for-gestational age z score and treatment group in both DOMInO and PINK studies. In 
addition, treatment group in the DOMInO study was also added to the adjusted models when analysing the DOMInO data. DOMInO, DHA to 
Optimize Mother Infant Outcome; MD, mean difference; PINK, Pregnancy Iodine and Neurodevelopment in Kids; ref, reference category; RR, 
relative risks; TSH, thyroid-stimulating hormone.  
2Developmental delay was defined as Bayley-III scores below 85. 
3The Mean Differences (95% CIs) were estimated with multivariable linear regression model.  




Supplemental Table 7. 6 Adjusted associations between newborn TSH~age and Bayley-III outcomes at 18 months of age1     
 DOMInO PINK 
 n Bayley-III score Developmental delay2  n Bayley-III Score  Developmental delay2  
  MD (95% CI)3 RR (95% CI)4  MD (95% CIs)3 RR (95% CI)4 
Cognitive scale        
1 mIU/L increase in 
TSH~age5  
726 -0.3 (-0.8, 0.3) 1.0 (0.8, 1.3) 
794 
0.2 (-0.4, 0.7) 
0.9 (0.7, 1.0) 
TSH~age in 
quartiles6 




Quartile 1 198 ref ref 198 ref ref 
Quartile 2 164 -1.1 (-3.8, 1.6) 1.6 (0.5, 5.0) 179 0.0 (-2.5, 2.5) 0.9 (0.4, 1.8) 
Quartile 3 173 -1.3 (-3.9, 1.4)  1.5 (0.5, 4.7) 205 -1.5 (-4.1, 0.9) 1.1 (0.6, 2.0) 
Quartile 4 191 -2.1 (-4.7, 0.4) 1.6 (0.5, 5.3) 205 1.2 (-1.4, 3.8) 0.6 (0.3, 1.2) 
Language scale       
1 mIU/L increase in 
TSH~age5 
726 -0.3 (-1.0, 0.5) 1.0 (0.9, 1.1) 
794 
0.5 (-0.2, 1.2) 
1.0 (1.0, 1.1) 
TSH~age in 
quartiles6 




Quartile 1 198 ref ref 198 ref ref 
Quartile 2 164 0.3 (-2.7, 3.4) 1.1 (0.7, 1.9) 179 -2.2 (-5.5, 1.1) 1.1 (0.8, 1.6) 
Quartile 3 173 -1.1 (-4.3, 2.2) 1.4 (0.8, 2.4) 205 0.4 (-3.1, 4.0) 1.1 (0.8, 1.5) 
Quartile 4 191 -1.7 (-4.9, 1.4) 1.4 (0.8, 2.2) 205 2.1 (-1.2, 5.5) 1.1 (0.8, 1.5) 
Motor scale       
1 mIU/L increase in 
TSH~age5 
726 
-0.2 (-0.8, 0.4) 
1.2 (1.0, 1.4) 
794 
0.2 (-0.3, 0.7) 









Quartile 1 198 ref ref 198 ref ref 
Quartile 2 164 -0.6 (-3.0, 1.7) 2.1 (0.7, 6.6) 179 -1.2 (-3.5, 1.1) 0.9 (0.3, 2.6) 
Quartile 3 173 -1.6 (-4.4, 1.1) 1.8 (0.6, 5.9) 205 -1.8 (-4.2, 0.7) 1.0 (0.4, 2.8) 










 DOMInO PINK 
 n Bayley-III score Developmental delay2  n Bayley-III Score  Developmental delay2  
  MD (95% CI)3 RR (95% CI)4  MD (95% CIs)3 RR (95% CI)4 
1 mIU/L increase in 
TSH~age5 
726 
0.3 (-0.7, 1.3) 
0.9 (0.7, 1.2) 
794 
0.5 (-0.2, 1.1) 









Quartile 1 198 ref ref 198 ref ref 
Quartile 2 164 -1.3 (-5.4, 2.8) 1.0 (0.3, 3.0) 179 0.8 (-2.8, 4.4) 1.8 (0.6, 5.5) 
Quartile 3 173 -1.4 (-5.6, 2.7) 0.9 (0.3, 2.4) 205 1.9 (-1.4, 5.2) 1.4 (0.5, 4.1) 





   
 
1 mIU/L increase in 
TSH~age5 
726 
0.1 (-0.6, 0.8) 
1.0 (0.9, 1.1) 
794 
0.1 (-0.7, 0.8) 









Quartile 1 198 ref ref 198 ref ref 
Quartile 2 164 -0.4 (-3.7, 2.9) 1.0 (0.5, 2.0) 179 -2.6 (-5.7, 0.5) 1.3 (0.7, 2.6) 
Quartile 3 173 -1.7 (-5.0, 1.6) 1.4 (0.8, 2.7) 205 0.9 (-2.0, 4.0) 0.8 (0.4, 1.5) 
Quartile 4 191 0.3 (-3.1, 3.8) 1.0 (0.5, 2.0) 205 0.7 (-2.1, 3.6) 0.7 (0.3, 1.6) 
 
1The regression models were adjusted for sex, parity, race, occupation, education, qualification, smoking during second trimester, previous 
smoking, alcohol consumption during second trimester, previous alcohol consumption, supplement intake during second trimester, previous 
depression, depression during second trimester, mode of delivery, mothers age, gestational age at birth, 5 minute Apgar score, mothers BMI, 
home screening questionnaire score and birthweight-for-gestational age z score in both DOMInO and PINK studies. In addition, treatment group 
in the DOMInO study was also added to the adjusted models when analysing the DOMInO data.CI, confidence interval; DOMInO, DHA to 
Optimize Mother Infant Outcome; MD, mean difference; n, number of participants, PINK, Pregnancy Iodine and Neurodevelopment in Kids; ref, 





2Developmental delay was defined as Bayley-III scores below 85. 
3The Mean Differences (95% CIs) were estimated with multivariable linear regression model. 
4The Relative Risks (95% CIs) were estimated with multivariable Poisson regression model with robust variance estimation. 
5TSH~age is modelled continuously.  
6TSH~age was categorised into quartiles in both DOMInO and PINK. TSH~age was created by regressing TSH on age at blood sampling [64, 
221]. DOMInO quartile 1 (Lowest): <1.0 mIU/L; quartile 2: 1.1-1.8 mIU/L; quartile 3: 1.9-2.8 mIU/L; quartile 4 (Highest): ≥2.9 mIU/L. PINK 





Supplemental Table 7. 7 Unadjusted associations between newborn TSH concentration and Bayley-III outcomes at 18 months of age1     
 DOMInO PINK 
 n Bayley-III Score  Developmental delay2  n Bayley-III Score  Developmental delay2  
  MD (95% CI)3 RR (95% CI)4  MD (95% CIs)3 RR (95% CI)4 
Cognitive scale         
1 mIU/L increase in TSH5  726 -0.5 (-1.1, 0.1) 1.1 (0.9, 1.3) 794 0.1 (-0.4, 0.7) 0.9 (0.8, 1.1) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -1.7 (-4.5, 1.1) 0.9 (0.3, 3.3) 196 -0.2 (-2.8, 2.4) 1.0 (0.5, 1.9) 
Quartile 3 185 -1.6 (-4.5, 1.4) 1.5 (0.5, 4.5) 201 -1.2 (-3.7, 1.2) 1.2 (0.7, 2.3) 
Quartile 4 181 -3.1 (-6.0, -0.2) 1.7 (0.6, 5.1) 197 1.5 (-1.0, 4.1) 0.7 (0.3, 1.4) 
Language scale        
1 mIU/L increase in TSH5 726 -0.8 (-1.5, 0.0) 1.1 (1.0, 1.2) 794 0.4 (-0.4, 1.3) 1.0 (1.0, 1.1) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -0.6 (-4.1, 2.8) 1.3 (0.7, 2.3) 196 -1.1 (-4.8, 2.6) 1.0 (0.7, 1.5) 
Quartile 3 185 -1.9 (-5.4,1.6) 1.5 (0.9, 2.7) 201 0.4 (-3.7, 4.3) 1.1 (0.8, 1.6) 
Quartile 4 181 -4.1 (-7.6, -0.7) 1.7 (1.0, 2.8) 197 1.8 (-2.0, 5.6) 1.1 (0.8, 1.5) 
Motor scale        
1 mIU/L increase in TSH5 726 -0.4 (-1.1, 0.2) 1.2 (1.0, 1.4) 794 0.1 (-0.4, 0.6) 0.9 (0.7, 1.2) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -1.2 (-3.6, 1.2) 1.4 (0.4, 4.5) 196 -1.3 (-3.7, 1.1) 0.7 (0.3, 2.0) 
Quartile 3 185 -1.2 (-3.8, 1.4) 1.3 (0.4, 4.3) 201 -1.9 (-4.4, 0.7) 1.0 (0.4, 2.5) 
Quartile 4 181 -2.8 (-5.5, -0.1) 2.5 (0.9, 7.4) 197 0.9 (-1.1, 3.0) 0.6 (0.2, 1.8) 
Social emotional scale        
1 mIU/L increase in TSH5 726 -0.3 (-1.3, 0.6) 1.0 (0.8, 1.2) 794 0.2 (-0.4, 0.8) 1.0 (0.8, 1.2) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -0.4 (-4.5, 3.6) 0.9 (0.3, 2.5) 196 0.7 (-2.6, 3.9) 1.5 (0.6, 3.9) 




 DOMInO PINK 
 n Bayley-III Score  Developmental delay2  n Bayley-III Score  Developmental delay2  
  MD (95% CI)3 RR (95% CI)4  MD (95% CIs)3 RR (95% CI)4 
Quartile 4 181 -3.4 (-7.7, 1.0) 1.0 (0.4, 2.6) 197 2.1 (-1.0, 5.2) 1.0 (0.3, 3.0) 
Adaptive behaviour scale        
1 mIU/L increase in TSH4 726 -0.2 (-1.0, 0.5) 1.0 (0.9, 1.2) 794 0.0 (-0.7, 0.8) 1.0 (0.8, 1.2) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -0.1 (-3.5, 3.3) 1.2 (0.6, 2.2) 196 -1.9 (-5.1, 1.4) 1.6 (0.8, 3.0) 
Quartile 3 185 -0.1 (-3.5, 3.4) 1.1 (0.5, 2.2) 201 0.3 (-2.8, 3.5) 0.9 (0.4, 1.8) 
Quartile 4 181 -1.2 (-4.9, 2.4) 1.4 (0.7, 2.8) 197 0.7 (-2.3, 3.7) 0.8 (0.4, 1.6) 
 
1CI, confidence interval; DOMInO, DHA to Optimize Mother Infant Outcome; MD, mean difference; n, number of participants, PINK, 
Pregnancy Iodine and Neurodevelopment in Kids; ref, reference; RR, relative risks; TSH, thyroid-stimulating hormone; SD, standard deviation. 
2Developmental delay was defined as Bayley-III scores below 85. 
3The Mean Differences (95% CIs) were estimated using Univariable linear regression model. 
4The Relative Risks (95% CIs) were estimated using Univariable Poisson regression model with robust variance estimation. 
5TSH is modelled continuously. 
6TSH was categorised into quartiles in both DOMInO and PINK. DOMInO quartile 1 (Lowest): <1.1 mIU/L; quartile 2: 1.1-1.7 mIU/L; quartile 
3: 1.8-2.9 mIU/L; quartile 4 (Highest): ≥3.0 mIU/L. PINK quartile 1 (Lowest): <1.5 mIU/L; quartile 2: 1.5-2.2 mIU/L; quartile 3: 2.3-3.3 mIU/L; 
















1The TSH classification was based on the World Health Organization‘s recommendation to classify population iodine status based on the 
percentage of TSH >5 mIU/L. The regression models were adjusted for sex, parity, race, occupation, education, qualification, smoking during 
second trimester, previous smoking, alcohol consumption during second trimester, previous alcohol consumption, supplement intake during 
second trimester, previous depression, depression during second trimester, mode of delivery, mothers age, gestational age at birth, 5 minute 
Apgar score, mothers BMI, home screening questionnaire score and birthweight-for-gestational age z score in both DOMInO and PINK studies. 
In addition, treatment group in the DOMInO study was also added to the adjusted models when analysing the DOMInO data. CI, confidence 
interval; DOMInO, DHA to Optimize Mother Infant Outcome; HAZ, length-for-age z score; HCZ, head circumference-for-age z score; MD; 
mean difference; n, number of participants, PINK, Pregnancy Iodine and Neurodevelopment in Kids; ref, reference category; RR, relative risks; 
TSH, thyroid-stimulating hormone; WAZ, weight-for-age z score; WLZ, weight-for-length z score.  
2Growth delay was defined as z scores below 1 SD. 
3The Mean Differences (95% CIs) were estimated with Univariable and multivariable linear regression model. 
 DOMInO PINK 
  Anthropometric z score Growth delay2  Anthropometric z score Growth delay2 
 n MD (95% CI)3 RR (95% CI)4 n MD (95% CI)3 RR (95% CI)4 
WLZ       
TSH ≤5 mIU/L 693 ref  751 ref ref 
TSH >5 mIU/L 33 -0.2 (-0.5, 0.1) 5 43 0.1 (-0.2, 0.5) 0.7 (0.2, 2.5) 
LAZ       
TSH ≤5 mIU/L 693 ref ref 751 ref ref 
TSH >5 mIU/L 33 0.1 (-0.3, 0.4) 1.0 (0.4, 2.5) 43 0.2 (-0.2, 0.6) 0.4 (0.1, 1.2) 
WAZ       
TSH ≤5 mIU/L 693 ref ref 751 ref ref 
TSH >5 mIU/L 33 -0.1 (-0.4, 0.2) 1.0 (0.2, 4.7) 43 0.1 (-0.3, 0.4) 0.5 (0.1, 2.0) 
HCZ       
TSH ≤5 mIU/L 693 ref  751 ref ref 




4The Relative Risks (95% CIs) were estimated with Univariable and multivariable log Poisson regression model with robust variance estimation. 









Supplemental Table 7. 9 Adjusted associations between newborn TSH~age and growth outcomes at 18 months of age1     
 
 
 DOMInO PINK 
 n Anthropometric z core Growth delay2  n Anthropometric z score Growth delay2  
  MD (95% CI)3 RR (95% CI)4  MD (95% CI)3 RR (95% CI)4 
WLZ       
1 mIU/L increase in TSH~age5  726 0.0 (0.0, 0.1) 0.8 (0.6, 1.1) 794 0.0 (-0.1, 0.0) 1.0 (0.9, 1.2) 
TSH~age in quartiles6       
Quartile 1 198 ref ref 198 ref ref 
Quartile 2 164 0.0 (-0.2, 0.2) 1.1 (0.2, 5.7) 179 -0.1 (-0.3, 0.1) 0.9 (0.3, 3.2) 
Quartile 3 173 0.0 (-0.2, 0.2) 1.1 (0.3, 4.0) 205 -0.1 (-0.4, 0.1) 1.0 (0.3, 3.3) 
Quartile 4 191 0.1 (-0.1, 0.3) 0.5 (0.1, 2.5) 205 -0.1 (-0.5, 0.2) 1.2 (0.4, 3.2) 
LAZ       
1 mIU/L increase in TSH~age5 726 0.0 (-0.1, 0.1) 1.0 (0.9, 1.1) 794 0.0 (-0.1, 0.0) 1.0 (0.9, 1.1) 
TSH~age in quartiles6       
Quartile 1 198 ref ref 198 ref ref 
Quartile 2 164 -0.1 (-0.3, 0.1) 1.3 (0.7, 2.4) 179 0.0 (-0.2, 0.3) 1.2 (0.6, 2.3) 
Quartile 3 173 -0.2 (-0.4, 0.0) 1.2 (0.7, 2.1) 205 0.0 (-0.2, 0.3) 1.3 (0.7, 2.3) 
Quartile 4 191 -0.2 (-0.4, 0.1) 1.3 (0.7, 2.1) 205 -0.2 (-0.4, 0.1) 1.4 (0.8, 2.5) 
WAZ       
1 mIU/L increase in TSH~age5 726 0.0 (0.0, 0.1) 1.0 (0.8, 1.2) 794 -0.1 (-0.2, 0.0) 1.1 (0.9, 1.2) 
TSH~age in quartiles6       
Quartile 1 198 ref ref 198 ref ref 
Quartile 2 164 0.0 (-0.2, 0.2) 0.5 (0.1, 2.6) 179 -0.2 (-0.5, 0.2) 1.1 (0.3, 3.7) 
Quartile 3 173 -0.1 (-0.3, 0.1) 1.3 (0.5, 3.6) 205 -0.3 (-0.7, -0.2) 1.4 (0.5, 3.7) 
Quartile 4 191 0.0 (-0.2, 0.2) 1.1 (0.4, 2.9) 205 -0.4 (-0.8, -0.1) 1.9 (0.7, 5.0) 
HCZ       
1 mIU/L increase in TSH~age5 726 0.0 (-0.1, 0.0) 1.1 (0.9, 1.3) 794 0.0 (-0.1, 0.1) 0.8 (0.7, 1.1) 
TSH~age in quartiles6       
Quartile 1 198 ref ref 198 ref ref 
Quartile 2 164 -0.2 (-0.4, 0.1) 2.2 (0.6, 8.6) 179 -0.1 (-0.4, 0.3) 1.4 (0.4, 4.7) 
Quartile 3 173 -0.2 (-0.4, 0.1) 3.3 (1.0, 10.8) 205 -0.2 (-0.5, 0.2) 1.0 (0.2, 4.1) 




1The regression models were adjusted for sex, parity, race, occupation, education, qualification, smoking during second trimester, previous 
smoking, alcohol consumption during second trimester, previous alcohol consumption, supplement intake during second trimester, previous 
depression, depression during second trimester, mode of delivery, mothers age, gestational age at birth, 5 minute Apgar score, mothers BMI, 
home screening questionnaire score and birthweight-for-gestational age z score in both DOMInO and PINK studies. In addition, treatment group 
in the DOMInO study was also added to the adjusted models when analysing the DOMInO data. CI, confidence interval; DOMInO, DHA to 
Optimize Mother Infant Outcome; HAZ, length-for-age z score; HCZ, head circumference-for-age z score; MD, mean difference; n, number of 
participants, PINK, Pregnancy Iodine and Neurodevelopment in Kids; ref, reference category; RR, relative risks; TSH, thyroid-stimulating 
hormone; TSH~age, thyroid stimulating hormone corrected for age at blood sampling; WAZ, weight-for-age z score; WLZ, weight-for-length z 
score. 
2Growth delay was defined as z scores below 1 SD. 
3The Mean Differences (95% CIs) were estimated with multivariable linear regression model. 
4The Relative Risks (95% CIs) were estimated with multivariable Poisson regression model with robust variance estimation. 
5TSH~age is modelled continuously. 
6TSH~age was categorised into quartiles in both DOMInO and PINK. TSH~age was created by regressing TSH on age at blood sampling [64, 
221]. DOMInO quartile 1 (Lowest): <1.0 mIU/L; quartile 2: 1.1-1.8 mIU/L; quartile 3: 1.9-2.8 mIU/L; quartile 4 (Highest): ≥2.9 mIU/L. PINK 



























 DOMInO PINK 
 n Anthropometric z score  Growth delay2  n Anthropometric z score  Growth delay2  
  MD (95% CI)3 RR (95% CI)4  MD (95% CIs)3 RR (95% CI)4 
WLZ       
1 mIU/L increase in TSH5 726 0.0 (-0.1, 0.0) 0.9 (0.7, 1.2) 794 -0.1 (-0.1, 0.0) 1.2 (1.0, 1.4) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -0.1 (-0.3, 0.2) 0.8 (0.2, 3.3) 196 -0.2 (-0.4, 0.0) 1.5 (0.5, 5.0) 
Quartile 3 185 -0.1 (-0.3, 0.2) 1.6 (0.5, 4.7) 201 -0.3 (-0.5, 0.0) 1.9 (0.6, 6.3) 
Quartile 4 181 0.0 (-0.3, 0.2) 0.8 (0.2, 3.5) 197 -0.3 (-0.6, 0.1) 1.8 (0.5, 6.1) 
LAZ       
1 mIU/L increase in TSH5 726 0.0 (-0.1, 0.0) 1.1 (0.9, 1.2) 794 -0.1 (-0.1, 0.0) 1.0 (0.9, 1.1) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 0.0 (-0.3, 0.2) 1.1 (0.6, 2.0) 196 0.1 (-0.2, 0.3) 1.2 (0.6, 2.3) 
Quartile 3 185 -0.1 (-0.3, 0.2) 1.1 (0.6, 1.9) 201 -0.1 (-0.4, 0.1) 1.9 (1.1, 3.3) 
Quartile 4 181 -0.2 (-0.5, 0.0) 1.6 (0.9, 2.7) 197 -0.2 (-0.5, 0.1) 1.4 (0.7, 2.6) 
WAZ       
1 mIU/L increase in TSH5 726 0.0 (-0.1, 0.0) 1.0 (0.8, 1.3) 794 -0.1 (-0.2, 0.1) 1.2 (1.0, 1.3) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -0.1 (-0.3, 0.2) 0.4 (0.1, 1.5) 196 -0.2 (-0.6, 0.2) 1.4 (0.5, 4.3) 
Quartile 3 185 -0.1 (-0.3, 0.2) 0.6 (0.2, 1.7) 201 -0.4 (-0.8, 0.1) 2.1 (0.8, 5.2) 
Quartile 4 181 -0.1 (-0.4, 0.1) 1.3 (0.6, 2.9) 197 -0.5 (-0.8, 0.2) 2.1 (0.8, 5.6) 
HCZ       
1 mIU/L increase in TSH5 726 0.0 (-0.1, 0.0) 1.1 (0.9, 1.3) 794 -0.1 (-0.1, 0.0) 0.9 (0.7, 1.2) 
TSH in quartiles6       
Quartile 1 184 ref ref 200 ref ref 
Quartile 2 176 -0.1 (-0.3, 0.1) 1.1 (0.3, 4.4) 196 -0.1 (-0.5, 0.2) 1.2 (0.3, 4.2) 
Quartile 3 185 -0.1 (-0.3, 0.1) 1.8 (0.6, 6.0) 201 -0.3 (-0.6, 0.1) 1.7 (0.6, 5.3) 




1CI, confidence interval; DOMInO, DHA to Optimize Mother Infant Outcome; HAZ, length-for-age z score; HCZ, head circumference-for-age z 
score; MD; mean difference; N, number of participants, p, p-value; PINK, Pregnancy Iodine and Neurodevelopment in Kids; ref, reference; RR, 
relative risks; TSH, thyroid-stimulating hormone; SD, standard deviation; WAZ, weight-for-age z score; WLZ, weight-for-length z score. 
2Growth delay was defined as z scores below 1 SD. 
3The Mean Differences (95% CIs) were estimated with Univariable linear regression model. 
4The Relative Risks (95% CIs) were estimated with Univariable Poisson regression model with robust variance estimation. 
5TSH~age is modelled continuously. 
6TSH was categorised into quartiles in both DOMInO and PINK. DOMInO quartile 1 (Lowest): <1.1 mIU/L; quartile 2: 1.1-1.7 mIU/L; quartile 
3: 1.8-2.9 mIU/L; quartile 4 (Highest): ≥3.0 mIU/L. PINK quartile 1 (Lowest): <1.5 mIU/L; quartile 2: 1.5-2.2 mIU/L; quartile 3: 2.3-3.3 mIU/L; 










Supplemental Figure 7. 1 Direct Acyclic Graph for association between newborn TSH and child neurodevelopment.  
BWGA Z score, birth-weight for gestational age z score; DHA, Docosahexaenoic acid; HSQ, home screening questionnaire; SES, socio-
economic status; TSH, thyroid stimulating hormone. DHA treatment group was only for the DHA to Optimize Mother Infant Outcome 





Supplemental Figure 7. 2 Direct Acyclic Graph for association between newborn TSH and child growth.  
BWGA Z score, birth-weight for gestational age z score; DHA, Docosahexaenoic acid; HSQ, home screening questionnaire; SES, socio-



























Supplemental Figure 7. 3 Associations between newborn TSH as continuous exposure and A) Bayley-III scores and B) neurodevelopmental 
delay at 18 months of age.  
CI, confidence interval; DOMInO, DHA to Optimize Mother Infant Outcome; MD, mean difference; PINK, Pregnancy Iodine and 

























Supplemental Figure 7. 4 Associations between newborn TSH in quartiles and A) Bayley-III scores and B) neurodevelopmental delay at 18 
months of age. 
 
CI, confidence interval; DOMInO, DHA to Optimize Mother Infant Outcome; MD, mean difference; PINK, Pregnancy Iodine and 



























Supplemental Figure 7. 5 Associations between newborn TSH as continuous exposure and A) anthropometric indices and B) growth delay at 18 
months of age.  
CI, confidence interval; DOMInO, DHA to Optimize Mother Infant Outcome; HAZ, length-for-age z score; HCZ, head circumference-for-age z 
score; MD, mean difference; PINK, Pregnancy Iodine and Neurodevelopment in Kids; RR, relative risk; TSH, thyroid-stimulating hormone; 

























Supplemental Figure 7. 6 Associations between newborn TSH in quartiles and A) anthropometric indices and B) growth delay at 18 months of 
age.  
CI, confidence interval; DOMInO, DHA to Optimize Mother Infant Outcome; HAZ, length-for-age z score; HCZ, head circumference-for-age z 
score; MD, mean difference; PINK, Pregnancy Iodine and Neurodevelopment in Kids; RR, relative risk; TSH, thyroid-stimulating hormone; 
WAZ, weight-for-age z score; WLZ, weight-for-length z score.  
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